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Endothelial damage and dysfunction are implicated in cardiovascular pathological 
changes and the development of vascular diseases. In view of the fact that the 
spontaneous endothelial cell (EC) regeneration is a slow and insufficient process, it 
would be of great significance to explore alternative cell sources capable of 
generating functional ECs to repair damaged endothelium. Indeed, recent 
achievements of cell reprogramming to convert somatic cells directly to other cell 
types provide new powerful approaches to study endothelial regeneration. 
Endothelial damage is often followed by smooth muscle cell (SMC) proliferation 
and accumulation. If we could arbitrarily convert SMC into EC, a novel cell 
regeneration strategy may be achieved. The aim of the present study is to test the 
hypothesis whether functional ECs could be derived from human vascular SMCs 
through reprogramming.    
Based on a combined protocol of reprogramming and differentiation, human 
vascular SMCs were first reprogrammed for 4 days to achieve a partially converted 
state expressing vascular progenitor marker CD34, by introducing four transcription 
factors OCT4, SOX2, KLF4 and c-MYC. Partially reprogrammed SMCs were then 
subjected to defined media and culture conditions to induce the differentiation 
towards an endothelial lineage. The differentiated cells expressed EC markers at the 
mRNA and protein level. Next, CD34-positive cells were selected from the 
heterogeneous population of vascular progenitors and further maintained in 
endothelial-promoting conditions. The CD34-positive cells were able to give rise to a 
more homogenous endothelial population with a repertoire of endothelial 
characteristics. These SMC-converted ECs displayed typical endothelial functional 
properties including Nitric Oxide (NO) production, acetylated-low density 
lipoprotein (LDL) uptake and angiogenic ability in vitro and in vivo. More 
importantly, these human SMC-derived ECs showed therapeutic angiogenic capacity 
that improved blood flow recovery when applied in a murine hindlimb ischaemia 
model as well as the ability to assemble into endothelium-like layer in tissue 
engineered vascular graft. Furthermore, the mechanisms involved in SMC to EC 
conversion were explored. Comprehensive analyses indicated that mesenchymal-to-
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epithelial transition was required to initiate the conversion from SMCs into vascular 
progenitors. In addition, components of the Notch signalling pathway, hairy and 
enhancer of split 5 (HES5) and Jagged1 (JAG1), regulated the differentiation of 
vascular progenitors towards an endothelial lineage.  
Together, we provide the first evidence of the conversion of human SMC towards 
functional endothelial lineage through mechanisms involving mesenchymal-to-
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1.1  The Vascular System 
1.1.1  Human Blood Vessel Structure and Function  
Human blood vessels compose the indispensable parts of the circulatory system to 
transport blood throughout the whole body. Blood vessels can be mainly classified 
into arteries, veins and capillaries based on the anatomic structures and function. 
Arteries deliver the blood carrying oxygen and nutrients from the heart to different 
organs and tissues, whereas capillaries allow the exchange of nutrients with 
metabolic wastes between the blood and the tissues. Veins function by carrying the 
blood back to the heart. Blood vessels generally consist of three layers: tunica intima, 
tunica media and tunica adventitia (Figure 1.1): 
Tunica intima is composed of endothelium, sub-endothelial layer and internal 
elastic lamina. An intact monolayer of endothelial cells (ECs) forms the endothelium 
and serves as a selectively permeable barrier between the blood and vessel wall. Sub-
endothelial layer is constructed by connective tissue and branch cells. Internal elastic 
lamina consists of a network of elastic fibres and has a role in the maintenance of 
blood pressure (McKinley and O'Loughlin 2006). 
Tunica media is a thick middle layer of smooth muscle cells (SMCs) and complex 
extracellular matrix. Due to the contractile ability of SMCs, tunica media provides 
support to the vessel and regulates blood flow and blood pressure via controlling the 
vessel diameter. 
Tunica adventitia is the outermost layer and is primarily composed of connective 
tissue and matrix-secreting fibroblasts. It provides structural support to the vessel 
and helps it to fit into the surrounding structure. Recent evidence indicates that the 
tunica adventitia also serves as an important vascular stem/progenitor cells reservoir 




Figure 1.1 Basic structure of human vessels 
Human vessels generally consist of three main layers: tunica intima, tunica 
media and tunica adventitia. ECs array the most inner layer of the vessels. 
SMCs predominantly contribute to the tunica media to support the vascular 
structure and to control the blood flow by contractility. Figure is adapted from  
(McKinley and O'Loughlin 2006). 
 
1.1.2  Vascular Endothelial Cell 
Vascular ECs array the most inner layer of the entire circulatory system, from the 
largest arteries and veins to the smallest capillaries, which serve as a semi-selective 
and non-adherent interface between blood and the underlying tissues. In response to 
diverse physiological and pathological stimuli, ECs are actively involved in 
regulating endothelium permeability, modulating vascular tone, regulating blood 
coagulation, and many other biological processes. EC dysfunctions precede the 
development of many vascular pathological conditions such as atherosclerosis, 
hypertension, and diabetes (Deanfield, Halcox et al. 2007).  
Under in vitro culture conditions, confluent ECs have the typical “cobblestone-like” 
morphology with slow rates of growth and motility. In contrary, sparse ECs exhibit 
spindle or flat shapes, are actively motile and are sensitive to growth factor 
stimulation (Aird 2007). There is no exclusive marker that is solely restricted to EC. 
Generally, a cluster of markers are recognised to identify EC including platelet 
endothelial cell adhesion molecule-1 (PECAM-1), vascular endothelial-cadherin 
26 
 
(VE-Cadherin), Claudin 5, endothelial nitric oxide synthase (eNOS), von-Willebrand 
factor (VWF), vascular endothelial growth factor (VEGF) receptors, etc. In vitro, the 
physiological function of ECs can be assessed by a series of tests such as the uptake 
of low-density lipoprotein, angiogenic ability, synthesis and release of nitric oxide 
(NO), regulation of permeability, inflammatory activation response to TNF-α and 
production of appropriate extracellular matrix to form basal lamina (Glaser, Gower 
et al. 2011). 
The physiological functions of EC in vivo are briefly summarised as follows (Figure 
1.2):  
Endothelial Cell Barrier 
The integrity of the endothelium is the foundation of vascular homeostasis.  The cell-
cell junctional structures, which link EC with each other to form a continuous 
monolayer, profoundly contribute to the regulation of permeability and the 
maintenance of the endothelium integrity. Furthermore, EC junctions actively 
participate in transferring intercellular signals between adjacent cells. EC junctions 
are formed by transmembrane adhesive proteins that link to specific cytoplasmic and 
cytoskeletal molecules. Based on the molecular structure and functional 
characterisation, EC junctions can be mainly classified into tight junctions and 
adherens junctions (Dejana 2004).  
Tight junctions serve as the physical barrier and control the permeability of ions and 
water-soluble solutes through the paracellular gaps. Tight junctions of EC consist of 
claudin family, occludin, junctional adhesion molecules (JAMs) and endothelial cell 
selective adhesion molecule (ESAM), among which Claudin 5 is an EC-specific 
transmembrane adhesion protein (Morita, Sasaki et al. 1999). Claudin 5-deficient 
mice died within 10 hours after birth due to the defect in the blood-brain barrier 
(Nitta, Hata et al. 2003).  
Adherens junctions among ECs mainly refer to VE-Cadherin, which is a calcium 
dependent transmembrane receptor and is one of the most representative markers for 
ECs. VE-Cadherin plays a key role in modulating endothelium activities by 
interacting with a variety of intracellular components which trigger complex 
signalling networks including reorganising the cytoskeleton and regulating gene 
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transcription. VE-Cadherin deficient embryos exhibit extensive endothelium 
remodelling and maturation failures that lead to lethality at day 9.5 of gestation 
(Carmeliet, Lampugnani et al. 1999). The cytoplasmic domain of VE-Cadherin 
interacts with β-catenin, plakoglobin and p120 to transmit signalling downstream 
(Vestweber 2008).  
PECAM-1 is another important EC intercellular junction protein belonging to the 
immunoglobulin super-family. In addition to its adhesive property, PECAM-1 also 
functions as a scaffold for signalling and adaptor molecules (Ilan and Madri 2003). 
PECAM-1 mediates the transduction of multiple signalling pathways mainly through 
the phosphorylation of the specific tyrosine residues within the cytoplasmic tail 
(Newman and Newman 2003).  
Vascular Tone Regulation 
Endothelium regulates vascular tone through secreting EC-derived vasodilators 
including NO, prostacyclin and other factors. These EC-derived factors mediate the 
relaxation of SMCs to achieve vasodilation. NO is recognised as the primary factor 
for vasodilation which is synthesised in ECs by eNOS and that are dependent on its 
cofactors including free calcium (Ca
2+
) and L-arginine (Michel and Vanhoutte 2010). 
Soluble guanylate cyclase (sGC) within SMCs can be activated by EC-released NO 
to dephosphorylate GTP to cGMP, which serves as a second messenger for 
signalling SMC relaxation (Carvajal, Germain et al. 2000). In addition to the 
modulation of vascular tone, NO also has other vessel-protective roles including 
regulating the growth of local cells, and inhibiting the aggregation and adhesion of 
inflammatory cells and platelets to endothelial surface (Tousoulis, Kampoli et al. 
2012).  
Regulation of Blood Coagulation and Platelet Aggregation 
Healthy ECs possess anticoagulant and antithrombotic functions to keep the vascular 
patency. Blood coagulation is prevented by ECs through synthesising and displaying 
inhibitors for tissue factor pathway and thrombins. ECs also express molecules for 
protein C activation which can demolish certain clotting factors and inhibits 
coagulation (Pober and Sessa 2007). ECs can physically separate the interaction of 
platelets and collagen which can activates platelets. ECs also secrete anti-platelet 
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molecules like prostacyclin, NO and prostaglandin-E2 to inhibit the adhesion and 
activation of platelet on endothelial surface (van Hinsbergh 2012). Under 
physiological condition, endothelium prevents the inflammatory cells adhesion by 
failing to express adhesion molecules that mediate leukocytes attachment.   
 
Figure  1.2  Physiological functions of EC 
The intact endothelium form by functional ECs plays key role in maintaining 
vascular homeostasis. Endothelium is the frontline barrier to control vascular 
permeability, blood coagulation, platelet and inflammatory cells adhesion and 
aggregation. Functional endothelium regulates vascular tone through 
secreting vasodilators to react on the SMCs underneath. Figure is adapted 





1.1.3  Vascular Smooth Muscle Cell 
Vascular smooth muscle cells (SMCs) and their products extracellular matrix (ECM) 
compose the majority of the vascular wall. The thick layer of SMCs and surrounding 
ECM serve to maintain the structural integrity of blood vessels from the high 
pressure generated from circulating blood. The contraction and relaxation of vascular 
SMCs coordinate the vascular tone and vessel lumen diameter that are important in 
the regulation of blood pressure and blood flow distribution (Rensen, Doevendans et 
al. 2007). Normal adults vascular SMCs express a repertoire of contractile proteins, 
ion channels, calcium handling proteins and cell surface receptors (Metz, Patterson 
et al. 2012). 
One crucial feature of SMCs is that they retain phenotypic plasticity to switch 
between a quiescent, contractile phenotype and a proliferative, synthetic phenotype. 
Under normal physiological condition, SMCs maintain contractile phenotype with 
extremely low proliferation rate and synthetic activity. In response to environmental 
stimuli and extracellular signals, SMCs lose contractile proteins and shift to the 
synthetic phenotype with higher proliferative and migratory capacity and secrete 
high levels of ECM components such as collagen, elastin and proteoglycans (Owens, 
Kumar et al. 2004, Beamish, He et al. 2010). Morphologically, contractile SMCs 
exhibit elongated, spindle-like shape whereas synthetic SMCs (also referred as 
epitheloid SMCs) display a less elongated, more cobblestone-like morphology (Hao, 
Gabbiani et al. 2003).  The expression patterns of protein markers have been widely 
adopted to characterise the different phenotypic states of SMCs. Contractile SMCs 
display a profile of contractile proteins including α-smooth muscle actin (α-SMA), 
Calponin, SM22α, smooth muscle myosin heavy chain (SM-MHC). In contrary, 
synthetic SMCs contain minimal contractile proteins but large amounts of Golgi 
apparatus, rough endoplasmic reticulum and ribosomes related proteins (Beamish, 
He et al. 2010). The phenotypic modulation of SMCs is actively involved in different 
pathologic situations including atherosclerosis, restenosis, asthma, hypertension and 
cancer.  
A complex transcriptional network mediates the phenotypic switch of SMCs. The 
promoter/intronic sequences of most SMC signature genes contain one or more 
conserved CArG elements, which interact with transcription factor serum response 
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factor (SRF) homodimers and coactivator Myocardin. Many other factors can 
promote or repress the expression of SMC genes through regulating the 
SRF/Myocardin-CArG interactions (Alexander and Owens 2012).  For example, 
Krüpple-like factor 4 (KLF4), a member of the zinc finger-containing transcription 
factor family, can strongly inhibit Myocardin-SRF-CArG that leads to the 
suppression of SMC marker expression such as α-SMA, SM22α, and SM-MHC (Liu, 
Sinha et al. 2005). In addition, KLF4 can also suppress SMC marker expression 
through binding to the transforming growth factor (TGF)-β response element located 
within their promoter region (Liu, Sinha et al. 2003). Interestingly, a recent study 
showed that KLF4 initiate the phenotypic switch of SMCs to macrophage-like cells 
within atherosclerotic lesions, through binding to and inhibiting multiple SMC 
marker-encoding genes  (Shankman, Gomez et al. 2015).   
 
1.1.4  Vascular System Development 
1.1.4.1  Embryonic Vascular Development 
 
The formation of blood vessels during embryogenesis is usually through two types 
of biological processes: vasculogenesis and angiogenesis. Vasculogenesis is the 
primary process to form blood vessel de novo by the differentiation of mesoderm-
derived endothelial progenitors (angioblasts), while angiogenesis is the sprouting of 
the new blood vessels from the pre-existing vascular networks. Many events that 
occuring during embryonic vascular development are recapitulated under situations 
of neoangiogenesis in the adult (Coultas, Chawengsaksophak et al. 2005). 
Embryonic vasculogenesis occurs simultaneously with the differentiation and 
specification of ECs under the control of a spatiotemporally precise signalling 
network. During the gastrulation stage of mammalian embryogenesis, a VEGFR2-
positive mesoderm precursor population emerges in the posterior primitive streak in 
response to basic fibroblast growth factor (bFGF) and bone morphogenetic protein 
(BMP) signals. Next, these VEGFR2-positive angioblasts migrate to both the extra-
embryonic yolk sac and the embryo to independently differentiate into ECs and form 
vascular structures. Angioblasts migrate towards the extraembryonic yolk sac to 
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form the blood islands. The peripheral cells of the blood islands give rise to ECs, 
whereas the central cells become haematopoietic progenitors. The blood islands 
further remodel and form a primary vascular plexus. The angioblasts migrated into 
the embryo aggregate together and form the dorsal aorta, cardinal veins and vascular 
plexus with the specification of ECs into arterial or venous fates (Coultas, 
Chawengsaksophak et al. 2005).  
A variety of transcription factors have fundamental roles in regulating endothelial 
specification and differentiation including members of the E-twenty six (ETS), SOX, 
GATA, Forkhead (FOX), Krüppel-like families (KLF) (De Val and Black 2009). 
Different sets of transcription factors orchestrate distinct stages in EC development. 
ETS transcription factors can potentially regulate almost all typical endothelial genes 
by interacting with the ETS binding sites contained in their promoter regions (Dejana, 
Taddei et al. 2007). The transient activation of the most important ETS factor ETV2 
within a specific development window is requisite to guide the VEGFR2-positive 
precursor cells to differentiate towards EC lineage (Kataoka, Hayashi et al. 2011). 
KLF factors KLF2 and KLF4 are closely associated with EC development and 
maturation. The promoter regions of many endothelial genes including VEGFR2, 
eNOS, and thrombomodulin contain KLF binding sites (Atkins and Jain 2007).  
Angiogenesis is the formation of new capillaries from the pre-established vasculature, 
which contributes to the remodelling of the primary vascular plexus to form a 
functional mature circulatory network. The basic angiogenic steps include growth 
factors induced ECs activation, breakdown of vascular basement membranes, ECs 
migration and proliferation, and subsequent stabilisation and maturation of blood 
vessels (Folkman 2003). At the onset of angiogenesis, ECs are activated in response 
to the stimulation of proangiogenic factors such as VEGF, epidermal growth factor 
(EGF), fibroblast growth factor (FGF) and a number of other factors. Activated ECs 
start to proliferate and release proteolytic enzymes to dissolve the basement 
membrane. At the same time, ECs are specified into tip or stalk cells due to the 
cross-talk between VEGF and the Notch signalling pathway. Endothelial tip cells 
migrate toward the angiogenic stimulus and guide the direction for the proliferating 
endothelial stalk cells to form tubular structures. Stalk cells connect to each other 
through junctional proteins and produce basement membrane components to enforce 
the integrity of the sprout (Phng and Gerhardt 2009, Potente, Gerhardt et al. 2011). 
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Finally, the remodelling and maturation of vascular structures require dynamic 
interactions between ECs with neighbouring cells and basement membrane (Eilken 
and Adams 2010).  
Vascular SMCs arise from multiple independent origins during embryonic 
development. These include neural crest, second heart field, somites, splanchnic 
mesoderm, mesothelium, mesoangioblasts and various progenitor/stem cells 
(Majesky 2007). During vasculogenesis and angiogenesis, SMCs and pericytes are 
recruited by ECs from surrounding mesenchyme following the generation of primary 
vessels to form a mature vascular system. SMCs developed from different sources 
compose the whole circulatory system in a complex mosaic pattern. The versatility 
of SMCs developmental origins influences the pathologenesis of vascular disease in 
a site-specific way (Sinha, Iyer et al. 2014). Transforming growth factor β (TGF-β) 
signalling plays an important role in stimulating SMCs maturation, proliferation, 
migration and producing extracellular matrix (Pardali, Goumans et al. 2010). 
Deficiency of TGF-β receptors in mice cause abnormal mural cells development that 
leads to a fragile vascular structure and impaired integrity (Goumans and Mummery 
2000).  
 
1.1.4.2  Embryonic Stem Cell as a model to study vascular 
development 
Due to the ethical issues, most of our knowledge of in vivo vascular development 
during mammalian embryogenesis is based on mouse models. The discovery of 
embryonic stem cell (ESC) has made a breakthrough advance in the field of 
developmental biology. ESCs are pluripotent cells isolated from the inner cell mass 
of blastocyst that represent a revolutionary ex vivo tool to study the development of 
different system, especially for human. ESCs automatically aggregate into three-
dimensional (3D) embryoid body (EB) in culture, which can recapture the 
differentiation of the three germ layers during embryogenesis: ectoderm, mesoderm 
and endoderm. Using mouse EB formation to study vascular development, the 
expression of VEGFR2 appears at day 3 followed by the expression of PECAM-1, 
Tie1, Tie2, and VE-Cadherin on days 4 and 5 (Vittet, Prandini et al. 1996). Human 
EB shows different vascular development pattern than mouse. VEGFR2 and Tie2 are 
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already expressed at certain level in undifferentiated human ESCs. During the 
spontaneous differentiation of human EB, the level of a group of endothelial related 
markers including CD34, PECAM-1, and VE-Cadherin is gradually turned on and 
reach a maximum at day 13-15 (Levenberg, Golub et al. 2002). The extensive 
formation of vasculature-like structures can also be observed within the human EB. 
Interestingly, a study showed that CD34-positive cells isolated from human EBs at 
day 10 can be selectively induced to either endothelial-like or smooth muscle-like 
cells in response to different culture conditions (Ferreira, Gerecht et al. 2007). 
Many important developmental concepts have been tested using ESC model. For 
example, the concept of haemangioblast serving as the common precursor of 
haematopoietic and endothelial cells during development was first proved using the 
mouse EB model and then in human EB model. A VEGFR2-positive colony-forming 
precursor population is identified in the EB that can be further differentiated into 
both haematopoietic and endothelial lineage with the stimulation of VEGF (Choi, 
Kennedy et al. 1998, Kennedy, D'Souza et al. 2007). However, this VEGFR2-
positive population could also give rise to smooth muscle-like cells or 
cardiomyocytes with different stimulation, which indicated that the VEGFR2-
positive cells may represent a broader mesodermal progenitor (Yamashita, Itoh et al. 
2000, Schroeder, Fraser et al. 2003). 
 
1.1.4.3  Evidence of ECs and SMCs may share common progenitor 
during development 
Tracing back to the embryonic origins, both ECs and SMCs are mainly derived from 
the same location: mesoderm layer. ECs are derived from mesodermal angioblasts 
during embryogenesis. A large portion of SMCs are developed from multiple 
mesodermal origins including lateral plate mesoderm, splanchnic mesoderm and 
somatic or paraxial mesoderm (Sinha, Iyer et al. 2014). For example, descending 
aorta that is originated from dorsal aorta in the embryo for example, ECs and SMCs 
that form the dorsal aorta are both first derived from splanchnic lateral plate 
mesoderm, and then replaced by ECs and SMCs derived from somite-mesoderm 
(Wasteson, Johansson et al. 2008, Sato 2013). After grafting quail somites into chick 
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embryos, the contribution of somite-derived cells to both aortic ECs and SMCs was 
observed (Pouget, Gautier et al. 2006).  
An important study using mouse embryo supported the idea of common progenitor 
during development. Branchyury- and VEGFR2-positive colony-forming cells were 
isolated from embryonic day (E) 7.9-7.5 mouse embryo mesoderm area. These cells 
could give rise to the colony containing cells expressing markers of the endothelium 
and smooth muscle when cultured in vitro (Huber, Kouskoff et al. 2004). A variety 
of signals including bFGF, BMP, Wnt, and Notch have been implicated in mesoderm 
development. The extensive interaction with the establishment of precisely 
spatiotemporal concentration gradients of these signals lead to specific mesodermal 
patterning in the embryo (Sinha, Iyer et al. 2014). During chick embryogenesis, the 
cross-talks between Notch, Wnt and BMP control the differentiation potential of 
ventral mesoderm-derived precursors towards ECs or SMCs (Shin, Nagai et al. 
2009). 
Using ESC to vascular lineage differentiation as a model, the existence of common 
progenitors for ECs and SMCs have been demonstrated by many studies. Yamashita 
et al. first claimed that VEGFR2-positive cells from mouse ESCs could give rise to 
both ECs and SMCs in response to VEGF or PDGF-BB stimulation respectively 
(Yamashita, Itoh et al. 2000). Subsequently, Ferreira et al. isolated the CD34-
positive vascular progenitor cells during human EB growth which could differentiate 
into both endothelial and smooth muscle-like cells (Ferreira, Gerecht et al. 2007). 
The CD34-positive vascular progenitor cells with the EC and SMC differentiation 
capacity have also been identified in a 2D human ESCs culture system (Hill, 





Figure 1.3 The development of ECs and SMCs and the possible 
existence of common vascular progenitors 
ECs are developed from mesoderm-derived angioblasts and differentiate 
towards arterial or venous fate along with vasculogenesis. SMCs are derived 
from multiple origins including mesoderm. SMCs are recruited by ECs for 
vascular maturation. The existence of common vascular progenitors for both 
EC and SMC is supported by studies using ESCs as the model for vascular 
development. Figure is adapted from (Carmeliet 2000) 
 
1.1.4.4   The Notch signalling pathway and vascular development 
The Notch signalling pathway extensively participates in diverse vascular cell 
activities during embryonic and postnatal development. The Notch pathway is a 
highly conserved cell-cell signalling system consisting of transmembrane ligands 
(Jag1, Jag2, Dll1, Dll3, and Dll4), transmembrane receptors (Notch1-4), intracellular 
signal transducer and effectors. For canonical Notch signalling pathway, the 
receptors on the signal-receiving cells are activated upon ligands binding and the 
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intracellular domains of the receptors are proteolytic cleaved and released. The 
Notch intracellular domain then translocates into the nucleus and interacts with 
DNA-binding proteins recombination signal binding protein for immunoglobulin 
kappa J (RBP-J) to activate downstream targets genes such as Hairy enhancer-of-
splits (HES) and HES-related proteins (HEY) family (Bray 2006) (Figure 1.4). The 
Notch signalling is inhibited when the receptor is interacting with the ligand 
presented within the same cell, which is known as the cis-inhibition of Notch (del 
Alamo, Rouault et al. 2011). The cis-inhibition of Notch regulates the ability of a 
cell to receive the signal from the adjacent cells.  In addition, the Notch pathway can 
also function through non-canonical mechanism by interacting with Wnt signalling 
in a ligand/transcription-independent way (Andersen, Uosaki et al. 2012).  
 
Figure  1.4  The Notch signalling pathway 
The canonical Notch pathway is a ligand-receptor signalling system. Signal-
sending cells express ligands to bind to the receptors on the signal-receiving 
cells. The intracellular domain of the receptors are proteolytic cleaved and 
translocate into the nucleus to regulate downstream target genes. Figure is 
adapted from (Gridley 2007). 
 
The Notch ligands and receptors are widely expressed by vascular cells and the 
delicate spatial and temporal regulation of the Notch pathway control various 
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vascular processes including ECs and SMCs differentiation, angiogenesis, arterial-
venous specification. Loss-of-function studies showed that the null mutation of 
either receptor Notch1, Notch2 or ligand Jag1, Dll1, Dll4 all causes severe vascular 
defects and embryonic lethality (Gridley 2007).  
The Notch pathway actively controls multiple aspects of EC differentiation and 
specification. Using avian embryos, Sato et al. showed that Notch signalling guided 
the migration of the angioblasts within somites mesoderm towards dorsal aorta and 
their further differentiation towards ECs (Sato, Watanabe et al. 2008).  
The primary function of the Notch signalling during vascular development is to drive 
the decisions of the precursors between two alternative fates. The Notch signals 
regulate the specification of arterial or venous identity of ECs, which is achieved by 
the cross-talk with VEGFA signalling (Lawson, Scheer et al. 2001, Lawson, Vogel 
et al. 2002) (Figure 1.5A). The Notch signalling-deficient mice embryos exhibited 
defectively formed arteries with excessive vein formation (Gale, Dominguez et al. 
2004, Krebs, Shutter et al. 2004). Dll1 and Dll4-mediated Notch signalling directly 
regulate the expression of the specific arterial EC marker EphrinB2 (Iso, Maeno et al. 
2006, Sorensen, Adams et al. 2009). VEGFA acts upstream of the Notch signalling 
pathway during arterial-venous determination of ECs. VEGFA-deficient embryos 
show similar arteriovenous malformations like Notch-mutant embryos, which can be 
rescued from ectopic activation of the Notch signalling pathway (Lawson, Vogel et 
al. 2002). Some studies showed that VEGF exerts its effect on the Notch pathway for 
arterial specification through ERK pathway to induce the expression of Dll4 and 
NOTCH1 (Hong, Peterson et al. 2006). Other studies indicated that the cross-talk 
between VEGF and the Notch pathway is also mediated by transcription factors 
FOXC1/FOXC2, which can directly activate the promoters of NOTCH1, NOTCH4, 
Dll4 (Seo, Fujita et al. 2006). In contrary, transcription factor COUP-TFII suppresses 
the Notch signalling pathway which leads ECs towards venous fate (You, Lin et al. 
2005). 
The Notch signalling also plays the central role in coordinating angiogenesis process 
through controlling the EC specification into tip cells or stalk cells, which is also 
closely interacted with VEGF signalling (Figure 1.5B). In response to VEGFA 
stimulation, tip cells express Dll4 which binds to the Notch receptors expressed in 
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stalk cells.  Dll4-activated Notch signalling downregulates the expression of VEGF 
receptors in the stalk cells, which leads to the inhibition of stalk cells’ sprouting 
tendency towards VEGF stimulus. Therefore, tip cells actively sprout towards the 
angiogenic signals while the stalk cells maintain the integrity of the vascular bed 
(Hellstrom, Phng et al. 2007, Suchting, Freitas et al. 2007). Dll4-blockage or Dll4-
Notch interaction disruption result in dysregulated vascular formation due to 
extensive endothelial over-sprouting (Noguera-Troise, Daly et al. 2006). In addition, 
JAG1 can act as pro-angiogenic regulator by antagonising the Dll4-induced effects 
and promotes the sprouting and branching of vessels (Benedito, Roca et al. 2009).   
 
 
Figure 1.5 The Notch signalling pathway interacts with the VEGF 
signalling to regulate arterial-venous specification and angiogenesis of 
EC 
(A) The Notch signalling regulates the arterial-venous decision of ECs. In 
response to VEGF stimulus, the Notch signalling is activated and regulates 
the expression of arterial genes. (B) The crosstalk between the Notch 
signalling and VEGF signalling controls the angiogenesis process. Tip cells 
receive VEGF stimulation and start to express high level of Dll4 ligands to 





The Notch signalling also widely contributes to the SMCs development and 
physiology. Notch3 is the commonly expressed Notch receptor in SMCs, which is 
indispensable for the maturation and the acquisition of arterial identity of vascular 
SMCs. Notch3-deficient mice exhibited fragile arterial structures with abnormally 
thinner SMCs layer and disorganised elastic lamina compared to the wild-type mice 
(Domenga, Fardoux et al. 2004). NOTCH3 mutations in human leads to a disease 
called cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoecephelopathy (CADASIL) that is characterised by systemic vascular 
degeneration due to the extensive SMC death in small arteries (Joutel, Andreux et al. 
2000). This suggests that NOTCH3 is important for the maintenance of SMCs 
phenotypic stability. NOTCH3, together with the downstream HES5, are also 
implicated in promoting the development of pulmonary arterial hypertension by 
keeping the SMCs in an undifferentiated state with high proliferation ability (Li, 
Zhang et al. 2009). 
In vitro studies showed that the Notch signalling could either repress or promote 
smooth muscle gene expression in different context. Ectopic expressing Jag1 or 
active Notch1 intracellular domain in mouse fibroblasts repressed Myocardin-
dependent contractile markers including α-SMA, SMC22α, Calponin, and SM-MHC 
(Proweller, Pear et al. 2005). A similar result of extensive suppression of Myocardin-
dependent SMC markers was observed by overexpressing NOTCH1 and NOTCH3 
intracellular domains in human vascular SMCs (Morrow, Scheller et al. 2005). These 
suppression effects can be partially explained by the inhibitory roles of Notch 
downstream target genes of HES/HEY family on the binding of SRF/Myocardin to 
CArG elements to repress SMC genes (Doi, Iso et al. 2005, Tang, Urs et al. 2008). 
However, there were reports showing the Notch signalling could induce smooth 
muscle differentiation and promote the expression of contractile SMC markers (Doi, 
Iso et al. 2006, Noseda, Fu et al. 2006). Thus, these contradicting results suggested a 
dynamic regulatory role of the Notch signalling during SMC development and 
following injury. The eventual outcome depends on the efficacy and timing of these 
competing transcriptional events. 
In addition, the Notch signalling mediates the cross-talk between ECs and SMCs. 
The expression of Jag1 on ECs is important for the adjacent SMCs development and 
maturation. Endothelial-specific deletion of Jag1 caused severe defects in vascular 
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SMC maturation (High, Lu et al. 2008). Furthermore, the direct cell-cell contact 
between ECs and SMCs is requisite for the effective conduct of the Notch signalling 
(Xia, Bhattacharyya et al. 2012). In addition, Jag1 expressed by vascular SMCs can 
activate Notch1 on ECs to promote proliferation and angiogenesis (Yang and 





1.2   Vascular Cells Dysfunction leads to a typical 
vascular pathological condition:  Atherosclerosis 
1.2.1  Basic pathologenesis of Atherosclerosis  
Atherosclerosis is the chronic pathological condition of the arterial wall. It is the 
major pathological event for many cardiovascular diseases such as coronary artery 
disease, peripheral artery disease and stroke. The pathogenesis of atherosclerosis is a 
complex process with the participation of the vascular, metabolic, and immune 
systems (Loscalzo 2010). Atherosclerosis can be mainly divided into the following 
stages based on the pathological changes: initial lesion, fatty streak stage, 
preatheroma stage and atheroma stage (Figure 1.6). Endothelium injury and 
dysfunction are the initial events induced by genetic and/or environmental risk 
factors. Then, circulating blood leukocytes adhere to the activated endothelium 
surface and infiltrate into the tunica intima followed by lipid uptake and foam cells 
formation. As atherosclerosis deteriorates, SMCs migrate from tunica media into 
intima, proliferate and produce extracellular matrix macromolecules that form a 
fibrous cap covering the plaque. The dead SMCs and macrophages debris along with 
lipid deposition constitute the necrotic core of the plague. The plague causes the 
narrowing of the vascular lumen which leads to local tissue ischaemia. The rupture 
of the atherosclerotic plague causes the ultimate complication of atherosclerosis, 
thrombosis, which obliterates blood flow in situ or at the distal ends (Libby, Ridker 





Figure  1.6 A simplified diagram of atherosclerosis pathogenesis 
Atherosclerosis is a complex pathological condition featured by endothelial 
dysfunction, SMC migration and proliferation, lipid deposition, necrotic core 
and fibrous cap formation. Figure is adapted from (Madamanchi, Vendrov et 
al. 2005). 
 
1.2.2 Roles of Vascular Cells in Atherosclerosis 
Both ECs and SMCs profoundly contribute to the progression of atherosclerosis. The 
dysfunction of the endothelial monolayer is the key initiation event of atherosclerosis 
caused by atherogenic stimuli including hypertension, diabetes, dyslipidemia, 
oxidative stress and others. Endothelial dysfunction characterised by leukocytes 
recruitment and platelet aggregation, increased permeability, thrombus formation, 
and impaired endothelium-mediated vasodilation. The expression of surface 
adhesion molecules are changed within the injured ECs which initiate the 
recruitment of blood leukocytes and platelet. In parallel, the endothelium 
permeability and the sub-endothelial extracellular matrix composition are altered to 
permit the penetration and accumulation of leukocytes and oxidised LDL particles 
(Landmesser, Hornig et al. 2004). The NO synthesis capacity of ECs is also 
disturbed during atherosclerosis which impairs the endothelium-dependent 
vasodilation. Reduced NO synthesis occurs simultaneously with the increased 
generation of reactive oxygen species (ROS). Increased ROS bioavailability, 
together with the dysregulated oxidative stress, further damages the endothelial 
homeostasis (Endemann and Schiffrin 2004). To repair the injured endothelium and 
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reconstruct normal endothelial physiological function is a major target for anti-
atherosclerosis therapy.  
SMCs undergo phenotypic modulation during the atherosclerosis lesion formation 
and progression. In response to the growth factors and cytokines, contractile SMCs 
within the vessel media layer switch to a synthetic phenotype, characterised with 
reduced SMC-selective differentiation marker genes and elevated proliferation rate, 
migratory ability and synthetic activity (Gomez and Owens 2012). Activated SMCs 
migrate towards the intima where they proliferate and produce extracellular matrix to 
contribute to the formation of the neointima and the fibrous cap. Up to 70% of the 
mass of lesions is composed of SMCs and SMC derived cells (Raines and Ross 
1993). A recent lineage tracing study showed evidence that SMCs within 
atherosclerotic lesions could convert to diverse phenotypes expressing markers that 
are normally expressed by macrophages, mesenchymal stem cells (MSCs) and 
myofibroblasts (Shankman, Gomez et al. 2015). This study also demonstrated that 
selective loss of KLF4 profoundly contributes to the generation of SMC-derived 








1.3 Resident Endothelial Cells Regeneration for 
Endothelium Repair 
After endothelial dysfunction and denudation during atherosclerosis, endogenous 
resident ECs tend to proliferate and replace the injured endothelium. A number of 
studies from early years showed that local ECs participate in the repair of small areas 
of endothelial damage through migration and the repair of lager areas of damage 
through both proliferation and migration (Hagensen, Vanhoutte et al. 2012).  
Recently, by transplanting wire-injured carotid artery segments from wild type mice 
into Tie2-GFP mice, Hagensen et al. demonstrated the resident ECs from the 
transplanted graft contribute to the re-endothelialisation of the lesion (Hagensen, 
Raarup et al. 2012).  
Although the proliferation and migration of resident ECs represent a straightforward 
way for endothelial regeneration, it is a relatively slow and inefficient process 
(Hirase and Node 2012). In addition, with the effects of the cardiovascular risk 
factors, the adjacent ECs around injured endothelial area may also be in a 
dysfunctional state.  
 
The rejuvenation of ECs with normal function represents a significant target of 
vascular disease therapies. A number of different stem cell sources, that have been 
considered to contribute to EC regeneration, potentially provide promising methods 




1.4  Adult Stem Cells and Endothelial Regeneration 
1.4.1  Circulating Vascular Progenitor Cells 
Circulating vascular progenitor cells refer to the cells in peripheral blood that can 
differentiate into ECs and termed as Endothelial Progenitor Cells (EPCs) (Asahara, 
Murohara et al. 1997). A number of studies demonstrated that EPCs play important 
roles in vascular healing and remodelling processes.  
In general, EPC refers to an immature cell population existing in circulating blood 
that commits into endothelial lineage and possesses vasculogenic property. There are 
a motley variety of methods to identify and obtain EPCs and these can be mainly 
classified into two approaches. For the first approach, mononuclear cells are 
collected from human peripheral blood or cord blood and then cultured and selected 
using different in vitro culture conditions or colony assays. The second approach is 
based on the selection of cell subpopulation by surface marker expression. A panel 
of markers has been used to describe EPCs including CD34, VEGFR2, CD133, and 
others (Fadini, Losordo et al. 2012, Yoder 2012). Recent evidence shows that EPCs 
can participate in endothelial repair and compensatory angiogenesis directly as well 
as through paracrine effects (Yang, Di Santo et al. 2010). Furthermore, the level of 
circulating EPCs has been used as a biomarker that correlates with the progression of 
cardiovascular disease (Sen, McDonald et al. 2011). Several early stage clinical trials 
showed the therapeutic benefit of EPCs for revascularisation in atherosclerotic 
cardiovascular disease patients (Trounson, Thakar et al. 2011). 
Although the concept of EPC has been widely studies and many different methods 
have been developed to obtain EPCs from human body, the exact characterisation 
and identification of EPCs are still ambiguous and under debate. Firstly, it is hard to 
tell whether EPCs grew out of in vitro assay actually exist in the circulatory system 
or they are merely an artificial phenotype generated by certain culture conditions 
(Fadini, Losordo et al. 2012). Due to the lack of unique or specific markers, it is 
difficult to distinguish EPCs from subsets of haematopoietic cells, blood platelets or 
mature ECs (Yang, Di Santo et al. 2010). Another major limitation is that the level 
of EPC in patient peripheral blood is low. Finally, these so-called EPCs that grew 
out of circulating blood does not display superior functional properties compared to 
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mature ECs, questioning their identity as true progenitor or cells that are merely ECs 
sloughed off from vessel wall (Tura, Skinner et al. 2013). In conclusion, the 
application value of EPCs in a broad spectrum is still under discussion.   
 
1.4.2  Vascular Wall Resident Progenitor Cells 
A variety of resident progenitor cells that can differentiate into endothelial lineage 
cells have been identified in different sized vessels and all layers of the vessels.  
Ingram et al. selected endothelial progenitor cells by their proliferative and 
clonogenic potential among mature ECs in human adult vessel tunica intima (Ingram, 
Mead et al. 2005). Intima-derived EPCs express similar group of surface markers of 
ECs including PECAM-1, CD141, CD105, CD146, VE-Cadherin, VWF, and Flk-1. 
Another study reported a PECAM-1-positive, CD45-negative progenitor population 
at the inner surface of pre-existing mouse blood vessels (Naito, Kidoya et al. 2012). 
These EPCs possess colony-forming ability and can give rise to ECs which lead to 
de novo reconstitution of functional blood vessels in ischaemic lesions. EPCs within 
the intima have the potential to proliferate and may directly contribute to the local 
migration and repair of damaged endothelium.  
A Sca-1-positive, c-Kit-negative/low, Lin28-negative, and CD34-negative/low 
population of progenitor cells can be isolated from the tunica media of mouse 
arteries, which can give rise to functional ECs and SMCs in vitro (Sainz, Al Haj Zen 
et al. 2006). In the region between the media and the adventitia of human thoracic 
aortas and femoral arteries, Pasquinelli et al. showed the presence of CD34-positive 
and c-Kit-positive resident progenitor cells that can develop angiogenic capacity 
upon culture (Pasquinelli, Tazzari et al. 2007).  
The adventitia layer of the vascular wall serves as an important stem cell niche. By 
using different combination of progenitor markers such as Sca-1, CD34, CD133, 
VEGFR2 and others, the existences of the multipotent vascular progenitors and 
EPCs within the adventitia of human and mouse have been demonstrated by many 
studies (Majesky, Dong et al. 2012). For example, Zengin et al. reported that the 
adventitial layer of human internal thoracic artery contains CD34-positive EPCs that 
can give rise to capillary-forming ECs in vitro and in vivo (Zengin, Chalajour et al. 
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2006). In response to environmental and pathological stimuli, adventitia progenitor 
cells migrate and differentiate into vascular cells to participate various physiological 
or disease processes.   
The existence of abundant progenitor populations within the vascular wall provides 
promising prospects for vascular cell regeneration. However, there are no specific 
markers to define these progenitors while at the same time the origins of these 
populations are not well understood. In addition, it is difficult to rule out the 
possibility that the dedifferentiation and transdifferentiation of mature vascular cells 
are mistaken for novel progenitor population. For therapeutic purpose, how to 
efficiently and precisely induce the migration of vascular wall progenitors towards 
specific location for vascular repair is not yet clear.  
 
1.4.3  Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) were first isolated from bone marrow stroma, and 
then were reported to be presented in vascular walls, microvessels and perivascular 
adipose tissues. A panel of markers have been used to define the MSCs:  positive for 
CD105, CD73, CD29, CD90 and CD44, and negative for PECAM-1, CD34, CD45 
and CD14 (Uccelli, Moretta et al. 2008). MSCs have multi-lineage differentiation 
ability including towards ECs. Oswald et al. showed that human bone marrow-
derived MSCs differentiated towards angiogenic endothelial-like cells by simply 
culturing the cells in the presence of 2% fetal calf serum and 50 ng/ml VEGF 
(Oswald, Boxberger et al. 2004). Bone marrow-derived MSCs exhibited the ability 
to differentiate to both ECs and SMCs and facilitated revascularisation in a canine 
chronic ischaemic model (Silva, Litovsky et al. 2005).  
Clinical advantages of MSCs include the ease of isolation and expansion of the cells 
and the low immunogenicity (Huang and Li 2008). However, there are some 
obstacles in the way for the further applications of MSCs especially for vascular 
regeneration use. MSCs still lack accurate definition due to the absence of one or a 
group of specific MSC markers. MSCs isolated by different methods show varied 
differentiation capacities (Gomez-Gaviro, Lovell-Badge et al. 2012). In addition, the 
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true mesoderm lineage differentiation ability of MSCs is still under debate because 
of the lack of solid lineage tracing experiments (Bianco, Robey et al. 2008). 
 
Adult stem cells are able to give rise to vascular cells under normal and/or 
pathological conditions (Figure 1.7). However, their therapeutic values are 
compromised due to the limited population in human body as well as restricted 
replicative capacity and culture senescence, especially from adult patients. The 
definition and origin of many kinds of adult stem cells are also far from clear. Thus, 
it is of significant to explore more cell sources that can be used in vascular 




Figure  1.7 Adult stem cells serve as EC reservoirs 
In adult body, multiple stem cell sources can contribute to endothelial repair 
including circulating stem cells, vascular wall resident progenitor cells, 





1.5  Embryonic Stem Cell (ESC) and Endothelial 
Regeneration 
1.5.1  The Generation of ESC  
The successful generation of mouse embryonic stem cells (ESCs) was first reported 
in 1980s and human ESCs in 1990s, which marked momentous breakthroughs in 
stem cell research area (Evans and Kaufman 1981, Martin 1981, Thomson, Itskovitz-
Eldor et al. 1998). ESCs are isolated from the inner cell mass (ICM) of blastocyst-
stage embryos and can be cultured on feeder cells in vitro. ESC displays indefinite 
self-renewal, high proliferative capacity and the ability to differentiate into all cell 
types of the three germ layers: endoderm, mesoderm and ectoderm, rendering ESC 
as a promising cell source for regenerative medicine. Both mouse and human ESC 
are positive for alkaline phosphatase (AP) staining and express pluripotency markers 
including Oct3/4, Nanog, and Sox2. Nevertheless, there are several distinct 
characteristics of human ESC from mouse ESC: (1) different signalling networks to 
regulate the maintenance and the differentiation, especially human ESCs do not 
require leukaemia inhibitory factor (LIF) to keep the undifferentiated state; (2) 
expression of specific surface markers like SSEA-3/4, TRA-1-81, TRA-1-60; (3) 
longer proliferative cycle; (4) different colony shapes (Ginis, Luo et al. 2004, 
Schnerch, Cerdan et al. 2010). 
In culture, ESCs start to differentiate upon removal from feeder cells or LIF. In 
general, there are three basic approaches for mouse or human ESCs differentiation 
towards certain lineage: (1) inducing ESCs to aggregate and form 3D structured 
embryoid bodies (EBs) which further differentiate towards different cell types; (2) 
culturing ESCs on specific matrix surfaces with defined chemical conditions; (3) co-
culturing ESCs with other cell types (Keller 2005).   
 
1.5.2  ESC as a Cell Source for Endothelial Regeneration 
Number of studies successfully generated vascular lineage-committed cells from 
ESCs. The commonly used strategy is a stepwise protocol to differentiate ESCs first 
towards mesoderm specification and then vascular progenitor cells and finally 
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mature vascular cells including EC and SMC. CD34, Sca-1, and VEGFR2 are widely 
used markers to identify the vascular progenitor cells derived from ESCs which can 
give rise to both EC and SMC that are further capable of producing vessel-like 
structures (Yamashita, Itoh et al. 2000, Xiao, Zeng et al. 2006, Ferreira, Gerecht et al. 
2007, Xiao, Zeng et al. 2007) (Figure 1.8). 
Human ESC is considered to be a promising source for functional ECs for further 
therapeutic applications. By using the EB formation model of human ESCs, 
endothelial lineage cells can be isolated and propagated at different time points along 
differentiation. Levenberg et al. reported that CD34-positive or PECAM-1-positive 
cells, sorted from 10 to 13-day old EBs followed by culturing in VEGF 
supplemented EGM-2 media, could give rise to functional ECs (Levenberg, Golub et 
al. 2002, Levenberg, Ferreira et al. 2010). Another study segregated PECAM-1-
positive, Flk-1-positive, VE-Cadherin-positive, and CD45-negative cell population 
from day 10 human EB and demonstrated that these precursor cells could commit 
into functional ECs in endothelial-inducing conditions containing pituitary extracts 
and VEGF (Wang, Li et al. 2004). Although isolating endothelial lineage cells from 
EB of different stages is a relatively straightforward method, human EBs are difficult 
to handle and the efficiency of EC differentiation is generally low (1%-3%).   
Another approach is to co-culture human ESCs with feeder cells to induce 
endothelial lineage generation. Upon culturing on mouse embryonic fibroblasts in 
differentiation media for 10 days, 5-10% of differentiating human ESCs started to 
express CD34 which represented a vascular progenitor population. Sorted CD34-
positive cells were capable of differentiating into ECs in endothelial growth media 
(Wang, Au et al. 2007). Other methods including co-culture on OP9, S17, M210 and 
other mouse fibroblasts feeder cells could also successfully induce CD34-positive 
vascular progenitor population and further mature functional ECs (Woll, Morris et al. 
2008, Hill, Obrtlikova et al. 2010). However, one major obstacle associated with this 
kind of approach is the possible contamination of animal products to human cells.    
Many groups also established feeder cell-free monolayer culture system to efficiently 
generate ECs from human ESCs on acellular matrix. After seeding human ESCs on 
Matrigel and treating with bone morphogenetic protein 4 (BMP4) and inhibitors for 
MEK/ERK pathway for 3 days, ESCs differentiated into mesoderm-lineage cells 
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expressing T and WNT3. Additional 6 days treatments with VEGF and bFGF 
induced CD34-positive cells arising from the whole population. These CD34-
positive progenitor cells could further differentiate into functional ECs when 
cultured in EGM-2 supplemented with VEGF and bFGF (Park, Jun Koh et al. 2010). 
Another study showed that culturing human ESCs on fibronectin with defined 
endothelial differentiation media for 14-21 days could stimulate the generation of 
tube-forming ECs (Kane, Meloni et al. 2010).    
In general, human ESC derived EC (ESC-EC) shares key features with mature EC as 
the expression of a set of typical EC markers and endothelial physiologically 
relevant functions such as angiogenesis and vasculogenesis capacity, NO synthesis 
and release, acetylated-LDL uptake, activation by inflammatory cytokines (Wong, 
Huang et al. 2012). Furthermore, human ESC-ECs display therapeutic potential in 
various animal disease models. For example, using the mouse hindlimb ischaemia 
model, Cho et al. showed human ESC-ECs could improve blood perfusion and limb 
salvage by promoting postnatal neovascularisation (Cho, Moon et al. 2007). Another 
study demonstrated that human ESC-ECs improved cardiac function and reduced 
fibrotic scar tissue in a rat model of myocardial infarction (Prado-Lopez, Conesa et 
al. 2010).  
  




ESC can be differentiated towards vascular lineages through three 
approaches: (A) EB formation; (B) co-culture with feeder cells; (C) culture 
with defined chemical conditions. The vascular lineage inductions are usually 
based on the combined strategy of vascular marker selection and chemical 
condition stimulation. Figure is adapted from (Hynes 2008, Descamps and 
Emanueli 2012). 
 
Although ESC show strong potential for therapeutic purposes, the clinical 
applications of ESC-derived cells is procrastinated because of several major issues 
including ethical dilemma, tumourigenesis risk and immunological barriers. Due to 
these obstacles, ESC-ECs have not been tested in any clinical circumstances with 









1.6   Induced Pluripotent Stem Cell (iPS Cell) and 
Endothelial Regeneration 
1.6.1  The Generation of iPS cell 
In 2006, Takahashi and Yamanaka first described the process of converting a lineage 
committed somatic cell back to the pluripotent state by simultaneously 
overexpressing four transcription factors Oct4, Sox2, Klf4 and c-Myc using viral 
vectors (Takahashi and Yamanaka 2006). This Nobel Prize-winning hallmark study 
successfully reprogrammed mouse fibroblasts to a new type of pluripotent cell that 
highly resembled mouse ESC in morphology, proliferation, gene expression and 
DNA methylation patterns. The newly generated cell population was termed 
“induced pluripotent stem cell” or iPS cell (Figure 1.9). 
The following year, the derivation of human iPS cell from human fibroblast was 
achieved by using similar strategy. Yamanaka’s group generated human iPS cell 
with the identical set of four transcription factors for the generation of mouse iPS 
cell (Takahashi, Tanabe et al. 2007). At the same time, Thomson’s group managed to 
produce human iPS cells using another combination of factors of OCT4, SOX2, 
NANOG and LIN28 (Yu, Vodyanik et al. 2007). Human iPS cell exhibit the cellular 
characteristics that are highly similar to human ESC. 
Since then, iPS cells have been successfully generated from different somatic cell 
types with different combinations of reprogramming factors and various induction 
methods, which proved the universality of the concept of cell reprogramming 
(Yamanaka 2012). Till now, a variety of mouse or human cell types have been used 
to generate iPS cells such as neural progenitor cells, keratinocytes, hepatocytes, B 
cells (Stadtfeld, Brennand et al. 2008, Stadtfeld, Nagaya et al. 2008, Zhu, Li et al. 
2010). Key transcriptional factors including Oct4, Sox2, Klf4, c-Myc, Nanog, and 
Lin28 were demonstrated to be crucial in inducing iPS cell, although different 
permutation and combination of these factors can be applied. Regarding gene 
delivery strategy, retroviral or lentiviral vectors were initially used to deliver genes 
into somatic cells for iPS cells generation. However, viral transfection might lead to 
unpredictable genetic dysfunction or insertion mutagenesis (Kaji, Norrby et al. 2009). 
Therefore, methods to generate iPS cells without viral integration have been 
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explored including using plasmid, adenovirus, synthesised RNAs, piggyback 
transposon, and chemicals and small molecules (Yamanaka 2012). 
 
1.6.3  iPS cell-derived EC (iPS-EC) for Vascular 
Regeneration 
IPS cell have the potential to differentiate towards vascular cell lineages including 
SMC and EC. Due to the similarity shared by iPS cell and ESC, ECs can be derived 
from iPS cell by using similar strategies to differentiate ESC to the endothelial 
lineage: EB formation, coculture with feeder cells or defined chemical condition. In 
2009, two groups first showed that ECs could be generated from human iPS cells 
with comparable efficiency with ESC-derived ECs. Choi et al. cocultured different 
human iPS cell lines with OP9 feeder cells for 8 days and then selected CD34- and 
PECAM-1- double positive cell population which could give rise to functional ECs 
after 7 days under endothelial-promoting culture conditions (Choi, Yu et al. 2009). 
Using a similar approach, Taura et al. cocultured human iPS cells with OP9 feeder 
cells for 10 days and observed the emergence of a VEGFR2-positive population with 
EC differentiation capacity (Taura, Sone et al. 2009). Endothelial lineage-commited 
cells could also be derived from EB formed by iPS cells (Rufaihah, Huang et al. 
2011). Most commonly, feeder-free culture systems with the combination of 
different culture substrates and chemical conditions have been successfully applied 
to induce ECs from iPS cells (Wong, Huang et al. 2012).  
IPS-EC displays similar features with mature EC at the genetic and functional level. 
A major advantage of using iPS cells as EC source is the abundant origins of iPS cell 
and the potential to generate patient individualised ECs that bypass the 
immunogenicity and ethical issues. IPS-ECs have been tested in peripheral vascular 
disease mouse model to show their neoangiogenic capacity that led to the 
improvement of blood perfusion of ischaemic tissue (Rufaihah, Huang et al. 2011).  
In spite of the fact that iPS cell start a new era of regeneration medicine, the issue 
with possible tumour formation hangs dark shadow over their further clinical 
applications. The fact that many reprogramming factor cocktails contain oncogenes 
and many gene delivery methods use viral vectors raise the risk of tumour formation 
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in vivo (Grabel 2012). In addition, iPS cell exhibit more genetic and epigenetic 
instability compared to ESC due to the artificial reprogramming process (Pera 2011). 
Therefore, there is still a long way to go before the mature utilisation of iPS cells at 
the bedside. 
 
Figure  1.9  The generation and application of iPS cell 
iPS cell can be derived from mouse/human somatic cells via reprogramming 
with transcription factors. Mouse iPS cells can differentiate to distinct cell 
types of all germ layers as well as the entire mice. Differentiated cells from 
human iPS cells have the potential to be used for in vitro disease modelling 
and drug screening, transplantation and other applications. Figure is adapted 




1.7   Direct Cell Lineage Reprogramming and 
Endothelial Regeneration 
The first report of direct transdifferentiation from one mature cell type to another 
was the conversion of fibroblast to skeletal muscle cell via forced ectopic expression 
of transcriptional factor MyoD1 (Davis, Weintraub et al. 1987). However, the study 
of cell lineage conversion progressed slowly until the hallmark study of iPS cell 
generation and the development of cell reprogramming techniques (Takahashi and 
Yamanaka 2006). One type of somatic cells can be reverted to iPS cell first, and then 
differentiate towards another type of somatic cells. Nevertheless, this strategy is time 
consuming and raises tumour-forming hazards. To avoid issues associated with iPS 
cell generation, there was a revival in exploiting direct cell fate conversion between 




Figure  1.10 The differentiation potential and epigenetic states of cells 
at different stages of development 
The Waddington epigenetic model is used here to illustrate different states of 
cells and their mutual conversion. Cell differentiation refers to 
pluripotent/multipotent cells differentiate into lineage-committed cells. In 
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contrary, cell reprogramming describes the conversion of differentiated cell 
towards another cell type, either go back to the pluripotent state or to another 
differentiated cell type. Alteration of cell fates happens together with 
extensive epigenetic changes of global gene expression. Figure is adapted 
from (Hochedlinger and Plath 2009). 
 
Presently, based on the use of transcription factors, there are two dominant 
reprogramming strategies to achieve direct cell-lineage conversion. One is through 
introducing various combinations of target cell type-specific transcription factors to 
directly drive cell lineage switch. In 2008, a case of in vivo study demonstrated the 
direct conversion of pancreatic exocrine cell to functional β-cell by injecting 
adenoviruses encoding three transcription factors Nng3, Pdx1, and Mafa into adult 
mice pancreas (Zhou, Brown et al. 2008). In 2010, via overexpressing Gata4, Mef2c, 
and Tbx5, Srivastava’s group directly reprogrammed cardiac fibroblast into 
functional cardiomyocyte in vitro (Ieda, Fu et al. 2010).  The same group 
subsequently showed the in vivo reprogramming of murine cardiac fibroblast into 
cardiomyocyte through intra-myocardial injection of the identical set of the three 
transcription factors (Qian, Huang et al. 2012). In addition, a variety of reports 
provided evidence of directly reprogramming fibroblast into other cell types 
including neurons, hepatocytes, etc (Vierbuchen, Ostermeier et al. 2010, Huang, 
Zhang et al. 2014).  
Direct cell lineage reprogramming has also been applied to generate ECs from other 
somatic cell types by ectopic expression of EC-specific transcription factors. ETS 
transcription factors are potent regulators for almost all typical endothelial markers 
(Dejana, Taddei et al. 2007). Ginsberg et al. first reported the direct reprogramming 
of human amniotic fluid-derived cells into ECs by ETS transcription factors ETV2, 
FLI1, and ERG1 together with TGF-β suppression (Ginsberg, James et al. 2012). 
Within this year, there were two important studies published of directly converting 
fibroblasts into ECs through overexpressing selected endothelial related transcription 
factors. Han et al. converted adult mouse fibroblast into EC using a cocktail of five 
transcription factors: Foxo1, Er71, Klf2, Tal1 and Lmo2 (Han, Chang et al. 2014). 
Another study showed that solely overexpressing one ETS transcription factor ETV2 
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is sufficient to induce functional ECs from human fibroblasts (Morita, Suzuki et al. 
2015).  
Another fast and efficient approach to modulate cell fate is based on the use of iPS-
generating pluripotency factors such as Oct4, Sox2, Klf4, Nanog, etc to erase lineage 
particular signatures and reactivate repressed epigenetic network as a first step, but 
with shorter reprogramming time and different culture conditions to avoid the full 
induction of pluripotency. After this step, cells revert to an intermediate plastic state 
which permits further manipulations towards the desired cell types. Short-term 
reactivation of reprogramming genes Oct4, Sox2, and Klf4 plus chemically defined 
media and cardio-inductive growth factor BMP4 converted embryonic and adult 
fibroblasts to functional cardiomyocytes. During the conversion, the role of 
reprogramming factors is to erase the original cell identity via epigenetic 
mechanisms, instead of directly activate cardiomyocyte-specific genes (Efe, Hilcove 
et al. 2011).  
For the lineage conversion towards an endothelial fate, a study showed that by 
overexpressing Oct4, Sox2, Klf4 and c-Myc for 8 days, fibroblasts were reverted to 
an intermediate CD34-positive mesoderm progenitor state marked by which could be 
further differentiated towards endothelial or smooth muscle lineages under different 
stimulating conditions (Kurian, Sancho-Martinez et al. 2013). Our lab demonstrated 
the generation of functional endothelial- and smooth muscle-like cells from human 
fibroblast through short-term reprogramming with Oct4, Sox2, Klf4, and c-Myc 
which was followed by respective culture conditions (Margariti, Winkler et al. 2012, 
Karamariti, Margariti et al. 2013). 
Beyond the use of transcription factors, recent studies exploited novel approaches 
including microRNAs (miRNAs), epigenetic regulators, signal pathways modulators 
and other small molecules to drive cell lineage conversion (Figure 1.11). 
Conditionally adding these small molecules into the transcription factors cocktail can 
boost the efficiency of cell fate switching. Furthermore, some combinations of the 
small molecules alone could drive direct lineage conversion without the ectopic 
overexpression of transcription factors (Xu, Du et al. 2015).  





Figure  1.11 Direct cell lineage conversion strategies 
Currently, there are two dominant reprogramming strategies to achieve direct 
cell-lineage conversion. One is through introducing various combinations of 
transcription factors specific to target cell type to directly drive the cell 
lineage switch. Another approach is based on the use of iPS cell generating 
transcription factors with specific culture conditions. The use of microRNAs 
(miRNAs), epigenetic regulators, signal pathways modulators and other 
small molecules to carry out direct reprogramming have also been exploited.  
Figure is adapted from (Xu, Du et al. 2015). 
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Reprogramming Conditions In vitro  Characterisation  In vivo application Reference 




FLI1, ERG1 (Day 
0-Day 21) 
ETV2 (Day 0-Day 
14) 








In vitro tubulogenesis 
In vivo vessel tube 
formation assay; 
In vivo organ-specific 
vascular education (Liver 
sinusoidal ECs) 
(Ginsberg, 






Klf2, Tal1, and 
Lmo2 





VWF, Tie2, ICAM2; Ac-
LDL uptake; NO 
production; In vitro 
angiogenesis 
Enhancement of limb 
perfusion and salvage by 
implanting into murine 
model of ischaemic 
hindlimb  
(Han, Chang 








Collagen I-coated dish; EGM-2 
media with 10 ng/ml VEGF 
and bFGF;  
PECAM-1-positive cell sorting 




VWF, CD34, Tie2; 
Ac-LDL uptake; In vitro 
angiogenesis 
In vivo angiogenesis assay 
with Matrigel plugs; 
Increase of blood flow ratio 
in murine hindlimb 
ischaemia model  
(Morita, 
Suzuki et al. 
2015) 









KLF4, c-MYC (4 
days) 
Collagen-IV coated dish; 
Reprogramming media with 
10 ng/ml bFGF for 4 days, 
then EGM-2 media with 25 
ng/ml VEGF for 6 days 
Endothelial marker expression: 
PECAM-1, VE-Cadherin, 
eNOS, VWF, VEGFR2; 
Ac-LDL uptake; In vitro 
angiogenesis 
In vivo angiogenesis 
assay with Matrigel 
plugs; Increase of blood 






















and 367)(8 days) 
Collagen-I coated dish; 
Plastic induction media for 8 
days, then Mesoderm 
induction media for 8 days, 
then CD34-positive cell 
selection followed by EGM-2 
media for 8 days  
Endothelial marker expression: 
VE-Cadherin, VWF, VEGFR2, 
Endoglin; arterial-, venous-, 
and lymphatic-subtype EC 
markers; 
Ac-LDL uptake; In vitro 
angiogenesis 
In vivo angiogenesis 











DMEM/Stemline (1:1) media 
for 7 days, then Stemline 
media with BMP4, VEGF, 
bFGF for 21 days 
Endothelial marker expression: 
VE-Cadherin, PECAM-1, 
VWF; 
Ac-LDL uptake; In vitro 
angiogenesis 
In vivo angiogenesis 
assay with Matrigel 
plugs 
(Li, Huang et 
al. 2013) 






3 (TLR3) agonist 
Poly I:C (7 days) 
Induction media 
(DMEM+7.5%FBS+7.5%KO 
serum replacement) for 7 days, 
then EGM-2 media with 





Ac-LDL uptake; NO 
production; In vitro 
angiogenesis 
In vivo angiogenesis assay 
with Matrigel plugs; 
Increase of blood flow ratio 
in a murine hindlimb 
ischaemia model  
(Sayed, 




Similar to iPS cell applications, direct cell conversion technique can also be used for 
patient-specific disease modelling and drug screening. Moreover, an exceptional 
advantage of direct lineage conversion over iPS cell is the application potential of 
direct in vivo lineage reprogramming for cell replacement therapy, which avoids the 
unstable long term of in vitro cell culture, tumour-forming risks and the technical 
obstacles for cell transplantation. For example, direct injection of transcription 
factors cocktail Gata4, Mef2c and Tbx5 into the infracted cardiac area could 
reprogramme resident non-myocytes into cardiomyocyte-like cells with improved 
cardiac function (Qian, Huang et al. 2012).  The in vivo regeneration of functional 
insulin-producing pancreatic β-cells from other types of pancreatic cells has been 
reported by several studies for their potential benefits for treating diabetes (Zhou, 





1.8 Mechanisms of Cell Reprogramming 
1.8.1  Phases of Reprogramming 
Since the establishment of reprogramming technique to generate pluripotent iPS cells 
from lineage-committed somatic cells, researchers have endeavoured to exploit the 
underlying molecular mechanisms. In general, the complex transcriptional and 
epigenetic changes of the whole genome occur during the reprogramming to reverse 
the differentiated cells back to the pluripotent state. Genome-wide analyses of the 
cell populations at different time points during the reprogramming process revealed 
three phases for successful iPS cell generation: initiation, maturation, and 
stabilisation (Samavarchi-Tehrani, Golipour et al. 2010). Each phase characterised 
by the expression of a distinct group of genes. The initial phase is marked by a 
mesenchymal-to-epithelial transition. Interestingly, the signature genes associated 
with the maturation and stabilisation phases are not pluripotency regulators, but 
rather the genes related to cell cycle, cytoskeletal dynamics and signalling pathways 
(Golipour, David et al. 2012). Another study also used genome-wide analyses to 
show that there were two major gene expression changing waves. One occurred 
between 0-3 days, and the second wave happened between day 9 till the end (Polo, 
Anderssen et al. 2012). Genes responsible for proliferation and metabolic changes 
were activated and the genes related to fibroblast identity were suppressed during the 
first wave. The second wave was characterised by the expression of genes related to 
stem cell identity establishment and epigenetic remodelling. These cell population-
based studies suggested that reprogramming is a multi-step process with 
transcriptome resetting. 
In addition, single-cell studies indicated a stochastic model to describe the 
reprogramming process: reprogramming factors start a series of probabilistic events 
that finally lead to only a tiny fraction of cells becoming iPS cells (Hanna, Saha et al. 
2009). Buganim et al. showed that cell reprogramming process has an early 
stochastic and a late hierarchic phase by using single-cell gene expression analysis. 
In the later stage, the activation of Sox2 starts a sequence of gene expression and 
eventually results in the acquisition of pluripotency (Buganim, Faddah et al. 2012). 
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1.8.2  Roles of Reprogramming Factors 
In order to elucidate the molecular mechanisms regulating iPS cell generation, it is 
important to understand the roles of the key reprogramming factors Oct4, Sox2, Klf4, 
and c-Myc in stimulating pluripotency. All these four factors are vital in the 
establishment and maintenance of pluripotent state during early embryonic 
development.  
Oct4 is a POU domain-containing transcription factor encoded by Pou5f1 (Scholer, 
Ruppert et al. 1990). It is an essential pluripotency regulating gene expressed by 
early embryo cells. Oct4-deficient embryos failed to develop pluripotent cells within 
the inner cell mass (Nichols, Zevnik et al. 1998). Interestingly, the expression of 
Oct4 needs to be controlled at a precise level to maintain the pluripotency of ESCs. 
Either slight suppression or increase of Oct4 expression leads to distinct 
differentiation fates of ESCs to mesoderm, endoderm or ectoderm (Niwa, Miyazaki 
et al. 2000).  
Oct4 is arguably the most important factor to induce pluripotency. Oct4 itself can 
successfully induce pluripotency from somatic cell types that endogenously express 
canonical reprogramming factors (Kim, Greber et al. 2009, Kim, Sebastiano et al. 
2009, Tsai, Bouwman et al. 2011). Single overexpression of Oct4 combined with 
small chemical molecules could reprogramme fibroblast into iPS cell (Zhu, Li et al. 
2010).  
SRY (sex-determining region Y)-related high-mobility-group (HMG)-box 
protein-2, also known as Sox2, is a Sox family transcriptional factor involved in the 
maintenance of ESC pluripotency (Avilion, Nicolis et al. 2003). Sox2 and Oct4 act as 
partners and cooperatively regulate the expression of ESC-specific genes such as 
UTF1, Fgf4 and Fbx15 (Scaffidi and Bianchi 2001). Sox2-knockout mice die as 
embryos due to the epiblast lineage failure (Avilion, Nicolis et al. 2003).   
The switching on of endogenous Sox2 expression at the late phase of reprogramming 
marks the cells that are determined to become iPS cells (Buganim, Faddah et al. 
2012). Sox2 governs the establishment of the core pluripotency network in iPS cell.  
Krüppel-like factor 4 (Klf4) is expressed in different tissues and widely takes part 
in regulating cell development, differentiation, proliferation and apoptosis 
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(McConnell, Ghaleb et al. 2007). Klf4 is demonstrated to be required for maintaining 
the pluripotency of ESCs (Jiang, Chan et al. 2008).  
c-Myc is a transcription factor involved in various cellular processes including cell 
growth, cell-cycle regulation, proliferation and differentiation (Schmidt 1999). c-
Myc participates in the long-term self-renewal of ES cells in culture (Cartwright, 
McLean et al. 2005).  
 
The clear function of these four transcription factors during cell reprogramming has 
not been clarified. In general, these four factors act as pioneer factors for 
remodelling the epigenome. They open up chromatin regions and bind to the 
promoters of a wide range of genes to guide further epigenetic modification 
(Buganim, Faddah et al. 2013). Interestingly, in addition to the genes that they 
usually regulate in ESCs, they also bind to the genes that are not occupied by these 
factors in ESCs (Soufi, Donahue et al. 2012). This promiscuous binding 
phenomenon indicated that the roles of the reprogramming factors may be cell type 
dependent. Oct4, Sox2, and Klf4 collectively form a transcriptional network that 
associates with repressing somatic gene expression and upregulating pluripotent 
genes during reprogramming. c-Myc mainly acts as an transcriptional amplifier at all 
active promoters to enhance the kinetics and efficiency of reprogramming (Papp and 
Plath 2011). 
The fact that Oct4, Sox2, Klf4, and c-Myc are able to open chromatin and induce cell 
plasticity early in reprogramming support the direct lineage conversion strategy to 
transiently ectopic express these four factors to dedifferentiate the somatic cell back 





1.8.3 Mesenchymal-to-epithelial transition and Cell 
Reprogramming 
During the phase study for cell reprogramming, a biological process named 
Mesenchymal-to-Epithelial Transition (MET) has emerged to be a key event for the 
initial stage of somatic cell reprogramming.  
Mesenchymal-state cells and epithelial-state cells are two major animal cell 
classifications. Epithelial-state cells are closely bound with each other by a variety of 
cell-cell junctions and align in an apical-basal polarity pattern on the basement 
membrane. Epithelial-state cells usually express high level of cell junction markers 
especially E-Cadherin. On the contrary, mesenchymal-state cells represent a loose 
connected type of cells that lack polarity and can migrate through extracellular 
matrix (ECM). Typical mesenchymal markers include cytoskeleton components and 
ECM binding proteins like Fibronectin, Vimentin, N-Cadherin, etc. A phenotypic 
and morphologic switch from epithelial-state cell to mesenchymal-state cell is called 
Epithelial-to-Mesenchymal Transition (EMT), which extensively participates in 
different biological processes including embryonic development and cancer 
progression (Li, Pei et al. 2014). Some key transcription factors including Snai1, 
Twist, Slug, ZEB have been identified to promote EMT by repressing epithelial-
related gene expression (Kalluri and Weinberg 2009). MET is the reverse process of 
EMT and is characterised by the upregulation of epithelial-related genes especially 
E-Cadherin and the establishment of cell-cell adhesion along with the 
downregulation of mesenchymal-related genes. MET has been implicated during 
embryogenesis and cancer progression (Chaffer, Thompson et al. 2007). Recent 
studies demonstrated the novel role of MET in somatic reprogramming.  
Based on the temporal changes of global gene expression, an important study in 
2010 divided the mouse embryonic fibroblast (MEF) to iPS cell reprogramming into 
three main phases as initiation, maturation and stabilisation. Among which, the 
initiation stage was characterised by the MET driven by bone morphogenetic 
proteins (BMPs) signalling (Samavarchi-Tehrani, Golipour et al. 2010). At the same 
time, another group demonstrated the requisite role of MET at early stage for 
successful mouse iPS cells generation that was regulated by the interactions with 
reprogramming transcription factors and TGF-β signalling (Li, Liang et al. 2010).  
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During the generation of human iPS cell from fibroblast, the participation of MET 
was confirmed by a study that suggested the reprogramming promoting function of 
miRNA-302 and miRNA-372 by partly acting on MET (Liao, Bao et al. 2011). Later 
on, a comprehensive proteomics analysis for the whole course of reprogramming 
confirmed the existence of MET during early phase at protein level (Hansson, Rafiee 
et al. 2012).Till now, many studies have proved the occurrence of MET at early 
stage for successful somatic reprogramming in different cell systems .  
Detailed mechanism of the involvement of MET in reprogramming was further 
investigated (Figure 1.12). Li et al. discussed that reprogramming factors Sox2, Klf4, 
Oct4 and c-Myc collectively suppress TGF-β signalling which leads to the repression 
of Snai1 followed by the activation of E-Cadherin. The same study also showed that 
Klf4 can directly activate several epithelial genes including E-Cadherin (Li, Liang et 
al. 2010). The direct binding of Klf4 to E-Cadherin promoter region to 
transcriptionally enhance gene expression is also confirmed in the breast cancer cell 
line (Yori, Johnson et al. 2010). E-Cadherin-mediated cell-cell contact formation has 
been shown to be a critical step for the induction of pluripotency from somatic cells 
(Chen, Yuan et al. 2010). E-Cadherin can even directly replace Oct4 in 
reprogramming transcription factors cocktail to achieve successful iPS generation 
(Redmer, Diecke et al. 2011). It also has been shown that Oct4 and Sox2 could 
directly activate miRNA-200 which subsequently inhibited ZEB2 and promoted 




Figure  1.12  MET during the early stage of reprogramming 
MET is a vital event at the initial stage of reprogramming for successful iPS 
cell generation. Reprogramming factors coordinate a comprehensive 
molecular network that leads to the occurrence of MET and the further 
induction of pluripotent genes. Figure is adapted from (Polo and 
Hochedlinger 2010). 
 
In addition, recent studies indicated the involvement of MET during the early stage 
of direct cell lineage conversions, which suggested a more universal role of MET 
process in modulating cell-identity plasticity. Ectopic introduction of transcription 
factors Nr5a1, Wt1 and Dmrt1 into fibroblasts could initiate MET as a first step and 
finally convert the cells towards embryonic sertoli-like cells (Buganim, Itskovich et 
al. 2012). Another recent report on directly reprogramming fibroblasts into induced 
cardiomyocytes demonstrated the involvement of MET (Muraoka, Yamakawa et al. 
2014). Promoting MET through suppressing Snai1 by miR-133 could profoundly 




1.9 Comparison of Different Cell Sources for 
Endothelial Regeneration Purpose 
Because of the critical role of EC plays in cardiovascular physiological and 
pathological conditions, it is of great importance to investigate cells sources that can 
regenerate functional ECs and further obtain therapeutic value. Early studies 
attributed endothelial repair exclusively to the proliferation and migration of locally 
neighbouring ECs after vascular damage (Clopath, Muller et al. 1979). Since the 
development of the concept of stem cells from late 1990s, other cell sources have 
been considered to promote endothelial rejuvenation. For now, three major stem cell 
types are regarded to be promising therapeutic options for endothelial regeneration: 
EPC, ESC, and iPS cell. In addition, the emergence of direct cell reprogramming 
provides novel powerful cell sources. The advantages and deficiencies of these cell 
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Many promising alternative cell populations for endothelial regeneration have been 
explored. However, all these cell types have unsolved problems respectively. 
Therefore, it is still of great interest to explore other cell types that can regenerate 





1.10   Hypothesis, Aims, and Experimental Design of 
the Study 
Rationale: Endothelial denudation and dysfunction underscore many cardiovascular 
pathological changes and the development of vascular disease. In view of the fact 
that the spontaneous EC regeneration is a slow and insufficient process, it would be 
of great significance to explore alternative cell sources that are capable of endothelial 
regeneration. Stem cells represent promising sources for endothelial regeneration. 
However, each cell source has its own drawbacks (described in detail in section 1.9). 
Recent development of cell reprogramming that convert somatic cells directly to 
other cell types provide new powerful approaches to achieve endothelial 
regeneration. The original idea to test the feasibility of using SMCs as a new cell 
source for endothelial regeneration is based on following two points: 
(1) Significance: human SMC is an important vascular cell type that underlies 
the endothelium and composes the majority of vessel wall. In response to 
endothelial injury, SMCs proliferate and migrate towards tunica intima and 
accumulate underneath the injured endothelium (Gomez and Owens 2012). If 
SMC can be converted into functional EC, it may represent a promisingly 
abundant cell source for in situ re-endothelialisation.  
 
(2) Feasibility: developmentally, SMC and EC are both of mesoderm origin. 
SMCs can be derived from multiple types of progenitor cells during 
embryonic and postnatal development, among which the existence of 
vascular progenitors characterised with CD34-positive or VEGFR2-positive 
that can give rise to both SMC and EC has been reported by many studies 
(Yamashita, Itoh et al. 2000, Moretti, Caron et al. 2006, Ferreira, Gerecht et 
al. 2007, Majesky 2007). The fact that SMC shares common progenitor with 
EC under certain circumstances implies that SMC can be ontogenetically 
related to EC and share more epigenetic similarity compared to other cell 
types like fibroblast that has been used to induce ECs (Margariti, Winkler et 
al. 2012, Kurian, Sancho-Martinez et al. 2013, Morita, Suzuki et al. 2015).  
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Therefore, the hypothesis of this study is to investigate whether functional EC can 
be derived from human SMC by reprogramming through a plastic vascular 
progenitor state.   
The aims of this study are: 
(1)  To explore the feasibility of directly converting human SMC towards 
endothelial lineage through reprogramming. 
(2) Based on the establishment of the protocol, to test the function of the SMC-
derived ECs in vitro and in vivo. Especially their possible application in 
vascular disease models. 
(3) To explore the possible mechanisms underlying the derivation of ECs from 
SMCs.  
Experimental Design: A combined protocol of reprogramming and differentiation 
will be applied in this study. In a similar way as previous studies to convert human 
fibroblasts into functional ECs using short time reprogramming (Margariti, Winkler 
et al. 2012), SMCs will be reprogrammed by four transcription factors OCT4, SOX2, 
KLF4, and c-MYC for a short term to induce a plastic intermediate state. Then, based 
on the established protocols of differentiating pluripotent or progenitor cell to 
endothelial lineage, short term reprogrammed-SMCs will be transferred to 
endothelial-promoting conditions to induce the generation of endothelial-like cells 
(Figure 1.13). Subsequent studies on endothelial functions and underlying 
mechanisms will be performed based on the establishment of the protocol.  
 
Figure 1.13  Schematic overview of the basic strategy to derive EC from 
SMC 
A combined protocol of reprogramming and differentiation will be applied to 











Cell culture reagents, chemicals, buffers and kits used in this thesis are presented in 
Table 2.1. 
Table 2.1  Cell culture reagents, chemicals, buffers and kits 
















SmGM-2 Basal Medium Lonza CC-3181 
SmGM-2 SingleQuot Kit Lonza CC-4149 
EGM-2 Basal Medium Lonza CC-3156 
EGM-2 SingleQuot Kit Lonza CC-4176 
KnockOut DMEM/F-12 life technologies 12660-012 
KnockOut Serum Replacement life technologies 10828-028 
DMEM, high glucose, NEAA, no 
glutamine 
life technologies 10938-025 
Fetal Bovine Serum (FBS) life technologies  
Penicillin/Streptomycin Sigma-Aldrich P4333 
Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich D8537 
Gelatin Solution 2% Sigma G1393 
Mouse Collagen Type IV BD Biosciences 354233 
0.05%Typsin-EDTA life technologies 25300-054 
MEM NEAA 100 Invitrogen 11140 
Human FGF-2  MACS 130-093-837 
Recombinant Human VEGF 165 R&D 
SYSTEMS 
293-VE-010 
β-Mercaptoethanol Invitrogen 31350-010 
 
Dimethyl Sulfoxide Sigma D5879 















Ampicillin Sigma-Aldrich A5354 
FUGENE® HD Transfection Reagent  Promega E2311 
Polybrene Infection/Transfection Reagent Merck Millipore TR-1003-G 
Matrigel Basment Membrane Matrix BD Biosciences A6661 
10% SDS Stock Solution Severn Biotech CAS 151-
21-3 
RIPA lysis buffer Santa Cruz sc-24948 
Bio-Rad Protein Assay Dye Reagent 
Concentrate 
Bio-Rad 5000006 
Precision Plus Protein Ladder Bio-Rad 161-0374 
Tween 20 Sigma-Aldrich P2287 
NuPAGE® SDS Running Buffer life technologies NP0001 
NuPAGE® Transfer Buffer life technologies NP0006 
ECL Western Blotting Detection 
Reagents 
Fisher Scientific RPN2106 
Paraformaldehyde Sigma-Aldrich P6148 




p24 Antigen ELISA Kit Perkin Elmer 0801111 
NucleoBond Xtra Midi Macherey-Nagel 740410 
Basic SMC Nucleofector® Kit Lonza VPI-1004 
CD34 MicroBead Kit, human Miltenyi Biotec 130-046-702 
QIAshredder Qiagen 79656 
RNeasy Mini Kit Qiagen 74106 
QuantiTect Reverse Transcriptase Kit Qiagen 205314 
QuantiFast SYBR Green PCR Kit Qiagen 74106 







2.2  Methods 
2.2.1 Cell Culture   
2.2.2.1 Human Umbilical Artery Smooth Muscle Cell (Human 
UASMC) Culture 
Human Umbilical Artery Smooth Muscle Cell (UASMC) line (Lonza, CC-2579) was 
used as the SMC population in this study and hereinafter referred to SMC. Culture 
flasks were pre-coated with 0.05% Gelatin (from 2% Gelatin Solution in PBS, both 
from Sigma Aldrich) for 30 minutes. SMCs were cultured on Gelatin coated flasks in 
Smooth Muscle Cell Basal Medium (SmBM, Lonza) supplemented with SmBM plus 
SingleQuots of Growth Supplements (contain EGF; Insulin; bFBF; 5% FBS; 
Gentamicin/Amphotericin-B. Lonza). Cells were maintained in a humidified 
incubator with 5% CO2 at 37ºC. 
SMCs were passaged every other day at a ratio of 1:2. Cells were washed in PBS 
once before Trypsin (0.05% Trypsin-EDTA 1×,GIBCO) was added. The flasks were 
gently rocked 10-20 times and then the trypsin was discarded. The flasks were kept 
in the 37ºC incubator for 2-3 minutes until cells detached from the flasks. The cells 
were then resuspended and mixed with medium and transferred to the new Gelatin 
coated flasks. Cells up to passage 15 were used in this study. 
The pictures of live cell morphology were taken with Nikon Eclipse TS100 light 
microscope and Nikon ELWD 0.3/OD75 camera. 
 
2.2.2.2 Human Embryonic Kidney (HEK) 293T Cell Culture 
HEK 293T (ATCC, CRL-11268) cells were cultured in DMEM media with 10% 
FBS in a humidified incubator with 5% CO2 at 37ºC. 293T cells were passaged every 
other day at a ratio of 1:4. Trypsin was used to detach the cells for passaging.  
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2.2.2 Overexpressing the Four Reprogramming Factors in 
SMCs using Lentivirus TetO-OSKM 
2.2.2.1  Lentiviral TetO -OSKM Construction 
A lentiviral construct TetO-FUW-OSKM (TetO-OSKM) (Addgene, Plasmid 20321) 
containing Oct4, Sox2, Klf4, and c-Myc was used to overexpress the four 
transcription factors in SMCs (Figure 2.1). The four reprogramming factors were 
separated by 2A sequences in a single FUW lentiviral backbone (Carey, Markoulaki 
et al. 2009). The empty TetO vector without the encoding sequences of the four 
factors was used as the negative control vector.  
 
Polycistronic lentiviral vector carries the four reprogramming genes Oct4, 
Sox2, Klf4, and c-Myc. Each reprogramming gene is separated by a different 
2A sequence (Carey, Markoulaki et al. 2009). 
 
2.2.2.2  Lentivirus TetO-OSKM Production in HEK 293T Cell Line 
HEK 293T cells were used to produce lentivirus. 293T cells were co-transfected with 
the lentiviral vector and the packaging plasmids pCMV-dR8.2 and pCMV-VSV-G 
(both from Addgene, Plasmid 8455 and Plasmid 8454) using Fugene HD 
Transfection Reagent (Promega). The supernatant containing the lentiviral particles 
Figure 2.1 Map of the TetO-OSKM vector 
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was harvested 48 hours after transfection. The supernatant was filtered with 0.45 µm 
hydrophilic Polyvinylidene Fluoride (PVDF) membrane filter (Miltenyi Biotec). 
Then the filtered supernatant containing the lentivirus was aliquoted and stored at -
80ºC. The viral tilters were determined using the p24 antigen ELISA (Perkin Elmer). 
The Transducing Unit (TU) was calculated based on the conversion from the 
concentration of p24 to viral titer. For every pg of p24 antigen, there are around 
1×10
4
 physical particles of lentivirus. Based on ELISA results, there is 100 TU for 
every pg of p24 antigen (Barde, Salmon et al. 2010).  
 
2.2.2.3  Infection of SMCs with Lentivirus TetO-OSKM 
For lentiviral infection, SMCs were seeded on 0.05% Gelatin coated petri-dishes 
overnight. The following day the cells were incubated with lentivirus TetO-OSKM 
or control vector (1×10
7
 TU/ml) in complete reprogramming media supplemented 
with 10 μg/ml of polybrene (Merck Millipore) for 16 hours. Subsequently, media 
was changed to fresh reprogramming media. Reprogramming media consist of 
KnockOut DMEM/F12 (life technologies), 20% KnockOut (KO) Serum 
Replacement (life technologies), 0.1mM β-mercaptoethanol, 0.1 mM MEM Non-
Essential Amino Acids (NEAA) (life technologies) and 10 ng/ml basic Fibroblast 
Growth Factor (bFGF) (Miltenyi Biotec). 
 
2.2.3  Overexpressing the Four Reprogramming Factors in 
SMCs using pCAG-OSKM Plasmid 
2.2.3.1  Plasmid pCAG-OSKM Construction 
pCAG-OSKM plasmid (Addgene, Plasmid 20866: pCAG2LMKOSimO) is a 
polycistronic plasmid originally constructed by Kaji et al. in 2009. pCAG-OSKM 
plasmid contains Oct4, Sox2, Klf4 and c-Myc gene coding regions linked by 2A 
peptide sequence driven by CAG enhancer/promoter (Kaji, Norrby et al. 2009) 
(Figure 2.2). The control empty plasmid was generated from pCAG-OSKM plasmid 




Figure 2.2 Map of the pCAG-OSKM plasmid 
Oct4, Sox2, Klf4 and c-Myc gene encoding regions are linked by 2A peptide 
sequences which are driven by a CAG enhancer/promoter in the pCAG 
backbone. The reprogramming cassette is followed by an ires mOrange 
fragment (Kaji, Norrby et al. 2009). 
 
2.2.3.2 Restriction Digestions 
pCAG-OSKM plasmid was linearised by PvuI restriction enzyme (PvuI, New 
England BioLabs) at site 12413. Plasmid was incubated with restriction digestion 
reaction system at 37ºC for 3 hours. After linearisation, plasmid was purified with 
SureClean kit (Bioline). 
 
2.2.3.3  Transfection of SMCs with pCAG-OSKM Plasmid 
Transfection of SMCs with pCAG-OSKM or control plasmid was performed using 
Basic SMC Nucleofector Kit (LONZA) as specified by manufacturer. 2 μg of 
plasmids was used to transfect every 2×10
6
 cells. Cells were first washed with PBS, 
trypsinised, counted and pelleted. 2×10
6
 cells were resuspended with 100 μl 
Nucleofection solution and then the plasmids were added. The mixture was 
transfered to a nucleofection cuvette and placed in the LONZA nucleofection 
machine and the electroporation program for primary SMC line (program A-033) 
was selected. 1ml warm medium was added into the cuvette soon after the 
electroporation and mixed gently. The cell solution was transferred to a 0.05% 
Gelatin coated T25 flask in a drop-wise manner. 
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2.2.4  Cell Reprogramming 
SMCs transfected with the four reprogramming factor-expressing vector or control 
empty vector were maintained in reprogramming media consisted of Knockout 
DMEM/F12 (life technologies), 20% Knockout Serum Replacement (life 
technologies), 0.1 mM β-mercaptoethanol (life technologies), 0.1 mM MEM NEAA 
(life technologies) and 10 ng/ml bFGF (Miltenyi Biotec). Media was changed every 
day. 
 
2.2.5  Cell Differentiation towards an Endothelial Lineage 
Culture flasks were pre-coated with 5 μg/ml Collagen IV (BD mouse collagen IV) in 
PBS for 2 hours at room temperature. After 4 days of reprogramming, partially 
reprogrammed SMCs (PR-SMCs) were transferred to Collagen IV- coated flasks and 
maintained in EGM-2 Basal Media supplemented with EGM-2 SingleQuot Kit 
(contain EGF, IGF-1, VEGF, Ascorbic Acid, Hydrocortisone, bFGF, 5% FBS, 
Gentamicin/Amphotericin-B. Lonza). Additional 25 ng/ml VEGF (Recombinant 
Human VEGF165, R&D was supplemented to the culture media. PR-SMCs were 
cultured under these conditions for 6 days to promote endothelial differentiation. 
Media was changed every other day. SMC-derived ECs (SMC-ECs) were generated 
after 6 days of endothelial differentiation. 
 
2.2.6  Selection and Culture of CD34-positive Cells from 
PR-SMCs 
CD34 MicroBead Kit (Miltenyi Biotec) was used to select CD34-positive cells from 
partially reprogrammed SMCs (PR-SMCs) after 4 day reprogramming. PR-SMCs 
were washed with PBS, trypsinised, counted and pelleted. The cell pellet was 
resuspended in 300 μl of MACS Buffer (PBS contains 0.5% bovine serum albumin 
(BSA) and 2 mM EDTA) to which 100 μl of FcR Blocking Reagent and 100 μl 
CD34 MicroBeads were added. Cell suspension was mixed well and incubated for 
30 minutes at 4ºC. After incubation, cells were washed in 6ml of MACS Buffer, 
pelleted and resuspended in 500 μl of buffer. Cell suspension was applied to the MS 
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MACS separation column. Cells that labelled with CD34 Microbeads binded to the 
column and cells that passed through the column were discarded. The column was 
then washed three times with 500 μl MACS Buffer each time and then removed from 
the separator and placed in a collection tube. 1ml of MACS Buffer was applied into 
the column. The labelled cells were flushed out by firmly pushing the plunger into 
the column. Isolated CD34-positive cells were grown in T25 flask coated with 5 
ng/ml of Collagen IV and cultured in EGM-2 media supplemented with 25ng/ml 
VEGF (R&D Systems). 
 
2.2.7  Nucleic Acid Analyses  
2.2.7.1 Total RNA Extraction 
Cells were harvested from the tissue culture flasks by scrapping in ice-cold PBS. 
Cells were pelleted by centrifuging at 1000 rpm for 5 minutes. The supernatants 
were discarded. RNA extraction was performed with RNeasy Mini Kit (Qiagen) 
according to the protocol provided by the manufacturer. Cells were harvested and 
disrupted with 350 μl RLT Buffer. Lysate was pipetted into a QIAshredder spin 
column and centrifuged for 2 minutes to achieve homogenisation. 1 volume of 70% 
ethanol was added to the homogenised lysate and mixed well to create the optimised 
condition for the RNA to selectively binding to the RNeasy membrane. The samples 
were then applied to RNeasy spin column and centrifuged for 30s. Total RNA 
binded to the membrane and the contaminants were washed away with RW1 and 
RPE washing buffers. At last, the RNA was eluted with RNase-free water. The 
concentration of the RNA was measured with the Nanodrop® Spectrophtometer 
(Thermo Sccientific) and the purity of the RNA was assessed by the ratio of 
absorbance at 260 nm and 280 nm. RNA with an A260/A280 ratio value around 2.0 
was used in the downstream procedures.  
 
2.2.7.2  Reverse Transcription (RT) Reaction 
QuantiTect® Reverse Transcription System (Qiagen) was used as specified by the 
manufacturer to synthesis cDNA from total RNA. 1 µg of RNA sample was first 
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mixed with 2 µl of gDNA Wipeout Buffer and the total volume was adjusted to 14 µl 
with RNase-free water. The mixture was incubated at 42°C for 2 minutes to remove 
the genomic DNA contaminations. Then, 1 μl of Reverse Transcriptase, 1 μl of RT 
Primer Mix and 4 μl of RT buffer were added to the reaction system. The mixture 
was incubated for 15 minutes at 42°C and then 3 minutes at 95°C to inactivate the 
synthesis reaction. With the assumption that all the RNA was converted to cDNA, 
the final concentration of the cDNA was diluted to 10 ng/μl with 80 μl of RNase-free 
water. 
 
2.2.7.3  Quantitative Real-Time Polymerase Chain Reaction (Real-
Time PCR) 
Real-time PCR was performed to detect and quantify gene expression. The sample 
was prepared with 2 μg cDNA, 0.75 μl forward primer (from 2 μM stock), 0.75 μl 
reverse primer (from 2 μM stock), 10 μl SYBR Green PCR master mix (Qiagen) and 
6.5 μl RNase-free water. Sequences of the primers used were listed in Table 2.2. ABI 
Prism 7000 Sequence Detection System instrument (Applied Biosystems) was used 
to carry out the PCR reaction. cDNA samples in duplicates were denatured at 95ºC 
for 2 minutes, then amplified by 40 cycles at 95ºC for 15 seconds and 60ºC for 1 
minute and finally extended at 72ºC for 1 minute. Threshold cycle numbers (Ct) 
were measured in the exponential phase for all samples. Fold change was calculated 
as the relative fold difference of Ct value of target gene against GAPDH 
housekeeping gene. 
Table 2.2 Sequences of primers for real-time PCR 
Name Sequence (5’→3’) 
OCT4  Forward 
OCT4  Reverse 
ATGCATTCAAACTGAGGTGCCTGC 
AACTTCACCTTCCCTCCAACCAGT 
SOX2  Forward 
SOX2  Reverse 
CACATGAAGGAGCACCCGGATTAT 
GTTCATGTGCGCGTAACTGTCCAT 
KLF4  Forward 





c-MYC  Forward 
c-MYC  Reverse 
ACAGCTACGGAACTCTTGTGCGTA 
GCCCAAAGTCCAATTTGAGGCAGT 
α-SMA  Forward 
α-SMA  Reverse 
TGACAATGGCTCTGGGCTCTGTAA 
TTCGTCACCCACGTAGCTGTCTTT 
SM22 α  Forward 
SM22 α  Reverse 
TTGAAGGCAAAGACATGGCAGCAG 
TCCACGGTAGTGCCCATCATTCTT 
Calponin  Forward 
Calponin  Reverse 
TTGAGGCCAACGACCTGTTTGAGA 
TCGAATTTCCGCTCCTGCTTCTCT 
SM-MHC  Forward 
SM-MHC  Reverse 
AGAAGCCAGGGAGAAGGAAACCAA 
TGGAGCTGACCAGGTCTTCCATTT 
CD34  Forward 
CD34  Reverse 
CACTGAGCAAGATGTTGCAAGCCA 
TCAGGAAATAGCCAGTGATGCCCA 
VEGFR2  Forward 
VEGFR2  Reverse 
ATCCAGTGGGCTGATGACCAAGAA 
ACCAGAGATTCCATGCCACTTCCA 
PECAM-1   Forward 
PECAM-1   Reverse 
AGCCCGAACTGGAATCTTCCTTCA 
TCCTTCTGGATGGTGAAGTTGGCT 
VE-Cadherin   Forward 
VE-Cadherin   Reverse 
GCCAGGTATGAGATCGTGGT 
CAACAAACAGAGAGCCCACA 
eNOS  Forward 
eNOS  Reverse 
ACCCTCACCGCTACAACATC 
GCTCATTCTCCAGGTGCTTC 
VWF  Forward 
VWF  Reverse 
CTGAAGGGCTCGAGTGTACC 
CACATGGTCTGTGCAGTTCC 
Claudin5  Forward 
Claudin5  Reverse 
CTGCTGGTTCGCCAACATT 
TGCGACACGGGCACAG 
E-Cadherin  Forward 
E-Cadherin  Reverse 
GTCACTGACACCAACGATAATCCT 
CAGTGTGGTGATTACGACGTTA 
SNAI1  Forward 
SNAI1  Reverse 
TCGGAAGCCTAACTACAGCGA 
AGATGAGCATTGGCAGCGAG 
Fibronectin  Forward 
Fibronectin  Reverse 
AAACTTGCATCTGGAGGCAAACCC 
AGCTCTGATCAGCATGGACCACTT 
Mucin1  Forward 





Claudin1  Forward 
Claudin1  Reverse 
GCGCGATATTTCTTCTTGCAGG 
TTCGTACCTGGCATTGACTGG 




HES5  Forward 























GAPDH  Forward 




2.2.7.4  RNA-Sequencing Analysis 
The following groups were analysed: SMCs, HUVECs, PR-SMCs, SMC-ECs and 
SMC-CD34-ECs. Total RNA was extracted using RNeasy Mini Kit (Qiagen) 
following the manufacturer’s protocol. RNA quantity and quality were checked with 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) 
and electrophoresis on a denaturing agarose gel. cDNA libraries were prepared using 
Illumina TruSeq RNA-Seq sample preparation kit (Illumina, San Diego, CA). The 
libraries were analysed using Illumina HiSeq2500. Results were generated as fastq 
files and sequence reads were trimmed to remove low quality bases at ends. Then 
sequence reads were mapped to the reference of Homo sapiens genome using CLC 
Genomics Server program. Hit counts and reads per kilobase per million (RPKM) 
values were calculated for genes, which is first to align the raw read counts to exons 
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of mRNA transcripts in RefSeq and then normalised these values to total uniquely 
aligning reads and transcript length.  
Gene expression analysis was based on the normalised RPKM values of genes, 
including global gene expression analysis and expression comparisons for individual 
genes of interest. Differential expression was defined as a minimum 2 folds change. 
Global gene expression analysis was performed with Cluster 3.0 with average 
linkage. Genes with the RPKM values below 0.5 were removed from the analysis. 
The results were visualised with Java TreeView in the form of red-green heat map. 
Colour red represents the high gene expression level while colour green represents 
the low gene expression level. Gene Ontology (GO) analysis was performed on the 
upregulated genes in PR-SMCs or SMC-CD34-ECs compared to SMCs. DAVID 
bioinformatics resource 6.7 functional annotation tool suite was used to carry out the 
GO analysis. P-value is calculated by the software and represents the significance of 
the particular GO term associated with the group of genes. The closer the p-value is 
to zero, the more significant the GO term is annotated to the genes. 
 
2.2.8  Protein Analyses  
2.2.8.1  Total Protein Extraction 
Cells were harvested from the tissue culture flasks by scrapping in ice-cold PBS. 
Cells were pelleted by centrifuging at 1000 rpm for 5 minutes. The supernatants 
were discarded. Cell pellet was lysed in RIPA Lysis Buffer (1×, Santa Cruz). The 
lysate was then sonicated twice with Branson Snifier 150 (Emerson Industrial 
Automation) at lowest setting for 6 seconds and then incubated on ice for 45 minutes. 
Cell debris was removed by centrifuging at 13,200 rpm for 10 minutes at 4ºC. The 
supernatant which contained the whole cell lysate protein was collected.  
 
2.2.8.2  Quantification of Protein by Bradford Method 
To test the concentration of the extracted protein, 2 μl protein lysate from total 
protein extraction was combined with 998 μl Bio-Rad Protein Assay Dye Reagent 
(1:5 diluted in ddH2O) in a 1.5 ml Eppendorf tube and incubated for at least 5 
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minutes at room temperature. Absorbance at 595 nm was measured with the Bio-Rad 
SmartSpec
TM
 3000 spectrophotometer and protein concentration was calculated 
based on the BSA standard curve. 
 
2.2.8.3  Western Immunoblotting 
The extracted protein was mixed with 1/4 volume of 5×SDS Buffer and incubated 
for 5 minutes at 96ºC. Protein samples and Precision Plus Protein Ladder (Bio-Rad) 
were fractionated by size on NuPAGE® 4%-10% Bis-Tris pre-cast gel (life 
technologies) by electrophoresis at 160V constant voltage for approximate 1 hour in 
the running buffer. Nitrocellulose Membrane (Protran, Whatman) was placed against 
the gel containing the resolved proteins and sandwiched in a transfer cassette (XCell 
II Blot Module, life technologies) between two layers of filter paper and two layers 
of foam sponge. The resolved proteins were transferred from the gel to the 
membrane for 2 hours at 30 V in the transfer buffer (life technologies). 
The membrane was rinsed in PBS and blocked in 5% Milk with 0.002% NaN3 for at 
least 1 hour at room temperature. The membrane was then incubated with the 
appropriate primary antibody listed in Table 2.3 overnight at 4ºC. After primary 
antibody incubation, the membrane was washed three times, 15 minutes each in 
PBS-Tween Solution (0.01% Tween 20 in PBS). The membrane was then incubated 
with the appropriate secondary antibody for 1 hour at room temperature. Finally, the 
membrane was washed three times, 10 minutes each in PBS-Tween Solution. 
Protein expression was visualised by incubating the membrane with Enhanced 
Chemiluminescent (ECL) Western Blot Substrate (Amersham ECL Plus Western 
Blotting Detection Reagents, GE) for 2 minutes and then the chemiluminescent 
signal was detected by exposure of the membrane to the film (Amersham Hyperfilm 
ECL, GE) with the Compact X4 X-Ray film processor (Xograph Imaging system). 
 
Table 2.3  Antibodies used in Western Blotting analysis 
Primary Antibody  Host Dilution Supplier  Cat. No. 
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α-SMA Mouse 1:1000 Sigma Aldrich A5228 
SM22 α Rabbit 1:1000 Abcam ab14016 
Calponin Rabbit 1:1000 Abcam EP798Y 
SOX2 Rabbit 1:500 Abcam ab59776 
OCT4 Mouse 1:500 Santa Cruz sc5279 
KLF4 Rabbit 1:500 Santa Cruz sc20691 








ab33168 eNOS Rabbit 1:200 BD Biosciences 610297 
Claudin 5 (CLDN5) Mouse 1:500 life technologies 352588 
E-Cadherin Rabbit 1:500 Cell Signaling 3195P 
SNAI1 Rabbit 1:1000 Cell Signaling 3879P 
N-Cadherin Rabbit 1:300 Abcam ab12221 
HES5 Rabbit 1:400 Millipore Ab5708 
Jagged 1 (JAG1) Rabbit 1:300 Santa Cruz sc8303 
GAPDH Mouse 1:2000 Abcam ab8245 
Secondary Antibody Host Dilution Supplier Cat. No. 
Anti-Mouse Immonoglobulins Rabbit 1:3000 Dako P0260 
Anti-Rabbit Immonoglobulins Swine 1:3000 Dako P0217 
 
2.2.8.4  Immunofluorescence Staining 
Cells were seeded on slide and cultured in corresponding medium until achieved 70% 
confluency. After washing with PBS, cells were fixed with 4% Paraformaldehyde 
(PFA) made in PBS for 15 minutes and then permeabilised with 0.1% Triton X-100 
made in PBS for another 15 minutes. Frozen section samples were fixed in cold 
acetone for 10 minutes and then washed with PBS for three times. Samples were 
blocked by 5% serum from the host species of secondary antibodies in PBS for 30 
minutes, followed by the incubation with primary antibodies listed in Table 2.4 
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diluted in 5% serum overnight at 4ºC. After washing three times with PBS, samples 
were incubated with secondary antibodies for 45 minutes at 37ºC. Next, samples 
were washed with PBS three times and then 4'-6-diamidino-2-phenylindole (DAPI) 
was applied to stain the nuclei for 2 minutes. After further washing with PBS three 
times, the coverslips were added to the slide with a drop of Fluorescent Mounting 
Media (Dako). Images were taken by Olympus IX81 microscope equipped with 
TRITC, FITC and DAPI filters. 
 
Table 2.4 Antibodies used in Immunofluorescence Staining 
Primary Antibody Host Dilution Supplier Cat. No. 
SM22 α Rabbit 1:100 Abcam ab14016 
Calponin Rabbit 1:100 Abcam EP798Y 
CD34 Mouse 1:50 Santa Cruz sc7324 
eNOS Rabbit 1:50 BD Biosciences 610297 
PECAM-1 Goat 1:50 Santa Cruz sc1506 
VE-Cadherin Goat 1:50 Santa Cruz sc6458 
VEGFR2 Mouse 1:100 Abcam ab9530 
Human-specific PECAM-1 Rabbit 1:100 Abcam ab32457 




Rabbit 1:50 Millipore Ab5708 
α-SMA-Cy3 (conjugated) Mouse 1:100 Sigma Aldrich C6198 
Secondary Antibody Host Dilution Supplier Cat. No. 
Anti-Mouse Alexa Fluor 488 Donkey 1:500 life technologies A21202 
Anti-Rabbit Alexa Fluor 488 Donkey 1:500 life technologies A21207 
Anti-Goat Alexa Fluor 488 Donkey 1:500 life technologies A11055 
Anti-Mouse Alexa Fluor 594 Goat 1:500 life technologies A11005 




2.2.8.5  Flow Cytometry Analysis  
Flow cytometry analysis was performed to analyse the percentage of surface marker 
expression in different cell samples. Cells were harvested and fixed with 4% PFA for 
15 minutes and then blocked with 5% serum from the host species of secondary 
antibodies in PBS for 20 minutes on ice. The specific fluorochrome-conjugated 
primary antibodies as listed in Table 2.5 were applied to stain the cell surface and 
isotype-matched IgG antibodies were used as control. After incubation for 1 hour in 
dark on ice, cells were washed with PBS three times and centrifuged. Cell pellet was 
resuspended in 1% PFA and keep at 4ºC till analysis.  
Fluorescence activated cell sorting flow cytometer (Becton Dickinson 
Immunocytometry system) was used to perform the analysis. Data was collected and 
analysed with BD CellQuest Pro software. Histograms were used to shown the 
increase of the percentage of EC surface markers in the differentiated cells compared 
to the control cells after adjustment for background fluorescence with control 
isotype-matched antibody-stained cells. The gate M1 region was set with <1% of the 
peak of the control cells inside the gate’s left edge.  
 
Table 2.5 Antibodies for Flow Cytometry Analysis 
Conjugated Antibody  Host Supplier  Cat. No. 
Anti-human VEGFR2-FITC Mouse IgG R&D FAB357F 
Anti-human CD34-PE Mouse IgG MACS 130-081-002 
Anti-human PECAM-1-PE Mouse IgG Abcam ab30349 
Anti-VE-Cadherin -FITC Rabbit IgG Abcam ab33321 
Mouse IgG-PE, Isotype Control Mouse IgG MACS 130-091-835 
Mouse IgG-FITC, Isotype Control Mouse IgG R&D IC002F 
Rabbit IgG-FITC, Isotype Control Rabbit IgG Abcam ab37406 
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2.2.9  Cell Function Analyses 
2.2.9.1  Nitric Oxide (NO) Fluorometric Assay 
The NO cell-based assay kit (Cayman Chemical) was used to measure cellular NO 
level. Fluorescein amine methyl ester (FA-OMe) can form fluorescent deamination 
product (da-FA-OMe) when senses free NO in living cells. SMC-ECs or empty 
vector transfected control cells were incubated with FA-OMe staining solution for 24 
hours. Cells were then washed with assay buffer and stained with Hoechst Dye for 
nuclei. The fluorescent signals were then detected by fluorescent microscope.  
 
2.2.9.2  Acetylated-LDL Uptake Assay 
70% confluent converted ECs on slide were incubated with 10 μg/ml Alexa Fluor 
594 conjugated Ac-LDL (life technologies) for 4 hours in culture media at 37 ºC. 
Cells were then washed with PBS and stained with DAPI. Samples were 
immediately visualised under fluorescent microscope.  
 
2.2.9.3  In vitro Matrigel Tube Formation Assay 
100 μl Matrigel (BD Biosciences) was added to each chamber of an 8-chamber slide 
and allowed to solidify for 1 hour at 37ºC. 1×105 SMC-CD34-ECs or control SMCs 
were suspended in 300 μl EGM-2 media supplemented with 25 ng/ml VEGF and 
added into each Matrigel-coated chamber. Chamber slide was maintained in a 
humidified incubator with 5% CO2 at 37ºC. Tube formations were assessed and 
images were taken at the time point of 6 hours with light microscope. Total tube 
length was quantified with ImageJ processing program with tool Angiogenesis 
Analyzer. The immunofluorescence staining was then performed similarly to the cell 
staining described above but with prolonged incubation times each step.  
 
2.2.9.4  In vivo Matrigel Plug Assay  
5×10
5
 SMC-CD34-ECs or control SMCs were mixed well with 250 μl Matrigel and 
50 μl EGM-2 media supplemented with 25 ng/ml VEGF. The cell mixture was 
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injected subcutaneously into the NOD.CB17-Prkdc
scid
/NcrCrl mice where it rapidly 
solidified. Six injections were conducted for each group. The plugs were harvested 
14 days later. Samples were fixed in liquid nitrogen, cryosections were prepared and 
immunofluorescence staining with PECAM-1 antibody was then performed to detect 
the capillary structures.  
 
2.2.10  Mouse Hindlimb Ischaemia Model 
6-8 weeks old mice were used to create the hindlimb ischaemia model. Mouse was 
placed at a supine position after anesthetisation and the medial side of the right hind 
limb was shaved and disinfected. An approximately 1cm long skin incision was 
made from the knee towards the medial thigh. Next, the femoral artery and vein were 
exposed and dissected from the surrounding connective tissue. Then the femoral 
artery was separated from the vein and ligated twice at the distal and proximal ends. 
Then the artery was dissected between the two ligations. The paleness level of the 
foot was checked to confirm the successful induction of limb ischaemia. Then the 
incision is closed by sutures.  
SMC-CD34-ECs or empty vector transfected SMCs (control) were injected 
intramuscularly into the adductors of ischaemic SCID mice. The blood flow of 
ischaemic hindlimb was evaluated by LDI Doppler laser scanner (Moor Instruments) 
30 minutes post surgery and 2 weeks after. The blood flow ratio was defined as the 
ratio of mean measurement in the foot area of ligated hindlimb to the contralateral 
unligated hindlimb. Local muscular tissues were harvested following cryosectioning 
and immunofluorescence staining with human-specific PECAM-1 antibody.  
 
2.2.11  Generation of Dual Seeding Vascular Graft Using ex 
vivo Bioreactor System  
The thoracic aorta was excised from the mouse and immediately flushed with saline 
solution containing 100U heparin to prevent the formation of blood clots. Peri-aortic 
connective tissue was gently removed with forceps. The aortic graft lumen was 
flushed with 5 ml 0.075% SDS solution (Severn Biotech Ltd) diluted in PBS and 
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then soaked in the same solution for 2 hours on an orbital shaker. Then the aorta was 
flushed and washed in PBS to finish the decellularisation process. The decellularised 
aorta graft was then fixed in the incubation chamber of a special customised 
bioreactor circulation system (Zyoxel Ltd, Oxford, UK). The complete setup was 
maintained in a standard at 37 ºC incubator (Figure 2.3). 
 1×10
6
 SMC-CD34-ECs were mixed with 50 μl of EGM-2 media and seeded inside 
the decellularised vessel graft via direct injection. 1×10
6
 SMCs were mixed with 100 
μl of Matrigel and pipetted onto the graft to form a gel-like wrap. After 12 hours of 
static incubation to allow the attachment of the cells to the graft, EGM-2 media was 
delivered through the lumen by a peristaltic pump (Cole-Parmer) with initial flow 
rate at 5ml/min followed by a stepwise increase to 20 ml/min over 24 hours. The 
flow rate was then kept at 20 ml/min for 5 days. The circulating and chamber media 
were changed every other day. The graft was harvested and cryosections was 
prepared for further analysis.  
 
Figure 2.3 Schematic representation of the decellularised graft 
bioreactor flow circuit 
Schematic representation of the decellularised graft bioreactor flow circuit. 
The decellularised vessel graft is assembled in the incubation chamber. A 
peristaltic pump is at the upstream of the incubation chamber to provide 
stable medium perfusion flow. The media reservoir is at the downstream of 
the incubation chamber. The compliance chamber is to improve the flow 
regime. The flow direction is indicated by arrows. 
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2.2.12  Gene Function Analyses 
2.2.12.1 Knockdown of target genes through delivery of Short 
Hairpin RNA (shRNA) Lentiviral Particles 
ShRNAs lentiviral particles have been used in this study to perform the knockdown 
of target genes and to further evaluate the effects caused by gene knockdown. HEK 
293T cells were used to produce shRNA lentiviral particles. HEK 293T cells were 
tranfected with the lentiviral vector and the packaging plasmids, pCMV-dR8.2 and 
pCMV-VSV-G (both from Addgene) using FuGENE HD (Promega). The 
supernatant containing the lentiviral particles was collected and filtered 48 hours 
after transfection. The viral tilters were determined using the p24 antigen ELISA 
(Zeptometrix).  
ShRNA E-Cadherin (shECAD, sequence is listed in Table 2.6) (CDH1 MISSION 
shRNA, SHCLNG_NM_004360, Sigma Aldrich) in lentiviral vector were delivered 
into PR-SMCs to suppress E-Cadherin expression during reprogramming. The 
shRNA Non-Targeting (shNT) vector was used as negative control to eliminate off-
target effects. 2 day-reprogrammed SMCs were incubated with the shECAD or shNT 
control (1×10
7
 TU/ml) in the complete media supplemented with 10 µg/ml of 
Polybrene for 16 hours. Media were changed the next day and the cells were 
harvested 48 hours after transduction for analysis. 
ShRNA HES5 (shHES5, sequence is listed in Table 2.6) (HES5 MISSION shRNA, 
SHCLNG_XM_371215, Sigma Aldrich) or shRNA JAG1 (shJAG1, sequence is 
listed in Table 2.6) (JAG1 MISSION shRNA, SHCLNG_NM_000214, Sigma 
Aldrich) in lentiviral vectors were delivered into SMC-ECs to suppress the 
expression of HES5 or JAG1 during endothelial differentiation. The shRNA Non-
Targeting (shNT) vector was used as negative control to eliminate off-target effects. 
3 day-reprogrammed PR-SMCs were incubated with the shHES5/shJAG1 or shNT 
control (1×10
7
 TU/ml) in the complete media supplemented with 10 µg/ml of 
Polybrene for 16 hours. Media were changed the next day and the cells were 
harvested 3 days after transduction for analysis. 
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Table 2.6  shRNA Sequences 









2.2.12.2  Overexpression of HES5 by Plasmid pCMV6-HES5  
Plasmid pCMV6-HES5 (RG215311, Origene) containing the full length human 
HES5 cDNA fragment in a pCMV6-AC vector was used to overexpress HES5 
during PR-SMC to the endothelial lineage differentiation. Empty pCMV6 vector was 
used as the negative control. 3 day-endothelial differentiated PR-SMCs were 
transfected with pCMV6-HES5 or pCMV6 empty vector using Basic SMC 
Nucleofector Kit (LONZA) as described in section 2.2.3.3. The expression of the 
endothelial markers was evaluated at the mRNA and protein levels after 3 days of 
overexpression.  














2.2.12.3  Luciferase Activity Assay  
Luciferase activity assay was performed to assess the regulatory role of HES5 or 
JAG1 on eNOS promoter region during PR-SMC to endothelial lineage 
differentiation. PR-SMCs were seeded on Collagen IV coated 12-well plate and were 
differentiated in endothelial-promoting condition for 3 days. 3 day endothelial-
differentiated PR-SMCs were transiently co-transfected with 0.33 µg/well reporter 
plasmid pGL2-eNOS (Plasmid 19297, Addgene) which contains firefly Luciferase 
under the control of the 1621 bp fragment of human eNOS promoter and 0.1 µg/well 
reporter plasmid Renilla (Promega) in the presence of 0.16 µg/well pCMV6-HES5 
or pCMV6-JAG1 (HG11648-M-N, Sino Biological) or pCMV6 empty vector using 
Fugene HD (Promega). After 48 hours of incubation, cells were lysed in lysis buffer 
(Promega). Luciferase and renilla activities were measured with the dual Luciferase 
Assay System (Promega) with a luminometer (Lumat LB 9507, Berthold 
Technologies). Renilla activity was used to normalise the transfection efficiency. 
Relative luciferase activity was defined as the ratio of luciferase activity to Renilla 
activity with that of empty pCMV6 vector transfected control set as 1.0.  
Luciferase assay was also performed to evaluate the effect of JAG1 on HES5 
promoter region. 3 day endothelial-differentiated PR-SMCs were co-transfected with 
luciferase reporter plasmid pGL3 for HES5 promoter and Renilla reporter plasmid in 
the presence of pCMV6-JAG1or pCMV6 empty vector.  
 
2.2.12.4  Immobilised Recombinant JAG1 Stimulation 
The recombinant human JAG1-FC chimera (R&D systems) was used to stimulate 
JAG1-induced signals during PR-SMCs to ECs differentiation. Six-well cell culture 
plates were coated with 50μg/ml of Protein G (life technologies) in PBS at room 
temperature over night. Then the plates were washed 3 times with PBS and further 
blocked with 10mg/ml BSA in PBS for 2 hours at room temperature. The plates were 
washed 3 times with PBS before incubation with 5 μg/ml of recombinant human 
JAG1-FC chimera in 0.1% BSA/PBS or only IgG as control for 4 hours at room 
temperature. After washing 3 times with PBS, 3 day-endothelial lineage 
differentiated PR-SMCs were seeded on the coated plates and maintained under the 
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same endothelial-promoting conditions. The samples were harvested 2 days after and 
analysis for endothelial markers was performed.  
 
2.2.13  Differentiation of Mouse iPS cells towards ECs 
Mouse iPS cells were seeded on Collagen IV coated flasks in 50 ng/ml VEGF 
supplemented differentiation media (DM) which consists of α-MEM media with 10% 
FBS, 0.05 mM β-mercaptoethanol, and 100 u/ml penicillin and 100 µg/ml 
streptomycin. Cells were maintained in this endothelial-promoting condition for 3, 6, 
and 9 days when the samples were harvested and analysed for endothelial marker 
expression at the mRNA and protein levels. 
 
 2.2.14  Statistical Analysis 
Statistical analyses were performed using the GraphPad Prism 5.0 software 
(GraphPad Software, Inc.). Data were analysed by two-tailed Student’s t test or 
analysis of variance (ANOVA), when t test is inappropriate, followed by multiple 
comparisons with Bonferroni’s method. Data were presented as the mean and 
standard error of the mean (S.E.M.). A value of p<0.05 was considered to be 
significant. 
 
2.2.15  Illustration Drawing 
Illustrations were drawn or adapted with software Adobe Illustrator CS5 (Adobe 
Systems Inc.) 
2.2.16  Study Approval  
All animal procedures were performed according to protocols approved by the 










3.1  Establishment and Optimisation of the Protocol 
to Derive ECs from Human Vascular SMCs through 
Reprogramming 
 
3.1.1  Characterisation of the Human Vascular SMC Line  
Human Umbilical Artery Smooth Muscle Cells (UASMCs) were used as the human 
vascular SMCs population in this study. First, it was important to verify that the 
characteristics of this SMC line comply with commonly recognised SMC features 
(Owens, Kumar et al. 2004). Under in vitro culture conditions, UASMC exhibited an 
elongated shape and oval nuclei. The cytoplasm was homogeneous and contained 
few visible inclusions. When confluence was achieved in culture, cells showed the 
typical SMC hill-and-valley growth pattern (Figure 3.1). Compared to human 
fibroblasts and Human Umbilical Vein Endothelial Cells (HUVECs), western blot 
analysis showed that UASMCs expressed a high level of the typical SMC markers 
including α-SMA, SM22α, and Calponin and had no expression of EC marker VE-
Cadherin (Figure 3.2 A). Immunofluorescence staining of UASMCs showed the 
representative staining patterns for cytoskeletal and contractile proteins: α-SMA, 
SM22α, and Calponin (Figure 3.2 B). To rule out possible EC contamination, 
UASMCs were immunofluorescence stained to show that they did not express VE-
Cadherin.  
  
Figure 3.1  Morphology of cultured UASMCs 
Representative morphological images showing UASMC displayed an 
elongated shape, oval nuclei and hill-and-valley growth pattern, which 
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complied with commonly accepted SMC morphological characteristics. Scale 
bar: 100 μm. 
 
Figure 3.2  Markers expressed by human UASMCs at the protein level 
(A) Western blot analysis showed that human UASMCs strongly expressed 
SMC markers α-SMA, SM22α, and Calponin compared to human fibroblasts 
and HUVECs. UASMCs did not express endothelial marker VE-Cadherin 
compared to HUVECs. (B) Representative images of the 
immunofluorescence staining of UASMCs for SMC markers α-SMA, SM22α, 
Calponin and endothelial marker VE-Cadherin. Scale bar: 25 μm. 
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3.1.2  Conversion of Human Vascular SMCs to a Vascular 
Progenitor State through Short Term Reprogramming  
To achieve the conversion of SMCs towards an endothelial lineage, a short term (4 
days) reprogramming strategy was used. The first step was to induce SMCs back to a 
partially reprogrammed state by ectopic overexpression of the four transcription 
factors OCT4, SOX2, KLF4, and c-MYC (Figure 3.3). The reprogramming time is set 
as 4 day based on following two reasons: (1) genome-wide and proteome-wide 
analyses during iPS cell generation revealed extensive cellular activities at 
transcriptional and translational levels from day 0 to day 4, which reflect the 
alteration of the cell identity- plasticity (Buganim, Faddah et al. 2013); (2) human 
fibroblasts can been reprogrammed for 4 days to back to a plastic partially iPS cell 
state that allows further differentiation towards EC or SMC (Margariti, Winkler et al. 
2012, Karamariti, Margariti et al. 2013). We named the SMCs after 4 day 
reprogramming as partially reprogrammed SMCs (PR-SMCs) because a 4 day 
reprogramming time is much shorter than the general time, 21-28 days, to induce 
fully reprogrammed iPS cells from human SMCs or human fibroblasts (Takahashi, 
Tanabe et al. 2007, Lee, Song et al. 2010). 
 
Figure 3.3  Schematic protocol of the short term reprogramming of 
SMCs towards the partially reprogrammed state. 
SMCs were transfected with lentiviral vector containing the four 
reprogramming factors Oct4, Sox2, Klf4, and c-Myc and then maintained in 





SMCs were transfected with the lentivirus TetO-OSKM encoding OCT4, SOX2, 
KLF4 and c-MYC or the empty vector as control and then maintained under the 
reprogramming conditions for 4 days. Transduced SMCs strongly overexpressed the 
corresponding mRNAs and proteins (Figure 3.4). After 4 days of reprogramming, 
PR-SMCs displayed distinct morphological changes compared to the empty vector 
transfected control group (Figure 3.5). PR-SMCs also lost the expression of typical 
SMC markers which can be seen in real-time PCR results (Figure 3.6). Notably, an 
upregulation of CD34, a vascular progenitor marker, was observed in the PR-SMCs 
population at the mRNA and the protein level at this point (Figure 3.7). Other 
commonly used vascular progenitor markers including KDR, C-KIT, CD133 showed 
no significant upregulation (Figure 3.8). Previous studies have shown that CD34-
positive vascular progenitors are able to give rise to both endothelial- and smooth 
muscle-like cells (Ferreira, Gerecht et al. 2007, Kurian, Sancho-Martinez et al. 2013). 
Thus, 4 day reprogramming with OCT4, SOX2, KLF4 and c-MYC erases the original 
cell identity of SMCs and reverses them to a vascular progenitor state.  
 
 
Figure 3.4  The overexpression of the four reprogramming factors after 
4 day reprogramming 
(A) Real-time PCR showed the successful overexpression of the four 
reprogramming factors OCT4, SOX2, KLF4 and c-MYC at the mRNA level of 
PR-SMCs. SMCs transfected with empty lentiviral vector and kept under 
identical reprogramming conditions were used as the control group. 
(***p<0.001 by Student’s t test, n=4) (B) Western blot analysis confirmed the 
overexpression of the transcription factors SOX2, OCT4, KLF4 and c-MYC at 




Figure 3.5  Cell morphology of PR-SMCs 
Representative image of PR-SMCs displayed a distinct morphology 
compared to the control group. SMCs transfected with empty lentiviral vector 
and maintained under the same reprogramming conditions were used as the 




Figure 3.6  The downregulation of SMC marker expression by PR-SMCs 
Real-time PCR analysis showed an overall suppression of typical SMC 
markers in PR-SMCs compared to control cells. SMCs started to lose their 
original identities after 4 day reprogramming (***p<0.001 by Student’s t test, 
n=3). SMCs transfected with empty lentiviral vector and maintained under the 





Figure 3.7  Upregulation of CD34 within a PR-SMCs population after 4 
day reprogramming 
(A) Real-time PCR showed an upregulation in transcription of vascular 
progenitor marker CD34 by PR-SMCs. (***p<0.001 by Student’s t test, n=4) 
(B) Representative images of immunofluorescence staining demonstrated 
the expression of CD34 in PR-SMCs. SMCs transfected with empty lentiviral 
vector and treated with the same reprogramming condition were used as the 




Figure 3.8 Expression of other vascular progenitor markers in PR-SMCs 
after 4 day reprogramming 
Real-time PCR showed no significant difference of other commonly used 
vascular progenitor markers including KDR, C-KIT, and CD133 in PR-SMCs 
after 4 day reprogramming. (Student’s t test, n=3). SMCs transfected with 
empty lentiviral vector and treated with the same reprogramming condition 




To further evaluate the upregulation of CD34 expression along reprogramming, real-
time PCR analysis was performed on samples from different time points during 
reprogramming. An increase of CD34 was observed along reprogramming that 
reached a significant level of upregulation at day 4 (Figure 3.9). Although there 
seemed to be a further CD34 upregulation when the reprogramming time prolonged 
to 6 days, we stayed with the 4 day reprogramming because the upregulation level 
was not significant and the longer reprogramming time with pluripotency factors 
always lead to higher tumour-forming risk.  
 
Figure 3.9  The expression of CD34 in reprogrammed SMC at different 
time point 
Real-time PCR was performed to evaluate the CD34 expression at different 
time point during SMCs reprogramming. CD34 expression in SMC 
transfected with empty lentiviral vector has no significant change along with 
reprogramming. CD34 expression in SMC transfected with TetO-OSKM 
increases along with reprogramming. (**p<0.01, ***p<0.001 by one-way 
ANOVA followed by multiple comparisons with Bonferroni’s method, n=3)  
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3.1.3  Partially Reprogrammed SMCs (PR-SMCs) Display 
the Potential to Differentiate towards an Endothelial 
Lineage 
To drive the differentiation of vascular progenitor state PR-SMCs towards an 
endothelial lineage, cells were treated using endothelial-promoting culture condition 
based on established protocols used for the differentiation of pluripotent cells or 
progenitor cells to ECs. In general, substrate Collagen IV and growth factor VEGF 
are important triggers for endothelial lineage induction (Hirashima, Kataoka et al. 
1999, Zeng, Xiao et al. 2006, Levenberg, Ferreira et al. 2010, Rufaihah, Huang et al. 
2011). A Collagen IV substrate provides a basal lamina-like structure in vitro to 
support the differentiation of stem cells towards an endothelial lineage (Schenke-
Layland, Angelis et al. 2007). VEGF is an essential growth factor for endothelial 
development during embryogenesis and a potent stimulus to induce stem cell 
differentiation into an endothelial lineage in vitro (Coultas, Chawengsaksophak et al. 
2005, Nourse, Halpin et al. 2010).  Thus, to induce endothelial differentiation, PR-
SMCs were seeded on Collagen IV coated petri-dishes and maintained in EGM-2 
media supplemented with 25 ng/ml VEGF (Figure 3.10). Under these conditions, 
SMC-derived ECs (SMC-ECs) were generated and further analysis was performed 
following 6 days of differentiation. SMCs transfected with the empty TetO lentiviral 
vector underwent the identical reprogramming and differentiation process and were 
used as the control group.  
 
 
Figure 3.10  Schematic protocol of the further differentiation of PR-




To drive the endothelial differentiation, PR-SMCs were seeded on Collagen 
IV coated petri-dishes and maintained in EGM-2 media supplemented with 
25 ng/ml VEGF.  
 
After 6 days of endothelial-promoting stimulation, SMC-ECs demonstrated altered 
morphology, appearing shorter and rounder than empty vector transfected control 
cells (Figure 3.11). At this point, real-time PCR analysis showed that a panel of 
typical endothelial markers including PECAM-1, VE-Cadherin, eNOS, VWF, and 
Claudin 5 (CLDN5) was significantly upregulated at the mRNA level in the SMC-
ECs (Figure 3.12 A). Western blot analysis confirmed the expression of specific 
endothelial markers PECAM-1 and VE-Cadherin by SMC-ECs at the protein level 
(Figure 3.12 B). Moreover, immunofluorescence staining showed the typical cell 
membrane staining pattern of PECAM-1 for SMC-ECs (Figure 3.13). Flow 
cytometric analysis further confirmed the increase of endothelial marker PECAM-1 
expression at 6.57% and CD34 at 37.72% compared to the empty vector control cells 
(Figure 3.14). The reprogramming factors were significantly downregulated in the 
differentiated SMC-ECs population compared to PR-SMCs (Figure 3.15). Altogether, 
these results indicate that PR-SMCs display the potential to commit to an endothelial 
lineage in response to endothelial-promoting stimuli.  
 
 
Figure 3.11  Cell morphology of SMC-ECs 
SMCs transfected with an empty lentiviral vector that underwent the same 
reprogramming and differentiation protocol were used as control group. 
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SMC-ECs exhibited profound morphological changes when compared to this 
control group. Scale bar: 100 μm. 
 
 
Figure 3.12  Endothelial markers identified in the SMC-ECs population 
(A) Real-time PCR results revealed an increase in endothelial markers 
including PECAM-1, VE-Cadherin, eNOS, VWF, and CLDN5 at the mRNA 
level. (*p<0.05, ***p<0.001 by Student’s t test, n=5) (B) Western blot analysis 
showed the expression of PECAM-1 and VE-Cadherin at the protein level of 
SMC-ECs. SMCs transfected with empty lentiviral vector that underwent the 




Figure 3.13  Immunofluoresence staining of SMC-ECs for endothelial 
markers 
Representative images of the immunofluorescence staining for endothelial 
markers PECAM-1 of SMC-ECs. SMC-ECs stained with PECAM-1 showed 
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the typical membrane staining pattern. SMCs transfected with empty 
lentiviral vector that underwent the same reprogramming and differentiation 
protocol were used as the control group. Scale bar: 25 μm. 
 
Figure 3.14  Flow cytometric analysis of SMC-ECs for endothelial 
markers 
Flow cytometric histograms demonstrated the increase of the expression of 
PECAM-1 for 6.57% and CD34 for 37.72% in SMC-ECs compared to the 
control group. SMCs transfected with empty lentiviral vector that underwent 
the same reprogramming and differentiation protocol were used as the 
control group. The gate M1 region was set with <1% of the peak of the 
control cells inside the gate’s left edge. 
 
 
 Figure 3.15  Downregulation of transfected reprogramming factors in 
the SMC-ECs population 
Real-time PCR results showed a decrease of ectopic overexpressed 
reprogramming factors including OCT4, SOX2 and KLF4 in differentiated 




3.1.4  Verifying the Protocol for Derivation of ECs from 
SMCs Using a Different Gene Delivery Method to 
Overexpress the Four Reprogramming Factors 
 
To verify that the four reprogramming factors were the main force that initiated 
SMC to endothelial lineage conversion, we employed an alternative method to 
ectopically overexpress OCT4, SOX2, KLF4, and c-MYC in SMCs. SMCs were 
transfected with a linearised pCAG2LMKOSimO (pCAG-OSKM) plasmid encoding 
the four factors or with an empty plasmid as control and then treated using an 
identical protocol of reprogramming and differentiation to that described above. 
SMCs transfected with pCAG-OSKM plasmid successfully overexpressed the four 
reprogramming factors (Figure 3.16). After 4 days of reprogramming, PR-SMCs 
generated using the pCAG-OSKM plasmid displayed a changed morphology 
compared to empty vector control cells (Figure 3.17). Real-time PCR analysis 
revealed the upregulation of CD34 at this point (Figure 3.18). The induction of 
typical endothelial markers was observed at both the mRNA and the protein level 
after 6 days endothelial-promoting differentiation (Figure 3.19). The above results 
further validated our finding that SMCs are amenable to conversion into an 
endothelial lineage through introduction of the four reprogramming factors and 
further endothelial-promoting stimulation.  
 
 




After 4 day reprogramming following pCAG-OSKM plasmid or empty plasmid 
vector transfection, real-time PCR detected the overexpression of OCT4, 
SOX2, KLF4 and c-MYC in PR-SMCs compared to the control cells. (*p<0.05 
by Student’s t test, n=3). SMCs transfected with empty pCAG vector that 
underwent the same reprogramming protocol were used as the control group. 
 
 
Figure 3.17  Cell morphology of PR-SMCs generated with plasmid 
pCAG-OSKM 
PR-SMCs generated with plasmid pCAG-OSKM displayed partially changed 
morphology, which were shorter and smaller, compared to the cells 
transfected with empty plasmid vector. Scale bar: 100 μm. 
 
 
Figure 3.18  PR-SMCs generated using pCAG-OSKM had increased 
CD34 expression after 4 day reprogramming 
Real-time PCR revealed an upregulation of CD34 in PR-SMCs generated 
with pCAG-OSKM. (*p<0.05 by Student’s t test, n=3). SMCs transfected with 
114 
 
empty pCAG vector that underwent the same reprogramming protocol were 




Figure 3.19  Endothelial marker expression in SMC-ECs generated 
using the pCAG-OSKM 
(A) After 6 days of endothelial-promoting differentiation, real-time PCR 
analysis confirmed that endothelial markers PECAM-1, eNOS, CD34 were 
upregulated in SMC-ECs at the mRNA level compared to the control cells. 
(**p<0.01, ***p<0.001 by Student’s t test, n=3) (B) Western blot analysis 
demonstrated the induction of VE-Cadherin and PECAM-1 expression of 
SMC-ECs. SMCs transfected with empty pCAG vector that underwent the 





3.1.5  CD34-Positive Cells Selected from PR-SMCs Give 
Rise to a More Homogenous Endothelial Population 
 
From the above results, the emergence of CD34-positive cells among PR-SMCs was 
observed. Previous studies have shown that CD34 can be considered as a marker of 
vascular progenitor cells that can give rise to ECs (Ferreira, Gerecht et al. 2007, 
Kurian, Sancho-Martinez et al. 2013). CD34 has also been identified as a marker of 
endothelial progenitor cells with the capacity to facilitate neovascularisation (Mackie 
and Losordo 2011, Fadini, Losordo et al. 2012). The emergence of a CD34-positive 
population after short term reprogramming with OCT4, SOX2, KLF4, and c-MYC 
indicated the potential induction of a vascular progenitor state from SMCs. Therefore, 
it was of great interest to test whether CD34-positive cells selected from the 
heterogeneous PR-SMCs population had enhanced endothelial differentiation 
capacity. CD34-positive cells were sorted from PR-SMCs using anti-CD34 
antibody-coupled magnetic microbeads, seeded on Collagen IV coated petri-dishes 
and cultured in the same endothelial-promoting 25 ng/ml VEGF-supplemented 
EGM-2 media as in previous studies shown above (Figure 3.20). 
 
 
Figure 3.20  Schematic protocol of selecting CD34-positive cells from 
PR-SMCs and further differentiating towards endothelial lineage 
CD34-positive cells were selected from PR-SMCs population and were kept 




After 10 days of differentiation, CD34-positive cells formed a homogeneous 
endothelial-like monolayer (Figure 3.21). CD34-positive cells selected from the 4 
days reprogrammed cells with a control vector were of too little amount and which 
could not survive. Therefore, the original SMCs population was used as control 
group. CD34-positive cells could be selected from SMCs, however, these cells only 
gave rise to SMC-like cells after 2 weeks in the same endothelial-promoting 
conditions.  
Real-time PCR analysis showed a significant induction of a full panel of endothelial 
markers including VEGFR2, PECAM-1, VE-Cadherin, eNOS, VWF and the 
suppression of SMC markers including α-SMA, SM22 α, Calponin, SM-MHC at the 
mRNA level in SMC-derived CD34-positive cells converted ECs (SMC-CD34-ECs) 
compared to SMCs (Figure 3.22). Transcriptome sequencing (RNA-Seq) was 
performed on the cell populations at different stages of the SMC to EC conversion 
including SMCs, PR-SMCs, SMC-CD34-ECs and HUVEC. These genome-wide 
analyses showed the global gene expression of SMC-CD34-ECs displayed an overall 
shift towards the human endothelial cell line (Figure 3.23). The upregulation of a 
cluster of endothelial enriched genes and downregulation of a cluster of SMC genes 
was detected at the transcriptome level of SMC-CD34-ECs (Figure 3.24). Gene 
ontology analysis of the upregulated gene profile of SMC-CD34-ECs indicated the 
enrichment of genes for immune response and cell adhesion related biological 
processes, which are usually identified in ECs (Figure 3.25).     
At the protein level, western blot analysis validated the strong induction of 
endothelial markers including VE-Cadherin, PECAM-1, and eNOS (Figure 3.26). 
Flow cytometric analysis revealed the elevated expression of endothelial markers 
PECAM-1, VE-Cadherin, and VEGFR2 at 30.19%, 32.56% and 40.19% respectively 
in SMC-CD34-ECs population compared to SMCs (Figure 3.27). Furthermore, 
immunofluorescence staining displayed the typical junctional expression pattern of 
PECAM-1 and VE-Cadherin and positive staining for VEGFR2 of SMC-CD34-ECs 
(Figure 3.28). Based on the above findings, CD34-positive PR-SMCs represented a 
more optimised cell population for endothelial lineage differentiation compared to 





Figure 3.21  Cell morphology of SMC-CD34-ECs 
SMC-CD34-ECs displayed a homogeneous endothelial-like morphology 




Figure 3.22  The expression of endothelial and smooth muscle markers 
in SMC-CD34-ECs 
Real-time PCR results showed a strong induction of endothelial markers 
including VEGFR2, PECAM-1, VE-Cadherin, eNOS, VWF and a significant 
suppression of smooth muscle markers α-SMA, SM22α, Calponin and SM-
MHC in SMC-CD34-ECs compared to SMC control. (*p<0.05, ***p<0.001 by 




           
Figure 3.23  Global gene expression of SMCs, PR-SMCs, SMC-CD34-
ECs and HUVECs 
Heat map shows the hierarchical clustering analysis of global gene 
expression from RNA-Seq results of SMCs, PR-SMCs, SMC-CD34-ECs and 
HUVECs. Colour bar indicates gene expression in scale. Genes expressed 
at low level are indicated with colour green while genes expressed at high 
level are indicated with colour red. The global gene expression pattern 




Figure 3.24  Heat map of EC and SMC enriched gene expression 
changes among SMC, SMC-ECs, SMC-CD34-ECs and HUVECs 
Based on RNA-Seq results, here shows the heat map of the changes of 
commonly recognised (A, B) EC and (C, D) SMC enriched genes expression 
among SMC, SMC-ECs, SMC-CD34-ECs, and HUVECs. Overall, EC 
enriched genes went up and SMC enriched genes went down in SMC-ECs 
and SMC-CD34-ECs compared to SMCs. Colour bar indicates gene 





Figure 3.25  Gene ontology analysis of the upregulated genes between 
SMC-CD34-ECs and SMCs 
Gene ontology (GO) analysis was performed on the upregulated genes of 
SMC-CD34-ECs compared to SMCs from the RNA-Seq data. An online 
DAVID bioinformatics resource 6.7 functional annotation tool suite was used 
to carry out the GO analysis. Enrichment in gene ontology of (A) biological 
process and (B) molecular function were revealed. Significance of 
enrichment was evaluated by p-value which is calculated by the software. 
The closer of p-value to zero, the more significant of the GO term annotated 





Figure 3.26  Western blot analysis of the expression of EC and SMC 
markers by SMC-CD34-ECs 
Western blot analysis confirmed the upregulation of endothelial markers 
eNOS, VE-Cadherin, PECAM-1 and the downregulation of SMC marker 
Calponin in SMC-CD34-ECs at the protein level compared to SMCs.  
 
 
Figure 3.27  Flow cytometric analysis of endothelial markers of SMC-
CD34-ECs 
Flow cytometric histograms evaluated the increase of the progenitor marker 
CD34 and endothelial markers PECAM-1, VE-Cadherin, VEGFR2 at 34.59%, 
30.19%, 32.56% and 40.19% respectively of SMC-CD34-ECs compared to 
SMCs. The marker region of gate M1 was set with <1% of the peak of the 




Figure 3.28  Immunofluorescence staining for endothelial markers in 
SMC-CD34-ECs 
Immunofluorescence staining of SMC-CD34-ECs revealed the typical 
junctional staining pattern of PECAM-1, VE-Cadherin and the positive 




3.1.6  Conclusion 
In this first part of the work, an optimised protocol for the conversion of human 
vascular SMC towards an endothelial lineage has been established. 
First, we reprogrammed the human vascular SMCs with the four transcription factors 
OCT4, SOX2, KLF4 and c-MYC for 4 days to generate partially reprogrammed 
SMCs (PR-SMCs). At this stage, PR-SMCs expressed an upregulated level of a 
vascular progenitor marker: CD34. SMCs were converted to a vascular progenitor 
state by short term reprogramming.  
Next, the PR-SMCs were treated with endothelial-promoting conditions: the 
combination of Collagen IV substrate and VEGF supplemented EGM-2 media. After 
6 days, the cells expressed a panel of endothelial markers at both the mRNA and the 
protein level. Thus, ECs were generated from the SMCs after 4 days of 
reprogramming and 6 days of differentiation.  
To further improve the protocol, CD34-positive cells were selected from the PR-
SMCs and then maintained in the endothelial-promoting conditions. CD34-positive 
PR-SMCs exhibited an enhanced capacity to give rise to a homogeneous endothelial 
population with a complete repertoire of endothelial features.  
Taken together, the feasibility of the conversion of human SMC to an endothelial 
lineage has been proven. We presented a two step protocol consisting first of 
reprogramming the SMCs to CD34-positive vascular progenitors and subsequently 
differentiating the cells towards the endothelial lineage.  
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3.2  Functional Characterisation of the SMC-derived 
ECs 
 
3.2.1 SMC-converted ECs Display Endothelial 
Functionality both In Vitro and In Vivo  
Following the gene and protein expression profile characterisation of SMC-derived 
ECs, it was of great interest to evaluate the endothelial related function of the 
converted endothelial population.  
The ability to produce vasodilator Nitric Oxide (NO) is one of the critical 
characteristics of functional ECs. The level of cellular NO was measured by a 
specific probe: fluorescein amine methyl ester (FA-OMe). Non-fluorescent FA-OMe 
transforms into intense fluorescent deamination product, da-FA-OMe, when sensing 
free NO in living cells (Shiue, Chen et al. 2012). By using this method, NO produced 
by SMC-ECs was detected within the cytoplasm while empty vector control cells did 
not exhibit the ability to produce NO (Figure 3.29).  
Another important endothelial function is to regulate lipid metabolism, which can be 
reflected in their ability to take up acetylated low density lipoprotein (ac-LDL) 
(Voyta, Via et al. 1984). SMC-CD34-ECs could effectively take up fluorescently 
labelled acetylated low density lipoprotein (ac-LDL), which demonstrated that their 
lipid metabolism regulatory ability resembled that of mature ECs (Figure 3.30).  
To assess the vasculogenic and angiogenic potential of the cells, in vitro Matrigel 
tube formation assay was performed. Matrigel is a type of biologically active 
reconstituted matrix extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, 
a tumour rich in all kinds of ECM proteins present in the basement membrane 
(Kleinman and Martin 2005). This assay is a quick method to evaluate the ability of 
ECs to form three dimensional tubular structures on in vitro ECM gel that mimics 
the in vivo cellular basement membrane environment. SMC-CD34-ECs or SMCs 
suspended in VEGF supplemented EGM-2 media were seeded onto Matrigel and 
maintained in a 37ºC incubator. SMC-CD34-ECs clearly aggregated into vessel-like 
tube structures on Matrigel after 6 hours of incubation (Figure 3.31 A). 
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Quantification of the total tube length revealed that converted ECs exhibited a much 
stronger tube-forming capacity than the SMCs control (Figure 3.31 B). Moreover, 
the tube-forming cells of the SMC-CD34-ECs group also stained positively for 
endothelial marker VE-Cadherin (Figure 3.31 C).   
Subsequently, a subcutaneous Matrigel plug assay in mice was performed to further 
assess the angiogenic ability of SMC-converted ECs in vivo. 5×10
5
 SMC-CD34-ECs 
or SMCs were mixed with 50 μl EGM-2 media and 250 μl Matrigel. The cell 
mixture was injected subcutaneously into the mice. After 2 weeks, the Matrigel plugs 
were harvested from the mice and further analysis was performed. By 
immunofluorescence staining of the Matrigel plug sections with endothelial marker 
PECAM-1, we showed that SMC-CD34-ECs displayed the capacity to form 














Figure 3.29   Cellular NO production assay on SMC-ECs  
By using a specific probe FA-OMe to sense cellular NO, SMC-ECs started to 
produce NO compared to empty vector control cells. Scale bar: 35 μm. 
SMCs transfected with empty lentiviral vector that underwent the same 




Figure 3.30  Ac-LDL uptake assay of SMC-CD34-ECs 
SMC-CD34-ECs were able to efficiently take up fluorescently labelled ac-





Figure 3.31  In vitro Matrigel angiogenesis assay of SMC-CD34-ECs 
(A) In vitro tube formation assay was performed on control SMCs and SMC-
CD34-ECs. SMC-CD34-ECs showed a much higher efficiency for tube 
structures forming compared to control SMCs after 6 hours seeded on 
Matrigel. Scale bar: 100 μm. (B) The tube forming cells of SMC-CD34-ECs 
group are immuno-stained positive for endothelial marker VE-Cadherin. 
Scale bar: 100 μm. (C) Total tube length quantified with Image J software 
displayed a significant increase with SMC-CD34-ECs group compared to 





Figure 3.32  In vivo Matrigel angiogenesis assay of SMC-CD34-ECs 
5×105 SMC-CD34-ECs or SMCs were mixed well with media and Matrigel 
and injected subcutaneously into the mice. After 2 weeks, the Matrigel plugs 
were harvested from the mice and immunofluorescence staining with 
PECAM-1 was performed on the plug sections. SMC-CD34-ECs displayed 




3.2.2  SMC-derived ECs Display Therapeutic Angiogenic 
Capacity in a Murine Hindlimb Ischaemia Model 
The murine hindlimb ischaemia model is a commonly used animal model to evaluate 
pro-angiogenic therapies for ischaemic diseases. The femoral artery of the mouse is 
ligated to create ischaemia of the lower extremity. By injecting cells or drugs locally 
into the ischaemic muscle, the therapeutic angiogenic capacity of treatments can be 
assessed straightforwardly by monitoring of blood flow recovery.   
Adopting this model, the therapeutic angiogenesis potential of SMC-derived ECs 
was tested. Trials of three treatment groups were conducted: a SMC-CD34-ECs 
treated group, a SMCs treated group and a PBS treated group. SMC-CD34-ECs, 
SMCs or PBS were injected intramuscularly into the ischaemic hindlimbs of mice 
right after the ischaemic area had been created. The blood flow ratio was evaluated 
immediately after the surgeries by laser Doppler imaging. After two weeks, the 
blood perfusion recoveries of the ischaemic hindlimbs from different treatment 
groups were evaluated again. The therapeutic value of SMC-CD34-ECs treatment 
was assessed by comparison of the blood flow recoveries with PBS or SMCs 
injected groups. SMC-CD34-ECs treated mice showed a significantly improved 
blood flow ratio compared to the PBS or SMCs treated groups (Figure 3.33).  
Hindlimb ischaemic area muscles were then harvested for cryosectioning and further 
analysis. To evaluate the total vascular structure difference, local adductor muscular 
tissue harvested from different treatment group and stained with mouse PECAM-1 
(Margariti, Winkler et al. 2012). Images showed a clearer vascular structure in SMC-
CD34-ECs treated group and quantification analysis confirmed a significant 
enhancement of capillary numbers of the SMC-CD34-ECs treated group compared 
to SMCs or PBS treated group (Figure 3.34 A, B). Furthermore, positive staining of 
human-specific PECAM-1 antibody within the capillaries suggested the successful 
engraftment of the injected human cells into in situ neovascularisation (Figure 3.34 
C). All together, SMC-converted ECs exhibited angiogenic capacity in the mouse 
ischaemic model, which indicated a promising therapeutic alternative cell source for 




Figure 3.33  Blood flow ratio recovery of ischaemic hindlimb after two 
weeks of treatment 
PBS, SMCs and SMC-CD34-ECs were intramuscularly injected into 
ischaemic hindlimbs of mice. Representative images from laser Doppler 
imaging exhibited that SMC-CD34-ECs injected group had a much better 
blood flow recovery after two weeks compared to PBS or SMCs injected 
group. The colour scale from blue to red indicates the increase in blood flow. 
Quantification analysis of blood flow ratio showed significantly higher foot 
blood flow recovery with SMC-CD34-ECs treated group (***p<0.001 by one-






Figure 3.34  Analyses of the capillary density of the ischaemic area 
adductors tissue 
(A) Sections of ischaemic area adductor muscles were immunofluorescence 
stained with mouse PECAM-1 antibody to show the total capillary structures. 
The SMC-CD34-ECs injected group showed significantly clearer capillary 
structures when compared to the control SMCs and PBS injected group. 
(B)The capillary density of the SMC-CD34-ECs treated group is much higher 
than PBS or SMCs treated groups. Capillary density was quantified as the 
capillary number per mm2 (***p<0.001 by one-way ANOVA followed by 
multiple comparisons with Bonferroni’s method, n=3) (C) The incorporation of 
SMC-CD34-ECs, which are of human origin, with in situ capillary formation 






3.2.3  SMC-derived ECs Demonstrate the Capacity to 
Construct Tissue Engineered Vascular Graft 
Tissue engineered vascular grafts represent a valuable prospect for regenerative 
medicine. It is of great significance to explore suitable materials and techniques to 
generate functional vascular conduits. An ex vivo circulation bioreactor system 
developed in our lab has been used to seed cells to the decellularised mouse aortic 
graft to construct native vessel-comparable vascular graft (Wong, Hong et al. 2015). 
Vascular grafts generated using this method have been transplanted in vivo and 
demonstrate normal vascular function (Karamariti, Margariti et al. 2013).  
Mouse aorta was first treated with chemical and mechanical methods to remove all 
the cells within the vascular wall. SMC-CD34-ECs were then seeded inside the 
decellularised vascular graft to form the endothelial layer and SMCs were seeded on 
the outside. Following culturing in the bioreactor circulation system for 5 days, the 
graft was harvested, sectioned and immunofluorescence stained for endothelial 
marker PECAM-1 and SMC marker α-SMA. The reconstructed vascular graft 
displayed a vascular like structure with most inner endothelium-like layer formed by 










Figure 3.35  Application of SMC-CD34-ECs in constructing tissue 
engineered vascular grafts 
Decellularised mouse aortic graft was double seeded with SMC-CD34-ECs 
and SMCs. After 5 days of maintenance in the ex vivo bioreactor setting, the 
graft exhibited a vascular-like structure with the inner endothelium-like layer 
and multiple smooth muscle layers. Two re-constructed vascular grafts were 




3.2.4  Conclusion 
In this part of the work, the EC-related function of the SMC-derived EC has been 
tested. Furthermore, the application potential of the converted ECs has been 
evaluated for therapeutic angiogenesis in a mouse hindlimb ischaemia model and in 
the ex vivo circulation bioreactor system for the ability to construct tissue-engineered 
vascular graft. 
SMC-derived ECs exhibit the ability to produce vasodilator NO and to take up 
acetylated-LDL. They also show vasculogenic and angiogenic potential in vitro and 
in vivo. By using the murine hindlimb ischaemia model, we demonstrated the 
therapeutic angiogenic capacity of SMC-CD34-ECs to help with recovering the 
blood flow ratio of an ischaemic area. In addition, SMC-CD34-ECs were able to 
construct an endothelium-like layer in a tissue-engineered vascular graft.  
These functional analyses show that the ECs derived from SMCs not only express 
the typical endothelial markers, but also obtain endothelial-related functions and 
exhibit potential for further clinical application.  
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3.3  Mesenchymal-to-Epithelial Transition (MET) is 
Involved in Short Term Reprogramming to Induce a 
Vascular Progenitor State from SMC 
 
3.3.1  MET Occurs Simultaneously with the Induction of 
Vascular Progenitors Markers in SMCs 
After functionally characterising the SMC-derived endothelial population, we started 
to explore possible mechanisms underlying the conversion. It has been well 
established that mesenchymal-to-epithelial transition (MET) is an important event 
for the modulation of cellular plasticity. MET is essential in the initial stage of the 
successful reprogramming of somatic cells to iPS cells (Li, Liang et al. 2010, 
Samavarchi-Tehrani, Golipour et al. 2010). SMCs can be considered as 
mesenchymal-like cell due to their lack of intercellular adhesion, junction contacts 
and their ability to migrate through ECM. The four iPS-generating reprogramming 
factors were used in this study to induce SMCs to convert into the CD34-positive 
vascular progenitors. Morphologically, SMCs lost their mesenchymal-like shape 
during reprogramming (Figure 3.5). For these reasons, we checked the possible 
involvement of MET in the short term reprogramming phase.  
When comparing vascular progenitor state PR-SMCs to SMCs, RNA-Seq data 
revealed an overall MET tendency, as the decrease in levels of the typical 
mesenchymal markers corresponded with an increase of the epithelial markers at the 
transcriptome level (Figure 3.36). Gene ontology analysis of the upregulated gene 
profile of PR-SMCs revealed an enrichment in structural molecule activity (Figure 
3.37), which echoes a recent report that cytoskeletal remodelling is a key process for 
MET and reprogramming (Sakurai, Talukdar et al. 2014).  
Based on the above results, the participation of MET during the induction of the 
vascular progenitor state was further investigated. The changes in mesenchymal or 
epithelial associated markers were measured at the mRNA level during the 
reprogramming from SMCs to PR-SMCs. Mesenchymal related genes α-SMA, 
Fibronectin and SNAI1 were time-dependently downregulated accompanied with the 
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gradual upregulation of epithelial related genes E-Cadherin, Claudin 1 and Mucin 1 
(Figure 3.38). Western blot analysis confirmed the induction of E-Cadherin and the 
reduction of N-Cadherin and SNAI1 at the protein level during reprogramming 
(Figure 3.39). PR-SMCs stained positively for E-Cadherin further demonstrating the 
acquisition of epithelial characteristics in parallel with reprogramming (Figure 3.40). 
All these results suggest that MET occurs simultaneously with the induction of 




Figure 3.36  RNA-Seq results indicated a MET tendency during 4 day 
reprogramming 
The heat map based on RNA-Seq data shows the overall suppression of 
mesenchymal gene profile and activation of epithelial gene profile of PR-




Figure 3.37  Gene ontology analysis of the upregulated genes between 
PR-SMCs and SMCs 
Gene ontology analysis was performed on the upregulated genes of PR-
SMCs compared to SMCs from the RNA-Seq data. An online DAVID 
bioinformatics resource 6.7 functional annotation tool suite was used to carry 
out the GO analysis. Enrichment in gene ontology of (A) biological process 
and (B) molecular function were revealed. Significance of enrichment was 
evaluated by p-value which is calculated by the software. The closer of p-






Figure 3.38  Real-time PCR analyses of representative mesenchymal 
and epithelial markers during reprogramming 
Real-time PCR results showed that during SMCs to PR-SMCs 
reprogramming, mesenchymal markers SMA, Fibronectin, and SNAI1 were 
gradually downregulated and epithelial markers E-Cadherin, Claudin 1, and 
Mucin 1 were gradually induced (*p<0.05, **p<0.01, ***p<0.001 by one-way 
ANOVA followed by multiple comparisons with Bonferroni’s method, n=3). 
SMCs transfected with empty lentiviral vector without the four reprogramming 







Figure 3.39  Western blot analysis of the expression changes of typical 
epithelial and mesenchymal markers during reprogramming 
After the overexpression of OCT4, SOX2, KLF4, and c-MYC, the 
upregulation of epithelial marker E-Cadherin and suppression of 
mesenchymal markers SNAI1 and N-Cadherin during reprogramming were 
confirmed at the protein level by western blot analysis.  
 
 
Figure 3.40  Immunofluorescence staining of PR-SMCs for typical 
epithelial marker E-Cadherin  
PR-SMCs and empty vector control cells were immunofluorescence stained 
with E-Cadherin. The expression of E-Cadherin could be observed in PR-
SMCs (Scale bar: 25μm). SMCs transfected with empty lentiviral vector 
without the expression of the four factors that underwent the same 




3.3.2  Knockdown of E-Cadherin Impairs the Generation of 
Vascular Progenitors from SMCs and the Further 
Endothelial Lineage Differentiation 
 
E-Cadherin is the key regulator for epithelial homeostasis and knocking down E-
Cadherin at the initial stage of iPS cell generation impairs iPS cell induction (Li, 
Liang et al. 2010). To determine whether a shift of the cell state towards epithelial-
like cell is indispensable in the generation of PR-SMCs and subsequent endothelial 
lineage induction, we intended to knockdown E-Cadherin during reprogramming. 
The knockdown of E-Cadherin was achieved via lentiviral delivery of short hairpin 
E-Cadherin (shECAD) during reprogramming. Cells transfected with Non-Target 
shRNA (shNT) were used as the control to eliminate off-target effects. SMCs 
transfected with the four reprogramming factors were kept under reprogramming 
conditions for 2 days before transfection with shECAD or shNT. Cells were then 
maintained under the same reprogramming conditions for a further 2 days after 
transfection. Real-time PCR analysis showed that the CD34 expression was 
repressed corresponded with the suppression of E-Cadherin expression in PR-SMCs 
(Figure 3.41 A), which indicated that the generation of a vascular progenitor state 
was compromised due to the interruption of the induction of epithelial properties.  
To evaluate the impact of E-Cadherin knockdown during reprogramming on 
subsequent endothelial differentiation, PR-SMCs with or without E-Cadherin 
knockdown were subjected to the endothelial-promoting condition for 6 days. Real-
time PCR indicated that the successive endothelial differentiation capacity of PR-
SMCs was jeopardised with E-Cadherin knockdown as the upregulation of 






Figure 3.41  Knockdown of E-Cadherin during reprogramming impaired 
the generation of vascular progenitors and further induction of 
endothelial properties  
(A) Real-time PCR results indicated that knockdown of E-Cadherin with 
shRNA at day 2 of reprogramming resulted in the downregulation of CD34 in 
PR-SMCs at the mRNA level (**p<0.01 by Student’s t test, n=3). (B) When 
PR-SMCs with or without E-Cadherin knockdown were subjected to 
endothelial differentiation, PR-SMCs with E-Cadherin knockdown displayed 
impaired capacity for endothelial marker upregulation (***p<0.001 by 




3.3.3   Conclusion 
In this section of the work, the mechanism involved in the conversion of SMCs to 
vascular progenitor state PR-SMCs was explored. During the reprogramming from 
SMCs towards PR-SMCs, MET was identified as a key cellular process. The 
downregulation of mesenchymal properties and the induction of epithelial properties 
were observed along the reprogramming process. Furthermore, when we knocked 
down the crucial epithelial regulator E-Cadherin during reprogramming, the 
generation of CD34-positive vascular progenitor PR-SMCs was impaired as was the 
further differentiation towards an endothelial lineage.  
Taken together, during 4 days reprogramming phase, MET along with the induction 
of E-Cadherin are required events for the generation of vascular progenitor from 




3.4  Components of the Notch Signalling Pathway, 
HES5 and JAG1, are Implicated in Endothelial 
Lineage Derivation from PR-SMC 
 
3.4.1  Comprehensive Analyses Reveal the Involvement of 
HES5 and JAG1 during PR-SMC to Endothelial Lineage 
Differentiation 
The Notch signalling pathway plays an important yet complex role in regulating 
differentiation, proliferation, angiogenesis and other cellular processes of both EC 
and SMC (Gridley 2007). RNA-Seq analysis indicated that upregulation of several 
components of the Notch pathway occurred with the generation of SMC-derived ECs 
(Figure 3.42), which led to our particular interest in exploring the participation of the 
Notch pathway in endothelial differentiation. To verify the results from RNA-Seq, 
Real-time PCR analysis was performed to check the gene expression levels of the 
Notch pathway components that were shown to be upregulated in SMC-derived ECs 
from RNA-Seq data or have been reported to be associated with EC (Figure 3.43). 
Collectively, the results showed a consistent upregulation of HES5 and JAG1 during 
vascular progenitor to endothelial lineage differentiation. Furthermore, western blot 
analysis confirmed the upregulation of JAG1 and HES5 aligned with the increase of 
endothelial marker at the protein level (Figure 3.44). Taking all these into account, 
we decided to look at the possible regulatory roles of HES5 and JAG1 during 




Figure 3.42  Gene expression fold changes of the Notch signalling 
pathway members 
RNA-Seq analysis showed the gene expression fold changes of the Notch 
signalling pathway members in SMC-CD34-ECs compared to SMCs. Fold 
changes were calculated based on the normalised RPKM value of each gene 
in different cell samples. 
 
 
Figure 3.43  Real-time PCR analysis of the Notch pathway components 
in SMC-ECs  
Real-time PCR was performed to verify the upregulation of the Notch 
signalling pathway members from the RNA-Seq results plus other Notch 
pathway components that have been reported to be associated with EC. 
JAG1 and HES5 were upregulated in SMC-derived ECs (*p<0.05, **p<0.01 
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by Student’s t test, n=3). SMCs transfected with empty lentiviral vector 
without 4 factors expression that underwent the same reprogramming and 
differentiation protocol were used as the control group. 
 
 
Figure 3.44  Western blot analysis of HES5 and JAG1 expression in 
SMC-ECs 
Western blot analysis showed the upregulation of HES5 and JAG1 along 
with the induction of endothelial markers in SMC-ECs. SMCs transfected 
with empty lentiviral vector without the 4 factors expression that underwent 





3.4.2  HES5 is Required for the Endothelial Lineage 
induction from PR-SMC 
 
HES5 is a downstream target of the Notch signalling pathway and functions as 
transcription factor of the basic helix-loop-helix family (Kageyama, Ohtsuka et al. 
2007). HES5 has been associated with regulating the maintenance and the 
differentiation of progenitor cells of various organs and tissues. Several recent 
studies indicated a role for HES5 in cardiovascular development. Xu et al. suggested 
that HES5 might act as a key positive mediator for the differentiation of bone 
marrow stromal cell into EC (Xu, Liu et al. 2009). HES5 has also been implicated in 
endothelial proliferation in response to endothelial injury during atherosclerosis 
(Schober, Nazari-Jahantigh et al. 2014).   
To elucidate the involvement of HES5 during endothelial generation from PR-SMC, 
loss-of-function and gain-of-function analyses of HES5 were performed. PR-SMCs 
were treated with endothelial-promoting conditions to differentiate them towards an 
endothelial lineage for 3 days before transfection with lentivirus short hairpin HES5 
(shHES5) to suppress HES5 expression. Cells transfected with Non-Target shRNA 
(shNT) were used as a control. ShHES5 or shNT transfected cells were maintained in 
the same endothelial-promoting conditions for another 3 days. ShHES5-mediated 
HES5 knockdown resulted in the reduction of endothelial markers at the mRNA and 
the protein levels (Figure 3.45), which demonstrated that a lack of HES5 impaired 
the regulation of the key processes for endothelial differentiation. 
Next, HES5 was overexpressed at day 3 of PR-SMCs to endothelial differentiation 
via delivering HES5-encoding plasmid, pCMV6-HES5, into the cells. Cells 
transfected with empty pCMV6 plasmid were used as the control. After a further 3 
days of endothelial differentiation, HES5 overexpressing SMC-ECs exhibited a 
further enhancement of endothelial marker expression compared to empty vector 
delivered SMC-ECs (Figure 3.46). Interestingly, immunofluorescence staining 
suggested that the positive endothelial regulatory role of HES5 only functioned 
during PR-SMCs to endothelial differentiation. Overexpressing HES5 in cells 
without prior OCT4, SOX2, KLF4, c-MYC reprogramming failed to induce 
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endothelial marker expression (Figure 3.47). The above findings imply that the four 
reprogramming factors introduced certain frames for HES5’s further regulation of 
expression of endothelial related genes. 
We next wanted to check the possible targets of HES5 during endothelial 
differentiation. eNOS was the most highly induced endothelial marker during PR-
SMCs to SMC-ECs differentiation and eNOS could be induced to a higher level 
upon HES5 overexpression. Therefore, a luciferase assay was performed to check 
the potential regulatory role of HES5 on the promoter region of eNOS. PR-SMCs 
were first treated with endothelial-promoting condition for 3 days, and then 
transfected with the plasmid expressing luciferase under the control of eNOS 
promoter with the HES5-overexpressing plasmid or empty control plasmid. 
Luciferase activity was detected 48 hours after transfection. Result showed that the 
activity of the eNOS promoter was enhanced in the HES5-overexpressing cells 
(Figure 3.48). Thus, HES5 benefits the endothelial differentiation at least partly 
through activation of the eNOS promoter. HES5 might directly bind to the eNOS 
promoter region to activate it or act on the promoter through other factors.  
In addition, the expression of Hes5 was assessed in a mouse iPS cell to EC 
differentiation model. Mouse iPS cells were seeded on Collagen IV coated flasks and 
maintained in differentiation media supplemented with 50 ng/ml VEGF to induce 
endothelial differentiation. Hes5 expression was upregulated along with the 
induction of endothelial markers at the mRNA and the protein level (Figure 3.49). 
This interesting finding further indicated that HES5 might play an extended 










Figure 3.45  HES5 knockdown impaired the induction of endothelial 
markers in SMC-ECs 
(A) Real-time PCR results showed the knockdown of HES5 led to the 
impairment of endothelial marker induction in SMC-ECs (*p<0.05, **p<0.01, 
***p<0.001 by Student’s t test, n=3) (B) The suppression of endothelial 
marker PECAM-1 with HES5 knockdown in SMC-ECs was confirmed at the 
protein level by western blot analysis. SMCs transfected with empty lentiviral 
vector without the 4 factors expression that underwent the same 
reprogramming and differentiation protocol were used as the control group 
for SMC-ECs.  
 
 
Figure 3.46  Overexpression of HES5 in SMC-ECs further enhanced the 
expression of endothelial markers 
Overexpression of HES5 in SMC-ECs through plasmid delivery of pCMV6-
HES5 led to a further increase of the expression of endothelial markers at 
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the mRNA level compared to empty pCMV6 vector transfected SMC-ECs 
(*p<0.05, ***p<0.001 by Student’s t test, n=3) 
 
Figure 3.47  Immunofluoresence staining of the control cells or SMC-
ECs with HES5 overexpression 
Immunofluorescence staining of HES5 and PECAM-1 was performed on 
control cells (SMCs transfected with empty lentiviral vector without 4 factors 
expression that underwent the same reprogramming and differentiation 
protocol), SMC-ECs, control cells with HES5 overexpression and SMC-ECs 
with HES5 overexpression. Results showed that overexpression of HES5 in 
SMC-ECs by transfection with plasmid pCMV6-HES5 further induced the 
PECAM-1 expression compared to the empty pCMV6 vector transfected 
SMC-ECs. However, overexpression of HES5 in control cells that were not 
reprogrammed with OCT4, SOX2, KLF4, and c-MYC could not achieve the 




                    
Figure 3.48  Luciferase assay of eNOS promoter activity upon HES5 
overexpression in SMC-ECs 
After 3 days endothelial differentiation, PR-SMCs were co-transfected with 
reporter plasmid pGL2 for eNOS promoter and HES5-overexpressing 
plasmid pCMV6-HES5 or empty plasmid pCMV6. Measurement of relative 
luciferase activity indicated that eNOS promoter activity was enhanced upon 
HES5 overexpression. Cells were transfected with a Renilla-expressing 
vector at the same time as the normalisation control for transfection 
efficiency. Relative luciferase activity is the ratio of luciferase activity to 




Figure 3.49  Hes5 is implicated in mouse iPS cell to EC differentiation 
In a mouse iPS cell to EC differentiation model, Hes5 expression was 
upregulated corresponded with the increase of endothelial markers at (A) the 
mRNA level (n=2) and (B) the protein level. 
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3.4.3  JAG1 Participates in the PR-SMC to Endothelial 
Lineage Differentiation 
 
JAG1 is the upstream ligand of the Notch signalling pathway which serves a much 
more complicated context-dependent role in regulating vascular activity (Gridley 
2007, Benedito, Roca et al. 2009). A facilitating role of JAG1 in endothelial 
differentiation and angiogenesis has been indicated in several studies. For example, 
Benedito et al. showed the pro-angiogenic role of JAG1 during mouse 
embryogenesis and postnatal development through interaction with another Notch 
ligand Delta-like 4 (DLL4) (Benedito, Roca et al. 2009). Specific JAG1 stimulation 
in the bone marrow microenvironment has been shown to be critical for endothelial 
progenitor cell development and neovascularisation (Kwon, Eguchi et al. 2008). 
Considering that JAG1 has been upregulated through the endothelial profile 
induction from PR-SMCs, it is of great interest to further investigate the role of 
JAG1 during this process.   
First, we stimulated the cells with recombinant JAG1 during the PR-SMCs to 
endothelial differentiation. PR-SMCs were treated with endothelial-promoting 
condition for 3 days and then seeded on immobilised recombinant JAG1 or control 
IgG coated petri-dishes. The cells were maintained in endothelial-promoting 
condition for another 2 days. Upon recombinant JAG1 stimulation, some of the 
endothelial markers, especially eNOS, could be induced to a higher level compared 
to IgG treated cells (Figure 3.50).  
Next, we studied the impact of JAG1 suppression on endothelial differentiation from 
PR-SMCs. PR-SMCs were differentiated towards endothelial lineage for 3 days 
before they were transfected with short hairpin JAG1 (shJAG1) lentivirus or control 
shNT lentivirus. The cells were then treated with endothelial-promoting condition 
for another 3 days.  Suppression of JAG1 through shJAG1 delivery caused 
impairment of the expressions of the similar group of endothelial markers that could 
be upregulated with recombinant JAG1 stimulation (Figure 3.51).  
Previous studies showed that JAG1 stimulation could activate eNOS in the presence 
of VEGF (Patenaude, Fuller et al. 2014). Luciferase assay was performed to detect 
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the activity of eNOS promoter upon JAG1 overexpression. We observed that the 
activity of the eNOS promoter was increased by JAG1 overexpression (Figure 3.52).  
 
 
Figure 3.50  Stimulation of the cells with recombinant JAG1 led to the 
further upregulation of endothelial markers 
Real-time PCR revealed that after stimulating the cells with immobilised 
recombinant JAG1 from day 3 of differentiation, endothelial markers eNOS, 





Figure 3.51  JAG1 knockdown impaired the induction of endothelial 
markers of SMC-ECs 
(A) Real-time PCR analysis indicated that the knockdown of JAG1 led to the 
downregulation of levels of eNOS and Claudin 5 (*p<0.05 by Student’s t test, 
n=3). (B) Western blot analysis confirmed the downregulation of endothelial 
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markers in concert with the JAG1 suppression in SMC-ECs. SMCs 
transfected with empty lentiviral vector without the 4 factors expression that 
underwent the same reprogramming and differentiation protocol were used 




Figure 3.52  Luciferase assay of eNOS promoter activity upon JAG1 
overexpression in SMC-ECs 
3 day endothelial-differentiated PR-SMCs were transfected with reporter 
plasmid pGL2 for eNOS promoter and JAG1-overexpressing plasmid 
pCMV6-JAG1 or empty plasmid pCMV6. Measurement of relative luciferase 
activity indicated that eNOS promoter activity was enhanced upon JAG1 
overexpression. Cells were transfected with Renilla-expressing vector at the 
same time as the normalisation control for transfection efficiency. Relative 
luciferase activity is the ratio of luciferase activity to Renilla activity with 





3.4.4  JAG1 might Act through HES5 to Regulate 
Endothelial Differentiation from PR-SMC 
 
HES5 has been reported to be a downstream target of JAG1 in several cellular 
models: hair cell and support cell differentiation (Tang, Alger et al. 2006); 
glioblastoma stem cells to pericyte-like cell differentiation (Guichet, Guelfi et al. 
2015); lipopolysaccharide-induced inflammatory response of macrophage cells 
(Tsao, Wei et al. 2011) and others.  
In our study, both HES5 and JAG1 participated in regulation of endothelial 
differentiation. Interestingly, both of them could enhance eNOS promoter activity. 
JAG1 knockdown led to the suppression of HES5 expression (Figure 3.51 B) during 
PR-SMCs to endothelial differentiation. In addition, a luciferase assay was 
performed to evaluate HES5 promoter activity upon the overexpression of JAG1 
during endothelial differentiation. JAG1 overexpression could enhance HES5 
promoter activity (Figure 3.53). The above results suggest that JAG1 might act on 
the downstream HES5 to carry out its endothelial regulatory function. Further work 
should be performed to clarify the interaction between JAG and HES5 and their 




Figure 3.53  Luciferase assay of HES5 promoter activity upon JAG1 
overexpression in SMC-ECs 
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3 day endothelial-differentiated PR-SMCs were transfected with reporter 
plasmid pGL3 for HES5 promoter and JAG1-overexpressing plasmid 
pCMV6-JAG1 or empty plasmid pCMV6. Measurement of relative luciferase 
activity indicated that HES5 promoter activity was enhanced upon JAG1 
overexpression. Cells were transfected with Renilla-expressing vector at the 
same time as the normalisation control for transfection efficiency. Relative 
luciferase activity is the ratio of luciferase activity to Renilla activity with 




3.4.4  Conclusion 
The participation of two components of the Notch signalling pathway, HES5 and 
JAG1, during endothelial differentiation from PR-SMCs has been studied.  
Comprehensive analyses of RNA-Seq and Real-time PCR data revealed the 
concurrent upregulation of HES5 and JAG1 with endothelial differentiation. 
Knockdown or overexpression of HES5 during PR-SMCs to endothelial 
differentiation led to the suppression or further increase of endothelial markers 
respectively. HES5 regulates the activation of the eNOS promoter. Stimulating the 
cells under endothelial differentiation with JAG1 caused the enhancement of a group 
of endothelial-related genes. Knockdown of JAG1 during differentiation led to the 
suppression of a similar group of genes. JAG1 also played a role in modulating 
eNOS promoter activity. More interestingly, JAG1 could activate the promoter 
region of HES5. 
Taken together, our study focused on revealing the contribution of HES5 and JAG1 












4.1  Brief Summary of Major Findings 
 
In this study, we have demonstrated the feasibility of the derivation of ECs from 
human SMCs for the first time. The conversion was achieved using a two steps 
protocol consisting of first reprogramming SMCs to CD34-positive vascular 
progenitors and subsequently differentiating the cells towards a functional 
endothelial lineage. Importantly, the SMC-derived ECs display angiogenic capacity 
especially in an animal ischaemic disease model as well as the ability to assemble 
into an endothelial layer in tissue engineered vascular graft. Furthermore, our data 
reveal that the MET and the Notch signalling pathways are important mediators 
through which cell fate conversion can be attained. Our findings present the first 
indication that human SMCs may represent a new valuable source of functional ECs 







4.2  Establishment and Optimisation of the Protocol 
for the Conversion of Human SMC towards an 
Endothelial Fate 
 
4.2.1  Choosing the Basic Strategy for the Conversion from 
SMC to EC: EC-Specific Transcription Factors or iPS cell-
Generating Transcription Factors? 
 
First, the basic strategy for the direct conversion of SMC towards an endothelial 
lineage needed to be decided. Currently, there are two main approaches to achieve 
direct cell lineage conversion. One is to use target cell type-specific transcription 
factors to activate the target cell type’s gene regulatory network in the starting cell 
population. Another approach is to use iPS cell-generating reprogramming factors 
combined with specific culture conditions to erase the starting cells’ lineage-specific 
signatures and to reactivate repressed transcription and epigenetic networks without 
the full induction of pluripotency. Cells then revert to an intermediate plastic state 
which permits further manipulation and new lineage commitment towards the 
desired cell types.  
Although using the target cell-specific transcription factors for direct cell lineage 
reprogramming represents a straightforward strategy, a major concern related to this 
method is that the original gene regulatory network of the starting cell type may be 
insufficiently inactivated.  Indeed, a recent study provided evidence to support this 
concern by comparing the gene expression patterns of various directly 
reprogrammed cell types with cells derived from pluripotent stem cells using a 
computational network biology platform named CellNet. Comprehensive analysis 
showed that directly reprogrammed cells tend to inadequately silence the expression 
programs of the starting cell population (Cahan, Li et al. 2014). This suggests that 
using target cell-specific transcriptions factors to conduct the direct cell lineage 
conversion may fail to fully erase the identity of the starting cell type and result in 
the incomplete establishment of the gene regulatory networks of the target cell type. 
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Instead, iPS-generating pluripotent factors can provide the cells with a clean slate for 
the further full induction of target cell type characteristics.  
Specific to our study, SMC and EC may share common vascular progenitors under 
certain circumstances (reviewed in section 1.1.4.3). Therefore, it seemed more 
practical to use the reprogramming factors OCT4, SOX2, KLF4, and c-MYC to 
dedifferentiate the SMCs back to a plastic state to mimic the vascular progenitor 
state as a first step, and then differentiate the intermediate progenitor state cells 
towards an endothelial lineage.  
 
4.2.2  Conversion of SMCs to a Plastic Intermediate State 
through Short Time Reprogramming  
We used a lentiviral vector TetO-OSKM to efficiently overexpress OCT4, SOX2, 
KLF4, and c-MYC in the SMCs. Lentivirus enables efficient gene delivery into both 
dividing and non-dividing cells. Then the cells were cultured under reprogramming 
conditions which are the same as for iPS cells generation. However, the 
reprogramming time was set as 4 days which is much shorter than the time for full 
iPS generation: 21-28 days (Takahashi, Tanabe et al. 2007). After 4 days of 
reprogramming, partially reprogrammed SMCs (PR-SMCs) exhibited morphology 
changes and large-scale gene expression changes. PR-SMCs started to lose their 
SMC identity reflected by the downregulation of a group of SMC markers. 
Transcriptome sequencing analysis showed that many genes had been upregulated 
when compared to the original SMC population, which suggested that many 
suppressed genes had been re-activated and the plasticity of cell identity had been 
triggered after reprogramming. The gene ontology analysis of molecular function 
indicated that genes related to the regulation of structural molecule activity were 
upregulated, which explains the morphological changes and the erasure of SMC 
signature structures. Regarding biological processes, expression of genes associated 
with translational processes was significantly increased.      
It came as no surprise that short term reprogramming with OCT4, SOX2, KLF4, and 
c-MYC could fundamentally change the cellular state of SMCs. In time course 
studies for iPS cell generation, both genome-wide and proteome-wide analyses 
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revealed extensive changes at the gene and protein levels soon after the ectopic 
introduction of reprogramming factors, especially during the early phase from day 0 
to day 3 (Buganim, Faddah et al. 2013). Other studies have used the four 
transcription factors OCT4, SOX2, KLF4, and c-MYC to reprogramme fibroblasts in 
4-8 days to generate partially-iPS cells, which can be further differentiated towards 
EC or SMC in response to different stimulations (Margariti, Winkler et al. 2012, 
Karamariti, Margariti et al. 2013, Kurian, Sancho-Martinez et al. 2013). These 
studies also showed that the expression patterns of a broad range of genes related to 
developmental cellular activities are changed after 4-8 days of reprogramming. This 
supports the idea that cell identity can be significantly altered in a short time frame 
upon the ectopic expression of the reprogramming factors, which explains what we 
have observed in the 4 day-reprogrammed SMCs.   
A recent study revealed that during iPS cell generation, the reprogramming factors 
bind to the genes that are not occupied by these factors in ESCs (Soufi, Donahue et 
al. 2012). This interesting fact indicates that the reprogramming factors may function 
in a cell type-dependent way. When specifically considering the reprogramming 
towards vascular cell lineage, one of the iPS-inducing reprogramming factors, KLF4, 
is particularly significant. KLF4 has been shown to play a crucial role in regulating 
vascular cell development and activities in addition to its reprogramming role and 
has been identified as an important transcription factor for both SMC and EC. KLF4 
can inhibit the expression of SMC markers through directly binding to the TGF-β 
control element in their promoters or through preventing the interaction of serum 
response factor (SRF) with their promoters (Adam, Regan et al. 2000, Liu, Sinha et 
al. 2003, Liu, Sinha et al. 2005). KLF4 has been shown to directly bind to the 
promoter of VE-Cadherin in mature ECs to improve cell barrier function (Cowan, 
Kohler et al. 2010). Another study indicated that KLF4 plays a protective role in 
regulating the response of EC to inflammatory stimuli. Overexpressing KLF4 in ECs 
increases the expression of anti-inflammatory and anti-thrombotic factors including 
eNOS and thrombomodulin (Hamik, Lin et al. 2007). In c-Kit-positive vascular 
progenitor population derived from ESCs, Klf4 was shown to positively regulate 
their differentiation towards ECs. Overexpression of Klf4 in this population led to 
further upregulation of EC markers and knockdown of Klf4 resulted in an increase in 
SMC markers (Campagnolo, Tsai et al. 2015). The above studies suggest that KLF4 
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may play an additional favourable role in promoting SMC to EC conversion by 
suppressing SMC characteristics and possibly promoting EC identity.  
To further examine the PR-SMCs population, an upregulation of the expression of 
CD34 was observed after 4 days of reprogramming. CD34 has been identified as an 
important marker for vascular progenitor cells which have the potential to give rise 
to both EC and SMC lineage in response to different conditions (Ferreira, Gerecht et 
al. 2007). It is noteworthy that CD34 has also been used as a marker for circulating 
endothelial progenitor cells with the capacity to facilitate neovascularisation (Mackie 
and Losordo 2011, Fadini, Losordo et al. 2012). The emergence of a CD34-positive 
population after our first step of reprogramming suggested the generation of a 
vascular progenitor state from SMCs. Interestingly, previous studies showed that the 
same set of reprogramming factors or Oct4 alone could induce an upregulation of 
CD34 in fibroblasts in different culture conditions (Szabo, Rampalli et al. 2010, 
Kurian, Sancho-Martinez et al. 2013).  
Taken together, it appears that the short-term reprogramming step facilitates the 
erasure of the SMC signature and drives the SMCs back to a progenitor state marked 
by CD34 expression. The epigenetic plasticity of this progenitor stage permits the 
cells to be more actively responsive to certain lineage-promoting stimuli and commit 
into other cell type. A recent study overexpressed OCT4, SOX2, KLF4, and c-MYC 
for 8 days, which was doubled reprogramming time compared to our protocol, to 
induce a CD34-positive mesoderm progenitor state from fibroblasts for further 
differentiation towards endothelial lineage (Kurian, Sancho-Martinez et al. 2013). 
We stopped the reprogramming at day 4 because at this time point there was already 
altered cell state with the CD34 upregulation and longer reprogramming time with 
the four factors might raise the tumourigenesis risk. However, it is still of interest to 
further evaluate whether longer reprogramming time can significantly increase the 





4.2.3  Differentiation of Vascular Progenitor State PR-
SMCs towards an Endothelial Lineage  
 
Following reprogramming, PR-SMCs were subjected to endothelial-promoting 
conditions. We chose the combination of Collagen IV coating, EGM-2 media and 
VEGF supplementation to create an endothelial-favouring circumstance, which is 
based on the established protocols that have been used to differentiate progenitors or 
pluripotent stem cells towards the endothelial lineage (Ferreira, Gerecht et al. 2007, 
Benedito, Rocha et al. 2012).  
Collagen IV is an important type of ECM substrate synthesised by ECs which 
supports the in vitro differentiation of pluripotent cells towards mesoderm lineage. 
Collagen IV promotes the expression of mesodermal genes of endothelial and 
haematopoietic lineages from ESCs (Schenke-Layland, Angelis et al. 2007) and 
many protocols use Collagen IV to facilitate the differentiation of 
pluripotent/progenitor cells towards the endothelial lineage. CD34- or VEGFR2-
positive cells from mouse or human pluripotent cells gave rise to ECs when cultured 
on Collagen IV in VEGF supplemented differentiation media (Nishikawa, 
Nishikawa et al. 1998, Yamashita, Itoh et al. 2000, Blancas, Lauer et al. 2008).    
VEGF (more precisely VEGFA, but usually referred to just as VEGF) is a member 
of the secreted polypeptides VEGF family, which plays a prominent role in 
endothelial development and the organisation of the vasculature. Vegf gene knockout, 
even the heterozygous (+/-) knockout, causes early embryonic lethality of mice due 
to severe failures in vascular development (Carmeliet, Ferreira et al. 1996, Ferrara, 
Carver-Moore et al. 1996). VEGF mainly act through binding to VEGF receptors 
belonging to the receptor tyrosine kinase (RTK) family on the cell membrane: 
VEGFR1 (FLT1), VEGFR2 (KDR). VEGF receptors are activated through 
phosphorylation and carry out the effect of VEGF stimulation through several 
downstream signalling pathways including the PI3K/AKT pathway, MAPK/ERK 
pathway, etc.   
Due to its important physiological role in endothelial development, VEGF has 
commonly been added as a potent supplement to the culture media to induce 
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endothelial differentiation from multiple types of stem cells. VEGF can be further 
classified into different isoforms with different diffusibilities and receptor binding 
ability resulting from the alternative splicing of the VEGF gene from exons 5 to 
8(Tammela, Enholm et al. 2005). VEGF165 that has been used in this study is the 
most abundant and biologically active isoform with intermediate diffusion and 
matrix-binding properties, which is necessary for normal vascular development 
(Nagy, Dvorak et al. 2003).  
After 6 days of endothelial differentiation, a portion of the total PR-SMCs 
population was converted to endothelial-like cells with morphological changes and 
the expression of endothelial markers at the mRNA and protein levels. These results 
support the finding that the presented protocol can convert SMCs towards an 
endothelial lineage. However, not all of the SMCs had been switched to an 
endothelial fate. The flow cytometry results indicated that the upregulation of 
PECAM-1 expression was around 7%. The more likely explanation for this is that 
not every SMC responded in exactly the same way to the short time reprogramming 
with OCT4, SOX2, KLF4, and c-MYC. Studies of iPS cell generation process 
indicate that cells respond to reprogramming factors in a highly stochastic manner. 
Reprogramming factors initiate a sequence of probabilistic events that eventually 
result in a small and unpredictable portion of cells turning into pluripotent cells 
(Hanna, Saha et al. 2009, Buganim, Faddah et al. 2012). Comparably, the four 
reprogramming factors might trigger different reactions in individual SMCs 
stochastically which results in only a fraction of the whole population being 
converted towards an endothelial lineage.   
The practicability of the SMC to EC conversion protocol was further validated 
through use of an alternative gene delivery method to overexpress OCT4, SOX2, 
KLF4, and c-MYC in SMCs. SMCs transfected with a plasmid (pCAG-OSKM) that 
encoded the four reprogramming factors could also be steered towards the 
endothelial lineage through a CD34-positive intermediate vascular progenitor state. 
This alternative gene delivery method verifies that the four reprogramming factors 
are the main force to start the conversion of SMCs to vascular progenitors and 
further on to ECs. Another interesting finding here was that the overexpression 
levels of OCT4, SOX2, KLF4, and c-MYC were increased by between 10 and 25 fold 
when using the plasmid for gene delivery, which was much lower than using the 
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lentivirus (TetO-OSKM) which could achieve changes in hundreds of fold. This 
difference of gene delivery efficiency can be explained by that lentivirus is a better 
vector to accommodate larger transgenes and the electrporation method to deliver 
plasmids causes certain level of cell mortality. However, the upregulation of CD34 
was around 2 to 3 fold in PR-SMCs generated by pCAG-OSKM which was not 
significantly lower than the 4 to 5 fold CD34 induction through the lentiviral method. 
Therefore, the absolute expression level of reprogramming factors might not be a 
key issue for the efficiency of SMC to EC conversion. As previously suggested, it is 
possible that only a fraction of SMCs responded to stimulation with the 
reprogramming factors. Single cell tracing and analysis should be further performed 
to confirm this hypothesis. 
 
4.2.4  Selection of CD34-positive cells in PR-SMCs Displays 
the Ability to Differentiate towards a More Homogenous 
Endothelial Population 
 
To further improve the efficiency of the established protocol, CD34-positive cells 
were selected from the whole PR-SMCs population to reduce the negative effect 
caused by the heterogeneity of the cell population. CD34 selection has been applied 
in many endothelial differentiation protocols in order to generate a homogenous 
mesodermal vascular progenitor or endothelial progenitor population for subsequent 
differentiation towards ECs. For example, a recent study reprogrammed fibroblasts 
with OCT4, SOX2, KLF4, and c-MYC and then used CD34 as the marker to select 
mesoderm precursors for differentiation to ECs (Kurian, Sancho-Martinez et al. 
2013).  
Indeed, CD34-positive SMC-derived vascular progenitors exhibit an enhanced 
capacity to give rise to a more homogeneous endothelial population with a complete 
repertoire of endothelial features compared to the heterogeneous vascular progenitor 
population. PECAM-1 and VE-Cadherin expression levels had been enhanced to 
around 30% based on the flow cytometry analysis. The establishment of endothelial 
junctions formed by adhesive proteins and the signals transferred by them are 
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important indicators for successful EC generation. Expression of the typical 
endothelial junction markers PECAM-1, VE-Cadherin, and Claudin5 was detected at 
the mRNA and protein levels in SMC-CD34-ECs. In addition, gene ontology 
analysis for all the upregulated genes in SMC-CD34-ECs revealed genes that related 
to the biological processes of cell adhesion and cell surface receptor linked signal 
transduction were highly induced. Taken together, these data suggest a profile which 
supports the formation of endothelial cell-cell contacts. Gene ontology analysis of 
the molecular functions showed that genes related to calcium ion binding and 
carbohydrates binding were upregulated in SMC-CD34-ECs. Cytoplasmic calcium 
participates in regulating many aspects of endothelial function, including the 
synthesis and release of NO, signal transduction by membrane proteins, platelet 
adhesion, etc (Tran and Watanabe 2006). Selectins are one example of important EC 
adhesion molecules which are calcium-dependent and contain carbohydrate binding 
domains for interaction with specific glycans on platelets and leukocytes (Somers, 
Tang et al. 2000). The upregulation of genes related to calcium ion binding and 
carbohydrate binding therefore suggests the activation of endothelial function in 
SMC-derived ECs.  
The strongest evidence for efficiency of the protocol is that the SMC-derived ECs 
exhibit endothelial related functions in vitro and in vivo. In addition to the 
observation that endothelial marker eNOS was strongly upregulated during SMC to 
EC conversion, SMC-derived ECs were also shown to have acquired NO producing 
capacity, which is an important feature of functional ECs. SMC-CD34-ECs could 
efficiently take up acetylated-LDL which demonstrated that their lipid metabolic 
ability resembled normal ECs. In vitro and in vivo angiogenic capacity of the SMC-
derived ECs was assessed using an in vitro Matrigel tube formation assay and an in 
vivo Matrigel plug assay. SMC-CD34-ECs showed the ability to assemble capillary-






4.2.5  Summary of the Established Protocol 
Taken together, we presented here a short and efficient protocol allowing the 
conversion of SMCs into functional ECs (Figure 4.1). Compared with existing 
protocols to generate ECs from stem cells or other types of somatic cells, our 
protocol has a clear advantage in that it lasts only 10 to 15 days, which is time-
efficient compared to existing protocols. We have also used a novel cell type, SMCs, 
to achieve the generation of functional ECs expressing a full repertoire of EC 
markers. Compared to ESCs or iPS cells as cell sources for functional EC generation, 
SMC can be obtained autologously without any ethical concerns. The tumour 
formation also was not observed during the whole study. The finding that SMCs can 
be used as a potential new cell source for ECs brings interesting physiological, 
pathological and therapeutic implications. It is possible to develop a therapeutic 
strategy to directly convert native SMCs to repair damaged endothelium in vivo. 
These will be further discussed in Chapter 4.4. 
 
Figure 4.1  Schematic overview of the protocol to derive ECs from 
SMCs 
The derivation of ECs from the SMCs is achieved based on a combined 
protocol of reprogramming SMCs to CD34-positive progenitor and 
subsequent differentiation towards an endothelial lineage. SMCs are 
reprogrammed with four transcription factors for 4 days to generate PR-
SMCs. PR-SMCs are partially able to differentiate towards an endothelial 
lineage. To promote the efficiency, CD34-positive cells are selected from the 





4.3  Mechanisms Involved in the Conversion of SMC 
towards EC  
4.3.1  The Involvement of MET and E-Cadherin in the 
Induction of a Vascular Progenitor State from SMCs 
 
Accumulating evidence has shown that MET is a vital event that must occur at the 
initial stages of reprogramming for successful iPS cell generation (Li, Liang et al. 
2010, Samavarchi-Tehrani, Golipour et al. 2010, Hansson, Rafiee et al. 2012). 
Reprogramming factors coordinate a comprehensive molecular network to drive the 
occurrence of MET and the reversion of differentiated cells back to pluripotency. 
OCT4, SOX2, KLF4, and c-MYC have been indicated to regulate MET through 
several different mechanisms. In this study, we used the four reprogramming factors 
to induce the vascular progenitor state from SMCs. SMCs can be considered as 
mesenchymal-like cells due to their lack of intercellular adhesion/junction contacts 
and their ability to migrate through ECM. During the 4 days of reprogramming from 
SMCs to vascular progenitors, SMCs gradually lost their mesenchymal-like 
morphology. Simultaneously, there was an overall downregulation in mesenchymal 
markers and EMT-promoting transcription factors, corresponding with an overall 
upregulation in cell-cell adhesion markers, especially E-Cadherin, expression of 
which is a characteristic event of MET. The occurrence of MET, induced by the four 
reprogramming factors, indicated the modulation of SMC plasticity and identity 
during the 4 day reprogramming.  
E-Cadherin expression, a crucial indicator of MET, may has additional role in 
regulating the generation of the vascular progenitor state from SMCs, which is 
possibly through modulation of the establishment of cell-cell contacts. Knockdown 
of E-Cadherin during 4 day reprogramming disrupted CD34-positive population 
induction from SMCs and abolished further endothelial differentiation. E-Cadherin 
has been shown to play an important role in establishing proper cell-cell contacts 
during iPS cell generation (Chen, Yuan et al. 2010). An early study suggested a role 
of E-Cadherin in adhesion of a CD34-positive subset of human bone marrow stromal 
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cells (Turel and Rao 1998). In the context of SMC to EC conversion, cell junction 
proteins including CD34 and many important endothelial markers such as VE-
Cadherin, PECAM-1, and Claudin 5 are induced. The accurate establishment of 
contacts between neighbouring cells mediated by E-Cadherin may be a requisite 
event for the further establishment of vascular progenitor and endothelial junction 
proteins.  
 
4.3.2  Components of the Notch Signalling Pathway 
Participate in Endothelial Differentiation from a Vascular 
Progenitor State 
 
The Notch signalling pathway participates in regulation of diverse vascular cell 
activities during embryonic and postnatal development (Bray 2006). The Notch 
signals usually function to drive the decisions of the precursors between two 
alternative fates (Artavanis-Tsakonas and Muskavitch 2010). For example, Notch 
signals determine the arterial-venous fate of ECs and the tip or stalk cells selection of 
ECs during angiogenesis (reviewed in Chapter 1.1.4.4). Comprehensive analysis of 
RNA-Seq data demonstrated the likely involvement of several Notch components in 
SMC to EC conversion: JAG1, DLL4, HES5, and HEY2. To further confirm which 
Notch pathway members participate in endothelial induction, real-time PCR was 
performed to check these four candidates as well as several other Notch components 
that have been reported to be important for the regulation of endothelial development 
or function: NOTCH1, NOTCH4, HES1, and HEY1. During endothelial induction 
from the vascular progenitor state PR-SMCs, HES5 and JAG1 showed increased 
expression at the transcriptome and mRNA levels. The activation of HES5 and JAG1 
expression at the protein level was further confirmed. Therefore, our interests 
expanded to exploring the roles of HES5 and JAG1 in regulating vascular progenitor 




4.3.2.1  The Involvement of HES5 in Endothelial Differentiation  
HES5 is a common downstream target of the Notch pathway which belongs to the 
basic helix-loop-helix transcription factor family and is usually associated with 
neural cell differentiation (Iso, Kedes et al. 2003). In our protocol, HES5 was 
upregulated in concert with EC markers induction. Moreover, by knocking down or 
overexpressing HES5 during endothelial differentiation, we observed a repression or 
increase in EC marker expression respectively. These results indicated the positive 
regulatory function of HES5 during endothelial induction. HES5 has not been related 
to endothelial development or function in many published works. One study 
suggested a role for HES5 in vascular development, as it might be a key positive 
mediator for the statin-induced differentiation of bone marrow stromal cells into ECs 
(Xu, Liu et al. 2009). Another study has suggested that HES5 plays a part in 
promoting endothelial proliferation in response to endothelial injury during 
atherosclerosis (Schober, Nazari-Jahantigh et al. 2014). This study also demonstrated 
that MicroRNA-126-5p promotes endothelial regeneration and limits atherosclerosis 
by suppressing the Notch inhibitor delta-like 1 homologue (Dlk1), which leads to 
release of HES5 that has been suppressed by Dlk1 to play its role in endothelial 
repair. 
It is worth pointing out that the endothelial stimulation role of HES5 could only 
promote endothelial differentiation in the vascular progenitor population derived 
from SMCs after induction by the four reprogramming factors, whereas HES5 hardly 
triggered EC marker expression on its own when overexpressed in the control cell 
population. All the findings above imply that the four reprogramming factors open 
up certain opportunities for HES5’s further regulation of endothelial related gene 
expression. Using a mouse iPS cell to EC differentiation model, the upreguation of 
Hes5 had been observed along with the induction of endothelial markers. This result 
indicated that the endothelial-regulatory role of Hes5 may not only be restricted to 
the SMC to EC conversion.  
HES5 has usually been described as a transcription repressor, however in some cases 
it can also function as transcription activator (Iso, Kedes et al. 2003, Kamakura, 
Oishi et al. 2004). Our data suggest that HES5 might play a part in activating the 
eNOS promoter. Additional studies will be required to elucidate a more detailed 
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mechanism which could be HES5 directly binding to the promoter region or 
activating it through other factors. There have been reports about HES5 enhancement 
of the phosphorylation of JAK2, which plays an important role in eNOS activation 
(Cieslik, Abrams et al. 2001, Kamakura, Oishi et al. 2004).  
In addition to the promotion of EC profile induction, overexpression of HES5 led to 
the simultaneous further repression of SMC marker. HES5 has been reported to 
repress downstream transcriptional enhancers such as Mash (de la Pompa, Wakeham 
et al. 1997), MyoD (Kopan, Nye et al. 1994) and Myocardin (Proweller, Pear et al. 
2005), which are all related to the positive regulation of SMC marker promoters. 
Using pulmonary arterial hypertension (PAH) as a pathological model to study the 
plasticity and proliferation of vascular SMCs, Li et al. showed that HES5 
participated in regulation of arterial SMC proliferative capacity and differentiation. 
HES5, corresponding with NOTCH3, suppressed the contractile marker expression 
of vascular SMCs including SM-MHC and Smoothelin in response to hypoxia-
induced PAH (Li, Zhang et al. 2009). Therefore, HES5 might act to suppress the 
SMC transcription network to repress the SMC differentiation fate of PR-SMC and 
promote the endothelial differentiation fate.  
 
4.3.2.2  The Involvement of JAG1 in Endothelial Differentiation  
JAG1 is a Serrate/Jagged family transmembrane ligand for the Notch pathway 
containing multiple epidermal growth factor-like repeats (Fleming 1998). JAG1, as 
the upstream ligand of the transmembrane receptors in the Notch pathway, plays a 
complicated role in orchestrating cell fate. The homozygous mutation of the Jag1 
gene in mice causes early embryonic lethality due to extensive embryonic and yolk 
sac vascular defects (Xue, Gao et al. 1999). The mutation of the JAG1 gene in 
humans leads to Alagille syndrome characterised by abnormal development of 
multiple systems during childhood (Li, Krantz et al. 1997, Oda, Elkahloun et al. 
1997). Vascular anomalies including pulmonary artery abnormalities, intracranial 
haemorrhages and other events, frequently occur to Alagille syndrome patients and 
account for a large portion of mortality, which reflects the important role of JAG1 
during human vascular development (Kamath, Spinner et al. 2004).  
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The pro-angiogenic role of Jag1 has been shown using EC-specific and inducible 
knockout or overexpression in mice. Jag1 loss-of-function mutants exhibited 
reduced sprouting angiogenesis while Jag1 overexpression promotes sprouting 
angiogenesis (Benedito, Roca et al. 2009). Kwon et al. showed that Jag1-induced 
signals from the bone marrow microenvironment are critical for the development of 
angiogenic ability of endothelial progenitor cells (Kwon, Eguchi et al. 2008). An 
interesting study recently demonstrated that JAG1 could subsequently activate KLF4 
which induced the transdifferentiation of tumour cells into endothelial cells (Chen, 
Huang et al. 2014).  
The above studies provide evidence for JAG1 facilitating endothelial differentiation 
and angiogenesis. Nevertheless, there are reports of the opposite effect in other cell 
models. A recent study emphasised the role of JAG1 in promoting haematopoietic 
lineage over endothelial lineage specification during pluripotent stem cell 
differentiation (Lee, Werbowetski-Ogilvie et al. 2013). It is conceivable that in 
different cell types and in response to different environmental cues, the JAG1 
activated Notch pathway may delicately control a distinct regulation network which 
leads to altered consequences.  
In this study, we revealed that JAG1 participates in the regulation of the expression 
of some EC markers especially eNOS, during vascular progenitor to endothelial 
lineage differentiation. We detected that upon JAG1 stimulation, eNOS was 
upregulated at the mRNA level through the activation of its promoter. This finding 
coincided with a recent report which showed that JAG1 activation in response to 
VEGF stimulation is required for eNOS activation and NO production in ECs 
(Patenaude, Fuller et al. 2014). Furthermore, we showed that the HES5 promoter 
could be activated upon JAG1 overexpression. Therefore, it is possible that the 






4.4  Potential Applications of SMC-derived ECs 
 
Cell-based therapeutic angiogenesis is a recently arising approach to restore blood 
perfusion to ischaemic tissue. Successful therapeutic angiogenesis depends on the 
transplanted cells to directly incorporate into the neovasculature as well as to secrete 
angiogenic growth factors (Raval and Losordo 2013). This therapy is of special 
significance in treating peripheral artery disease (PAD) since current 
pharmacological and interventional revascularisation therapies are not beneficial 
enough (Annex 2013). However, researchers are still investigating the optimal 
starting cells to generate functional angiogenic cells. In a murine ischaemia model of 
PAD for this study, we demonstrated that SMC-derived ECs could efficiently engraft 
into local vasculogenesis of ischaemic tissue and profoundly improve the tissue 
perfusion. Moreover, to directly convert SMCs to ECs without reversing to a 
pluripotent state prevents the risk of tumour formation. Our results indicate that 
SMC-derived ECs could be a promising candidate for vascular regenerative therapies.  
Tissue engineered vascular graft represents another promising direction for vascular 
regenerative medicine. In addition to direct transplantation to replace injured vessels, 
tissue engineered graft can also serve as a useful ex vivo model to study the 
mechanisms related to vascular cell or ECM behaviours. Based on a previous 
established protocol from our laboratory, functional vascular-resembling conduits 
can be generated from seeding the decellularised mouse aorta with human origin 
cells using an ex vivo bioreactor circulation system (Karamariti, Margariti et al. 2013, 
Wong, Hong et al. 2015). Adopting this model in our study, seeding the lumen of the 
decellularised vascular grafts with SMC-derived ECs led to successful re-
endothelialisation which suggested their potential implications in constructing tissue 
engineered vascular graft. The evaluation of the in vivo function of the reconstructed 
vascular graft needs to be further performed.   
Another important implication of SMC-derived ECs is in the context of restenosis. 
Vascular intervention therapies such as balloon angioplasty or endovascular stent 
implantation provide beneficial solutions to patients suffering from narrowed vessels. 
However, one of the main concerns of intervention therapies is the further damage to 
the endothelium which can occur during the procedure which triggers restenosis, the 
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proliferation and migrating of SMCs into the intima and finally the re-narrowing of 
the vessel (Chaabane, Otsuka et al. 2013). Certain drugs like sirolimus, paclitaxel, 
everolimus have been applied with intervention therapies to inhibit SMCs 
proliferation and suppress neointima formation to prevent restenosis. The application 
of these drugs with intervention therapies significantly reduces the clinical incidence 
of restenosis (De Luca, Dirksen et al. 2012). However, these drugs indiscriminately 
inhibit the proliferation and migration of ECs at the same time, which further impair 
and delay the endothelial repair. It is of great interest to explore the endothelial 
regeneration strategy for restenosis.  
The proliferation and accumulation of SMCs following endothelial 
denudation/dysfunction profoundly contributes to the development of atherosclerosis 
and restenosis. Our protocol for the direct conversion from SMCs into functional 
ECs may provide a promising tool for in situ endothelial regeneration. However, the 
main obstacle to this future application is the lack of proper gene delivery technique 
aiming at the specific type of cell for in vivo reprogramming. A recent study 
demonstrated an in situ virus delivery method to specifically target vascular SMCs 
without effecting ECs by constructing a designated gene with EC enriched 
microRNA target sequences within the same vector (Santulli, Wronska et al. 2014). 
By employing a similar strategy, it is possible to develop a method to specifically 
switch local SMCs into the endothelial lineage to achieve autologous endothelium 
repair. 
The fast development in the field of bioengineering and biomaterial research 
provides new ideas for precise in vivo gene delivery. For example, a promising 
bioengineering technique for gene delivery is microfabricated microneedles. 
Microneedle techniques had originally been used for intra- and trans-cutaneous 
delivery of genes or drugs through transdermal tissue penetration (McAllister, Allen 
et al. 2000). A perivascular microneedle cuff has been developed to deliver genes or 
drugs to the tunica media layer of vascular wall (Lee, Park et al. 2014). A gene 
delivery strategy combination of SMC-target expressing vector and microneedle 
delivery system may provide a potential solution for in vivo conversion of SMCs to 
ECs and re-endothelialisation. 
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In conclusion, the feasibility of converting human SMCs into functional ECs 






4.5  Summary and Perspective 
 
In summary, this is the first study to show that functional ECs can be efficiently 
derived from SMCs through an intermediate vascular progenitor state which is 
induced by reprogramming factors OCT4, SOX2, KLF4 and c-MYC. We also 
provided insights into the mechanisms behind the process involving MET and the 
Notch signalling. However, there are limitations to the present study and further 
work need to be conducted.  
First, to use reprogramming factors, especially the oncogene c-MYC, as part of the 
protocol still raises tumourigenesis concerns. Although teratoma formation has not 
been observed in any in vivo experiments of this study, the long term effect of using 
reprogramming factors is difficult to predict. In addition, using lentivirus as the 
vector to deliver genes also has potential safety concerns. The technique of 
reprogramming has been rapidly developing since the design of this study. In 
addition to transcription factors, many other kinds of small molecules and chemical 
defined conditions have been applied to conduct reprogramming including 
microRNAs, epigenetic regulators, and signalling pathway regulators. For example, 
a recent study used a toll-like receptor agonist to successfully reprogramme 
fibroblasts into ECs (Sayed, Wong et al. 2015). Therefore, it is of great interest to 
explore the possibility of using small molecules to partly or fully replace 
reprogramming factors to achieve the direct conversion of SMCs towards ECs, 
which can reduce the safety concerns for using pluripotency factors and the 
lentivirus. In addition, further optimisation of the protocol could be carried out to 
improve the purity and stability of the converted ECs. Moreover, an optimised 
culture condition for the long term maintenance of the SMC-derived ECs needs to be 
established.  
We have shown that the SMC-derived ECs acquire EC-like characteristics and 
functions, especially the therapeutic angiogenic ability and bioengineered vascular 
graft constructing capacity. In this study, we have focused on evaluating the 
generation of the endothelial phenotype from SMC and the acquisition of endothelial 
functions. For our next step, it would be of great interest to directly compare this 
SMC-derived endothelial population with their native counterparts ECs and the ECs 
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derived from other cell sources such as ESC-ECs, iPS-ECs, and EPC-ECs at the 
molecular and functional levels. A detailed comparison among different cell source-
derived ECs could provide further indications for choosing the suitable cell 
population for therapeutic purposes.  
The regulatory roles of HES5 and JAG1 for endothelial differentiation have been 
discussed in the present study. However, further work need to be done to elucidate 
the exact regulatory mechanisms between HES5 and JAG1 and their precise roles on 
endothelial differentiation. In addition, the possibility of modulating the Notch 
signalling pathway to achieve SMC to EC conversion can be further explored.  
One of the promising therapeutic applications of the SMC to EC conversion is in the 
restenosis scenario, since the over-proliferating SMCs can be a direct source for in 
situ endothelial regeneration. The SMC-derived ECs can be transplanted to test their 
endothelial repair ability in the wire-injured vascular restenosis model. Furthermore, 
the appropriate in vivo gene delivery method, especially to precisely target SMCs 
within the vascular wall, will be explored.  
 
In conclusion, although future works are required to further complete and extend this 
subject, the present study has proven the hypothesis of this project that it is feasible 
to derive functional EC from human SMC. The aims of this study have also been 
achieved: (1) a protocol has been established to derived EC from human SMC 
through short time reprogramming and subsequent endothelial differentiation; (2) 
SMC-derived EC displays typical EC functions including NO production, ac-LDL 
uptake, in vitro and in vivo angiogenesis, and further therapeutic angiogenic capacity 
and the ability to construct an endothelial layer in tissue engineered vascular graft; (3) 
MET and components of the Notch signalling pathway have been implicated 
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